{"id":38370,"date":"2021-10-28T16:48:37","date_gmt":"2021-10-28T14:48:37","guid":{"rendered":"https:\/\/www.crct-inserm.fr\/v2\/?page_id=38370"},"modified":"2024-01-08T14:38:32","modified_gmt":"2024-01-08T13:38:32","slug":"diad","status":"publish","type":"page","link":"https:\/\/www.crct-inserm.fr\/diad\/","title":{"rendered":"DIAD"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”a00720d8-8e3f-4b20-83b7-6d54485f541c” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”694d3d5d-3e0a-4cd1-b2ba-4eea0d99d5b4″ background_image=”https:\/\/www.crct-inserm.fr\/wp-content\/uploads\/2021\/10\/bandeau2.png” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”8292df69-9d3c-4423-ab4f-a4755f6c1135″ width_tablet=”85%” width_phone=”95%” width_last_edited=”on|phone” custom_padding_last_edited=”off|desktop” global_colors_info=”{}”]<\/p>\n

\u00c9quipe
Etienne Chatelut<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ header_2_font=”Open Sans||||||||” global_colors_info=”{}”]<\/p>\n

DIAD : <\/strong><\/h2>\n

Individualisation des doses de m\u00e9dicaments anticanc\u00e9reux<\/strong><\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_2,1_2″ disabled_on=”on|on|on” _builder_version=”4.16″ _module_preset=”default” width=”50%” disabled=”on” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.crct-inserm.fr\/wp-content\/uploads\/2021\/03\/LOGO-TOUCAN-Horizontal.png” title_text=”LOGO-TOUCAN-Horizontal” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font_size=”22px” global_colors_info=”{}”]<\/p>\n

Le laboratoire d\u2019Excellence Toulouse Cancer est un projet qui vise \u00e0 comprendre les m\u00e9canismes de r\u00e9sistance et de rechute dans les cancers.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.16″ _module_preset=”default” use_background_color_gradient=”on” background_color_gradient_stops=”rgba(43,135,218,0) 50%|#f2efef 50%” background_color_gradient_start=”rgba(43,135,218,0)” background_color_gradient_start_position=”50%” background_color_gradient_end=”#f2efef” background_color_gradient_end_position=”0%” custom_padding=”0px|||||” disabled=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” custom_padding=”0px||0px|||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_video src=”https:\/\/www.youtube.com\/watch?v=FkQuawiGWUw” image_src=”https:\/\/www.crct-inserm.fr\/wp-content\/uploads\/2021\/03\/video.jpg” _builder_version=”4.16″ _module_preset=”default” width=”80%” module_alignment=”center” global_colors_info=”{}”][\/et_pb_video][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” background_color=”#f2efef” custom_padding=”0px||0px|||” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

Les sp\u00e9cificit\u00e9s
<\/strong>de notre axe de recherche<\/h2>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,1_4,1_4,1_4″ disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Pharmacocin\u00e9tique<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”5px||5px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Pharmacog\u00e9n\u00e9tique<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Individualisation des traitements<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Suivi th\u00e9rapeutique pharmacologique<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,1_4,1_4,1_4″ disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Chromatographie liquide<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Mol\u00e9cules radiomarqu\u00e9es th\u00e9ranostiques<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Pr\u00e9disposition g\u00e9n\u00e9tique familiale<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

DES PROJETS<\/strong>
DE RECHERCHE<\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”||0px|||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_blog fullwidth=”off” posts_number=”20″ include_categories=”320″ use_manual_excerpt=”off” show_more=”on” show_author=”off” show_date=”off” show_categories=”off” masonry_tile_background_color=”#f2efef” _builder_version=”4.16″ _module_preset=”default” header_level=”h3″ header_font=”|800|||||||” header_font_size=”20px” body_font_size=”20px” read_more_text_color=”#5EC7ED” read_more_font_size=”20px” read_more_line_height=”3em” background_enable_color=”off” border_width_all=”0px” global_colors_info=”{}”][\/et_pb_blog][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”default” custom_padding=”||0px|||” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

LES FOCUS<\/strong>
DE L\u2019\u00c9QUIPE<\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”default” use_background_color_gradient=”on” background_color_gradient_stops=”#ffffff 50%|rgba(174,227,246,0) 50%” background_color_gradient_overlays_image=”on” background_color_gradient_start=”#ffffff” background_color_gradient_start_position=”50%” background_color_gradient_end=”rgba(174,227,246,0)” background_color_gradient_end_position=”0%” background_image=”https:\/\/www.crct-inserm.fr\/wp-content\/uploads\/2021\/03\/Filets-bleu-actu.png” background_size=”contain” background_position=”bottom_center” custom_padding=”0px|||||” saved_tabs=”all” global_colors_info=”{}”][et_pb_row column_structure=”1_3,1_3,1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”4ae3b26e-eab0-4b6f-bd7b-05f173fca79b” custom_margin=”||-4px||false|false” header_font_size_tablet=”” header_font_size_phone=”” header_font_size_last_edited=”on|desktop” header_2_font_size_tablet=”” header_2_font_size_phone=”” header_2_font_size_last_edited=”on|desktop” header_4_font_size_tablet=”” header_4_font_size_phone=”” header_4_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n

D\u00e9couvrir<\/h4>\n

[\/et_pb_text][et_pb_post_slider posts_number=”5″ include_categories=”1015″ show_arrows=”off” use_manual_excerpt=”off” excerpt_length=”0″ show_meta=”off” image_placement=”top” use_bg_overlay=”off” use_text_overlay=”off” dot_nav_custom_color=”#5EC7ED” _builder_version=”4.16″ _module_preset=”412cf9f9-c22e-468d-92e3-f93d454642a9″ header_font=”Open Sans|600|||||||” header_text_color=”#5EC7ED” header_font_size=”20px” header_line_height=”1.2em” body_font=”Open Sans||||||||” body_text_align=”left” body_text_color=”#505659″ body_font_size=”18px” background_color=”#FFFFFF” custom_button=”on” button_text_size=”18px” button_bg_color=”#5EC7ED” button_border_width=”0px” button_border_radius=”0px” button_use_icon=”off” button_alignment=”center” button_custom_margin=”20px||0px||false|false” button_custom_padding=”10px|50px|10px|50px|true|true” custom_padding=”0px|||||” header_font_size_tablet=”” header_font_size_phone=”22px” header_font_size_last_edited=”on|phone” body_font_size_tablet=”” body_font_size_phone=”18px” body_font_size_last_edited=”on|phone” border_color_all_image=”#ffffff” border_width_bottom_image=”15px” text_shadow_style=”preset4″ text_shadow_vertical_length=”0em” global_colors_info=”{}”][\/et_pb_post_slider][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”4ae3b26e-eab0-4b6f-bd7b-05f173fca79b” custom_margin=”||-3px||false|false” global_colors_info=”{}”]<\/p>\n

Comprendre<\/h4>\n

[\/et_pb_text][et_pb_post_slider posts_number=”5″ include_categories=”1192,1216″ show_arrows=”off” use_manual_excerpt=”off” excerpt_length=”0″ show_meta=”off” image_placement=”top” use_bg_overlay=”off” use_text_overlay=”off” dot_nav_custom_color=”#5EC7ED” show_image_tablet=”” show_image_phone=”” show_image_last_edited=”on|phone” disabled_on=”off|off|off” _builder_version=”4.19.0″ _module_preset=”default” header_font=”Open Sans|600|||||||” header_text_color=”#5EC7ED” header_font_size=”20px” header_line_height=”1.2em” body_font=”Open Sans||||||||” body_text_align=”left” body_text_color=”#505659″ body_font_size=”18px” background_color=”#FFFFFF” custom_button=”on” button_text_size=”18px” button_bg_color=”#5EC7ED” button_border_width=”0px” button_border_radius=”0px” button_use_icon=”off” button_alignment=”center” button_custom_margin=”20px||0px||false|false” button_custom_padding=”10px|50px|10px|50px|true|true” custom_padding=”0px|||||” header_font_size_tablet=”” header_font_size_phone=”22px” header_font_size_last_edited=”on|phone” border_width_bottom_image=”15px” border_color_bottom_image=”#ffffff” text_shadow_style=”preset4″ text_shadow_vertical_length=”0em” global_colors_info=”{}”][\/et_pb_post_slider][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”4ae3b26e-eab0-4b6f-bd7b-05f173fca79b” custom_margin=”||-4px||false|false” global_colors_info=”{}”]<\/p>\n

Participer<\/h4>\n

[\/et_pb_text][et_pb_post_slider posts_number=”5″ include_categories=”1277,1319″ show_arrows=”off” use_manual_excerpt=”off” excerpt_length=”0″ show_meta=”off” image_placement=”top” use_bg_overlay=”off” use_text_overlay=”off” dot_nav_custom_color=”#5EC7ED” disabled_on=”off|off|off” _builder_version=”4.21.0″ _module_preset=”default” header_font=”Open Sans|600|||||||” header_text_color=”#5EC7ED” header_font_size=”20px” header_line_height=”1.2em” body_font=”Open Sans||||||||” body_text_align=”left” body_text_color=”#505659″ body_font_size=”18px” background_color=”#FFFFFF” custom_button=”on” button_text_size=”18px” button_bg_color=”#5EC7ED” button_border_width=”0px” button_border_radius=”0px” button_use_icon=”off” button_alignment=”center” button_custom_margin=”20px||0px||false|false” button_custom_padding=”10px|50px|10px|50px|true|true” custom_padding=”0px|||||” header_font_size_tablet=”” header_font_size_phone=”22px” header_font_size_last_edited=”on|phone” body_font_size_tablet=”” body_font_size_phone=”18px” body_font_size_last_edited=”on|phone” border_width_bottom_image=”15px” border_color_bottom_image=”#ffffff” text_shadow_style=”preset4″ text_shadow_vertical_length=”0em” global_colors_info=”{}”][\/et_pb_post_slider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.16″ _module_preset=”default” disabled=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

En live<\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][et_pb_code _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]\n\n

\n\t\n \n
\n \n
\n

\n CRCT-Oncopole<\/span>\n <\/span>\n Suivre<\/span>\n \n <\/path><\/svg>1,220<\/span>\n <\/path><\/svg>1,117<\/span>\n <\/span>\n <\/p>\n

\n Compte officiel du Centre de Recherches en Canc\u00e9rologie de Toulouse <\/p>\n <\/div>\n

\n
\n <\/path><\/svg> <\/div>\n \"crctoncopole\"\n <\/div>\n <\/a>\n<\/div>\n\n
\n \n
\n\n \n
\n
\n \n \"crctoncopole;\n <\/a>\n \n CRCT-Oncopole<\/a>\n @crctoncopole<\/a>\n \n \t\t ·<\/span>\n\t
\n 21 Ao\u00fbt 1693609681678217706<\/span><\/a>\n <\/div>\n <\/div>\n
\n <\/path><\/svg> <\/div>\n <\/div>\n\n
\n \t\t\t\t

Castelnau-Montratier c\u00e9l\u00e8bre la lutte contre le cancer. Jeudi 24 ao\u00fbt 2023 conf\u00e9rence avec Fr\u00e9d\u00e9ric Chibon responsable de l'\u00e9quipe @OncoSarc du @crctoncopole accompagn\u00e9 de Gwena\u00ebl Ferron et Martin Gauthier oncologue @IUCTOncopole
\nD\u00e9couvrir l'\u00e9quipe
\n\u27a1\ufe0fhttps:\/\/www.crct-inserm.fr\/oncosarc\/ <\/p>\n\t\t\t\t\t\t\n \n

\n \n \n <\/path><\/svg>
<\/path><\/svg><\/div>\n \n \"Image\n \n Image du flux Twitter.<\/span> <\/a>\n \n <\/div>\n\n\t \n \n <\/div>\n \n\t\n
\n \n <\/path><\/g><\/svg> R\u00e9pondre sur Twitter 1693609681678217706<\/span>\n <\/a>\n\n \n <\/path><\/svg> Retweeter sur Twitter 1693609681678217706<\/span>\n 0<\/span>\n <\/a>\n\n \n <\/path><\/g><\/svg> J\u2019aime sur Twitter 1693609681678217706<\/span>\n 6<\/span>\n <\/a>\n\n \n Twitter<\/span>\n 1693609681678217706<\/span>\n <\/a>\n \n\t<\/div>\n\n\t<\/div>\n\n <\/div>\n\n Voir plus<\/span><\/a>\n\n<\/span>\n<\/div>\n[\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”default” background_color=”#f2efef” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

PRODUCTIONS SCIENTIFIQUES<\/strong><\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_toggle title=”PUBLICATIONS 2024″ open=”on” open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_text_color=”#505659″ closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.22.1″ _module_preset=”default” title_text_color=”#ffffff” title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_font=”|600|||||||” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\tNMTDPBH9<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2024<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 38370<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-1e80ae3826b3896978c310905b465895%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22USLWEL2Y%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lambert%20et%20al.%22%2C%22parsedDate%22%3A%222024-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELambert%2C%20Marie%2C%20Mathieu%20Alonso%2C%20Caroline%20Munzer%2C%20Marie-Christine%20Zimoch%2C%20Laurence%20Malard%2C%20Marion%20Gambart%2C%20Marie-Pierre%20Castex%2C%20Carla%20Martins%2C%20Marl%26%23xE8%3Bne%20Pasquet%2C%20and%20Etienne%20Chatelut.%20%26%23x201C%3BProspective%20Validation%20of%20an%20Equation%20Based%20on%20Plasma%20Cystatin%20C%20for%20Monitoring%20the%20Glomerular%20Filtration%20Rate%20in%20Children%20Treated%20with%20Cisplatin%20or%20Ifosfamide%20for%20Cancer.%26%23x201D%3B%20%3Ci%3ECancer%20Chemotherapy%20and%20Pharmacology%3C%5C%2Fi%3E%2093%2C%20no.%204%20%28April%202024%29%3A%20393%26%23x2013%3B95.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00280-023-04597-6%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00280-023-04597-6%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prospective%20validation%20of%20an%20equation%20based%20on%20plasma%20cystatin%20C%20for%20monitoring%20the%20glomerular%20filtration%20rate%20in%20children%20treated%20with%20cisplatin%20or%20ifosfamide%20for%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Lambert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Alonso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Munzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Christine%22%2C%22lastName%22%3A%22Zimoch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Malard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Gambart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Pierre%22%2C%22lastName%22%3A%22Castex%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carla%22%2C%22lastName%22%3A%22Martins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marl%5Cu00e8ne%22%2C%22lastName%22%3A%22Pasquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%5D%2C%22abstractNote%22%3A%22We%20recently%20proposed%20an%20equation%20to%20estimate%20the%20glomerular%20filtration%20rate%20%28GFR%29%20in%20children%20with%20cancer%20based%20on%20plasma%20cystatin%20C%20and%20serum%20creatinine%20levels%20together%20with%20body%20weight%20%28the%20%5C%22CysPed%20equation%5C%22%29.%20The%20current%20clinical%20study%20reports%20a%20prospective%20evaluation%20of%20this%20equation%20in%2018%20children%20treated%20by%20nephrotoxic%20chemotherapy.%20The%20CysPed%20equation%20resulted%20in%20less%20bias%20and%20greater%20precision%20compared%20to%20two%20equations%20previously%20proposed%20equations%20by%20Schwartz%2C%20with%20or%20without%20plasma%20cystatin%20C.%20Moreover%2C%20the%20decrease%20in%20GFR%20due%20to%20chemotherapy%20was%20clearly%20identified%20by%20the%20CysPed%20equation.%20This%20equation%20may%20be%20used%20to%20monitor%20the%20renal%20function%20in%20childhood%20cancer%20units.%22%2C%22date%22%3A%222024-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00280-023-04597-6%22%2C%22ISSN%22%3A%221432-0843%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222024-04-03T09%3A57%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22CIBVLRTC%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Le%20Teuff%20et%20al.%22%2C%22parsedDate%22%3A%222024-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELe%20Teuff%2C%20Gw%26%23xE9%3Bna%26%23xEB%3Bl%2C%20Nathalie%20Cozic%2C%20Jean-Christophe%20Boyer%2C%20Val%26%23xE9%3Brie%20Boige%2C%20Robert%20B.%20Diasio%2C%20Julien%20Taieb%2C%20Didier%20Meulendijks%2C%20et%20al.%20%26%23x201C%3BDihydropyrimidine%20Dehydrogenase%20Gene%20Variants%20for%20Predicting%20Grade%204-5%20Fluoropyrimidine-Induced%20Toxicity%3A%20FUSAFE%20Individual%20Patient%20Data%20Meta-Analysis.%26%23x201D%3B%20%3Ci%3EBritish%20Journal%20of%20Cancer%3C%5C%2Fi%3E%20130%2C%20no.%205%20%28March%202024%29%3A%20808%26%23x2013%3B18.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41416-023-02517-2%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41416-023-02517-2%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Dihydropyrimidine%20dehydrogenase%20gene%20variants%20for%20predicting%20grade%204-5%20fluoropyrimidine-induced%20toxicity%3A%20FUSAFE%20individual%20patient%20data%20meta-analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gw%5Cu00e9na%5Cu00ebl%22%2C%22lastName%22%3A%22Le%20Teuff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Cozic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Christophe%22%2C%22lastName%22%3A%22Boyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Boige%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20B.%22%2C%22lastName%22%3A%22Diasio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Taieb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Meulendijks%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Palles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Schwab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maarten%22%2C%22lastName%22%3A%22Deenen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlo%20R.%22%2C%22lastName%22%3A%22Largiad%5Cu00e8r%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%22%2C%22lastName%22%3A%22Marinaki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%20A.%22%2C%22lastName%22%3A%22Jennings%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yvonne%22%2C%22lastName%22%3A%22Wettergren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonello%22%2C%22lastName%22%3A%22Di%20Paolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%22%2C%22lastName%22%3A%22Gross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barna%22%2C%22lastName%22%3A%22Budai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephen%20P.%22%2C%22lastName%22%3A%22Ackland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andr%5Cu00e9%20B.%20P.%22%2C%22lastName%22%3A%22van%20Kuilenburg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Howard%20L.%22%2C%22lastName%22%3A%22McLeod%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00e9rard%22%2C%22lastName%22%3A%22Milano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Anne%22%2C%22lastName%22%3A%22Loriot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Kerr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%20H.%20M.%22%2C%22lastName%22%3A%22Schellens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Laurent-Puig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qian%22%2C%22lastName%22%3A%22Shi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Pignon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Christine%22%2C%22lastName%22%3A%22Etienne-Grimaldi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22FUSAFE%20collaborative%20group%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Dihydropyrimidine%20dehydrogenase%20%28DPD%29%20deficiency%20is%20the%20main%20known%20cause%20of%20life-threatening%20fluoropyrimidine%20%28FP%29-induced%20toxicities.%20We%20conducted%20a%20meta-analysis%20on%20individual%20patient%20data%20to%20assess%20the%20contribution%20of%20deleterious%20DPYD%20variants%20%2A2A%5C%2FD949V%5C%2F%2A13%5C%2FHapB3%20%28recommended%20by%20EMA%29%20and%20clinical%20factors%2C%20for%20predicting%20G4-5%20toxicity.%5CnMETHODS%3A%20Study%20eligibility%20criteria%20included%20recruitment%20of%20Caucasian%20patients%20without%20DPD-based%20FP-dose%20adjustment.%20Main%20endpoint%20was%2012-week%20haematological%20or%20digestive%20G4-5%20toxicity.%20The%20value%20of%20DPYD%20variants%20%2A2A%5C%2Fp.D949V%5C%2F%2A13%20merged%2C%20HapB3%2C%20and%20MIR27A%20rs895819%20was%20evaluated%20using%20multivariable%20logistic%20models%20%28AUC%29.%5CnRESULTS%3A%20Among%2025%20eligible%20studies%2C%20complete%20clinical%20variables%20and%20primary%20endpoint%20were%20available%20in%2015%20studies%20%288733%20patients%29.%20Twelve-week%20G4-5%20toxicity%20prevalence%20was%207.3%25%20%28641%20events%29.%20The%20clinical%20model%20included%20age%2C%20sex%2C%20body%20mass%20index%2C%20schedule%20of%20FP-administration%2C%20concomitant%20anticancer%20drugs.%20Adding%20%2A2A%5C%2Fp.D949V%5C%2F%2A13%20variants%20%28at%20least%20one%20allele%2C%20prevalence%202.2%25%2C%20OR%209.5%20%5B95%25CI%206.7-13.5%5D%29%20significantly%20improved%20the%20model%20%28p%5Cu2009%3C%5Cu20090.0001%29.%20The%20addition%20of%20HapB3%20%28prevalence%204.0%25%2C%2098.6%25%20heterozygous%29%2C%20in%20spite%20of%20significant%20association%20with%20toxicity%20%28OR%201.8%20%5B95%25CI%201.2-2.7%5D%29%2C%20did%20not%20improve%20the%20model.%20MIR27A%20rs895819%20was%20not%20associated%20with%20toxicity%2C%20irrespective%20of%20DPYD%20variants.%5CnCONCLUSIONS%3A%20FUSAFE%20meta-analysis%20highlights%20the%20major%20relevance%20of%20DPYD%20%2A2A%5C%2Fp.D949V%5C%2F%2A13%20combined%20with%20clinical%20variables%20to%20identify%20patients%20at%20risk%20of%20very%20severe%20FP-related%20toxicity.%22%2C%22date%22%3A%222024-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41416-023-02517-2%22%2C%22ISSN%22%3A%221532-1827%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222024-03-13T10%3A19%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22JTP3IJLH%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Blanchet%20et%20al.%22%2C%22parsedDate%22%3A%222024-01-25%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBlanchet%2C%20Benoit%2C%20Alexandre%20Xu-Vuilard%2C%20Anne%20Jouinot%2C%20Florent%20Puisset%2C%20David%20Combarel%2C%20Olivier%20Huillard%2C%20F%26%23xE9%3Blicien%20Le%20Louedec%2C%20et%20al.%20%26%23x201C%3BExposure-Response%20Relationship%20of%20Cabozantinib%20in%20Patients%20with%20Metastatic%20Renal%20Cell%20Carcinoma%20Treated%20in%20Routine%20Care.%26%23x201D%3B%20%3Ci%3EBritish%20Journal%20of%20Cancer%3C%5C%2Fi%3E%2C%20January%2025%2C%202024.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41416-024-02585-y%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41416-024-02585-y%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Exposure-response%20relationship%20of%20cabozantinib%20in%20patients%20with%20metastatic%20renal%20cell%20carcinoma%20treated%20in%20routine%20care%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Blanchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Xu-Vuilard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Jouinot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Puisset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Combarel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Huillard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%5Cu00e9licien%22%2C%22lastName%22%3A%22Le%20Louedec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcus%22%2C%22lastName%22%3A%22Teixeira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronan%22%2C%22lastName%22%3A%22Flippot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Mourey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Albiges%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Pudlarz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Joly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Tournigand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Chauvin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alicja%22%2C%22lastName%22%3A%22Puszkiel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Decleves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Vidal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Goldwasser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Oudard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Medioni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann-Alexandre%22%2C%22lastName%22%3A%22Vano%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Interindividual%20pharmacokinetic%20variability%20may%20influence%20the%20clinical%20benefit%20or%20toxicity%20of%20cabozantinib%20in%20metastatic%20renal%20cell%20carcinoma%20%28mRCC%29.%20We%20aimed%20to%20investigate%20the%20exposure-toxicity%20and%20exposure-response%20relationship%20of%20cabozantinib%20in%20unselected%20mRCC%20patients%20treated%20in%20routine%20care.%5CnMETHODS%3A%20This%20ambispective%20multicenter%20study%20enrolled%20consecutive%20patients%20receiving%20cabozantinib%20in%20monotherapy.%20Steady-state%20trough%20concentration%20%28Cmin%2Css%29%20within%20the%20first%203%20months%20after%20treatment%20initiation%20was%20used%20for%20the%20PK%5C%2FPD%20analysis%20with%20dose-limiting%20toxicity%20%28DLT%29%20and%20survival%20outcomes.%20Logistic%20regression%20and%20Cox%20proportional-hazards%20models%20were%20used%20to%20identify%20the%20risk%20factors%20of%20DLT%20and%20inefficacy%20in%20patients%2C%20respectively.%5CnRESULTS%3A%20Seventy-eight%20mRCC%20patients%20were%20eligible%20for%20the%20statistical%20analysis.%20Fifty-two%20patients%20%2867%25%29%20experienced%20DLT%20with%20a%20median%20onset%20of%202.1%20months%20%2895%25CI%200.7-8.2%29.%20In%20multivariate%20analysis%2C%20Cmin%2Css%20was%20identified%20as%20an%20independent%20risk%20factor%20of%20DLT%20%28OR%201.46%2C%2095%25CI%20%5B1.04-2.04%5D%3B%20p%5Cu2009%3D%5Cu20090.029%29.%20PFS%20and%20OS%20were%20not%20statistically%20associated%20with%20the%20starting%20dose%20%28p%5Cu2009%3D%5Cu20090.81%20and%20p%5Cu2009%3D%5Cu20090.98%2C%20respectively%29.%20In%20the%20multivariate%20analysis%20of%20PFS%2C%20Cmin%2C%20ss%5Cu2009%3E%5Cu2009336%5Cu2009ng%5C%2FmL%20resulted%20in%20a%20hazard%20ratio%20of%200.28%20%2895%25CI%2C%200.10-0.77%2C%20p%5Cu2009%3D%5Cu20090.014%29.%20By%20contrast%2C%20Cmin%2C%20ss%5Cu2009%3E%5Cu2009336%5Cu2009ng%5C%2FmL%20was%20not%20statistically%20associated%20with%20longer%20OS.%5CnCONCLUSION%3A%20Early%20plasma%20drug%20monitoring%20may%20be%20useful%20to%20optimise%20cabozantinib%20treatment%20in%20mRCC%20patients%20treated%20in%20monotherapy%2C%20especially%20in%20frail%20patients%20starting%20at%20a%20lower%20than%20standard%20dose.%22%2C%22date%22%3A%222024-01-25%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41416-024-02585-y%22%2C%22ISSN%22%3A%221532-1827%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222024-04-03T10%3A00%3A32Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Lambert, Marie, Mathieu Alonso, Caroline Munzer, Marie-Christine Zimoch, Laurence Malard, Marion Gambart, Marie-Pierre Castex, Carla Martins, Marlène Pasquet, and Etienne Chatelut. “Prospective Validation of an Equation Based on Plasma Cystatin C for Monitoring the Glomerular Filtration Rate in Children Treated with Cisplatin or Ifosfamide for Cancer.” Cancer Chemotherapy and Pharmacology<\/i> 93, no. 4 (April 2024): 393–95. https:\/\/doi.org\/10.1007\/s00280-023-04597-6<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Le Teuff, Gwénaël, Nathalie Cozic, Jean-Christophe Boyer, Valérie Boige, Robert B. Diasio, Julien Taieb, Didier Meulendijks, et al. “Dihydropyrimidine Dehydrogenase Gene Variants for Predicting Grade 4-5 Fluoropyrimidine-Induced Toxicity: FUSAFE Individual Patient Data Meta-Analysis.” British Journal of Cancer<\/i> 130, no. 5 (March 2024): 808–18. https:\/\/doi.org\/10.1038\/s41416-023-02517-2<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Blanchet, Benoit, Alexandre Xu-Vuilard, Anne Jouinot, Florent Puisset, David Combarel, Olivier Huillard, Félicien Le Louedec, et al. “Exposure-Response Relationship of Cabozantinib in Patients with Metastatic Renal Cell Carcinoma Treated in Routine Care.” British Journal of Cancer<\/i>, January 25, 2024. https:\/\/doi.org\/10.1038\/s41416-024-02585-y<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][et_pb_toggle title=”PUBLICATIONS 2023″ open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_text_color=”#505659″ closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.22.1″ _module_preset=”default” title_text_color=”#ffffff” title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_font=”|600|||||||” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\tNMTDPBH9<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2023<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 38370<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-82a320f172837c288ad20f46a1dcc2a1%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22V25H5EUW%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ranchon%20et%20al.%22%2C%22parsedDate%22%3A%222023-10-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERanchon%2C%20Florence%2C%20%26%23xC9%3Btienne%20Chatelut%2C%20Juliette%20Lambert%2C%20Pierre%20Sesques%2C%20Constance%20Thibault%2C%20Isabelle%20Madelaine%2C%20Catherine%20Rioufol%2C%20V%26%23xE9%3Bronique%20Di%26%23xE9%3Bras%2C%20and%20Jean-Louis%20Cazin.%20%26%23x201C%3B%5BAntibody%20drug%20conjugates%20%28ADC%29%20and%20bispecific%20antibodies%20in%20oncology%26%23xA0%3B-%26%23xA0%3Breport%20of%20the%202022%26%23xA0%3BSaint%20Louis%20day%5D.%26%23x201D%3B%20%3Ci%3EBulletin%20Du%20Cancer%3C%5C%2Fi%3E%2C%20October%2010%2C%202023%2C%20S0007-4551%2823%2900345-4.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bulcan.2023.07.009%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bulcan.2023.07.009%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BAntibody%20drug%20conjugates%20%28ADC%29%20and%20bispecific%20antibodies%20in%20oncology%5Cu00a0-%5Cu00a0report%20of%20the%202022%5Cu00a0Saint%20Louis%20day%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Ranchon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c9tienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliette%22%2C%22lastName%22%3A%22Lambert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Sesques%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constance%22%2C%22lastName%22%3A%22Thibault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Madelaine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Rioufol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Di%5Cu00e9ras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Louis%22%2C%22lastName%22%3A%22Cazin%22%7D%5D%2C%22abstractNote%22%3A%22Antibody%20Drug%20Conjugates%20%28ADC%29%20and%20bispecific%20antibodies%20are%20booming%20and%20were%20the%20subject%20of%20the%20scientific%20event%20proposed%20by%20the%20French%20Society%20of%20Oncological%20Pharmacy%2C%20October%2013%2C%202022.%20An%20ADC%20is%20composed%20of%20the%20antibody%20targeting%20a%20receptor%20expressed%20on%20the%20tumor%20cell%2C%20the%20spacer%20making%20it%20possible%20to%20attach%20the%20cytotoxic%20to%20the%20antibody%20and%20to%20control%20its%20distribution%20in%20the%20body%2C%20and%20the%20cytotoxic.%20Therapeutic%20antibodies%2C%20monoclonal%20and%20conjugated%2C%20have%20particular%20pharmacokinetics.%20Unlike%20monoclonal%20antibodies%20for%20which%20the%20standard%20dose%20is%20most%20often%20fixed%2C%20this%20is%20expressed%20in%20mg%5C%2Fm2%20%28or%20mg%5C%2Fkg%29%20and%20capped%20at%202m2%20%28or%20100kg%29%20for%20conjugates.%20The%20linked%20cytotoxics%20are%20powerful%20cytotoxics%3A%20mitotic%20spindle%20poisons%20%28emtansine%2C%20monomethyl%20auristatin%20E%20or%20vedotin%29%2C%20topoisomerase%20I%20inhibitors%20%28deruxtecan%2C%20SN%2038%29%20or%20antibiotics%20%28ozogamicin%29.%20In%20senology%2C%20trastuzumab%20deruxtecan%20%28anti-HER2%29%20and%20sacituzumab%20govitecan%20%28anti-Trop%202%29%20are%20now%20modifying%20treatment%20standards%20for%20patients%20with%20metastatic%20breast%20cancer%2C%20respectively%20HER2%203X%20or%20HER2%5Cu00a0low%20and%20triple%20negative.%20In%20metastatic%20bladder%20cancer%2C%20enfortumab%20vedotin%20%28anti-nectin%204%29%20is%20positioned%20as%20the%202nd%20line%20of%20treatment.%20Bispecific%20antibodies%2C%20on%20the%20other%20hand%2C%20are%20able%20to%20target%20two%20epitopes%2C%20an%20antigen%20specific%20to%20a%20tumor%20cell%20and%20one%20to%20an%20immune%20cell%2C%20allowing%20a%20bridge%20between%20the%20killer%20immune%20cells%20and%20the%20tumor%20cells.%20For%20lymphoma%20proliferation%2C%20many%20bispecific%20antibodies%20are%20in%20development.%20The%20most%20advanced%20are%20glofitamab%2C%20epcoritamab%20and%20mosunetuzumab%2C%20which%20target%20the%20CD20%5Cu00a0of%20B%20lymphocytes%20and%20the%20CD3%5Cu00a0of%20T%20lymphocytes.%20Bispecific%20antibodies%20are%20also%20emerging%20in%20the%20treatment%20of%20myeloma%20with%20teclistamab%20and%20elranatamab%20%28anti-CD3%5Cu00a0and%20anti-BCMA%29%20or%20talquetamab%20%28anti-GPRC5D%20and%20anti-CD3%29.%20Conjugated%20antibodies%2C%20and%20more%20recently%20bispecific%20antibodies%2C%20are%20potential%20game%20changers%20in%20cancer%20treatment%20and%20researchs%20are%20needed%20to%20improve%20their%20efficacy%20and%20safety.%22%2C%22date%22%3A%222023-10-10%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.bulcan.2023.07.009%22%2C%22ISSN%22%3A%221769-6917%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222023-10-16T14%3A19%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22M3NC5E5C%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Al%20Saati%20et%20al.%22%2C%22parsedDate%22%3A%222023-09-20%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAl%20Saati%2C%20Ayman%2C%20Pierre%20Vande%20Perre%2C%20Julien%20Plenecassagnes%2C%20Julia%20Gilhodes%2C%20Nils%20Monselet%2C%20Bastien%20Cabarrou%2C%20Norbert%20Lignon%2C%20et%20al.%20%26%23x201C%3BMultigene%20Panel%20Sequencing%20Identifies%20a%20Novel%20Germline%20Mutation%20Profile%20in%20Male%20Breast%20Cancer%20Patients.%26%23x201D%3B%20%3Ci%3EInternational%20Journal%20of%20Molecular%20Sciences%3C%5C%2Fi%3E%2024%2C%20no.%2018%20%28September%2020%2C%202023%29%3A%2014348.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fijms241814348%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fijms241814348%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Multigene%20Panel%20Sequencing%20Identifies%20a%20Novel%20Germline%20Mutation%20Profile%20in%20Male%20Breast%20Cancer%20Patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ayman%22%2C%22lastName%22%3A%22Al%20Saati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Vande%20Perre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Plenecassagnes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Gilhodes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nils%22%2C%22lastName%22%3A%22Monselet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Cabarrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norbert%22%2C%22lastName%22%3A%22Lignon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Telly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Perello-Lestrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Viviane%22%2C%22lastName%22%3A%22Feillel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Staub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edith%22%2C%22lastName%22%3A%22Chipoulet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22Collet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Gladieff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Toulas%22%7D%5D%2C%22abstractNote%22%3A%22Even%20though%20male%20breast%20cancer%20%28MBC%29%20risk%20encompasses%20both%20genetic%20and%20environmental%20aetiologies%2C%20the%20primary%20risk%20factor%20is%20a%20germline%20pathogenic%20variant%20%28PV%29%20or%20likely%20pathogenic%20variant%20%28LPV%29%20in%20BRCA2%2C%20BRCA1%20and%5C%2For%20PALB2%20genes.%20To%20identify%20new%20potential%20MBC-specific%20predisposition%20genes%2C%20we%20sequenced%20a%20panel%20of%20585%20carcinogenesis%20genes%20in%20an%20MBC%20cohort%20without%20BRCA1%5C%2FBRCA2%5C%2FPALB2%20PV%5C%2FLPV.%20We%20identified%2014%20genes%20carrying%20rare%20PVs%5C%2FLPVs%20in%20the%20MBC%20population%20versus%20noncancer%20non-Finnish%20European%20men%2C%20predominantly%20coding%20for%20DNA%20repair%20and%20maintenance%20of%20genomic%20stability%20proteins.%20We%20identified%20for%20the%20first%20time%20PVs%5C%2FLPVs%20in%20PRCC%20%28pre-mRNA%20processing%29%2C%20HOXA9%20%28transcription%20regulation%29%2C%20RECQL4%20and%20WRN%20%28maintenance%20of%20genomic%20stability%29%20as%20well%20as%20in%20genes%20involved%20in%20other%20cellular%20processes.%20To%20study%20the%20specificity%20of%20this%20MBC%20PV%5C%2FLPV%20profile%2C%20we%20examined%20whether%20variants%20in%20the%20same%20genes%20could%20be%20detected%20in%20a%20female%20breast%20cancer%20%28FBC%29%20cohort%20without%20BRCA1%5C%2FBRCA2%5C%2FPALB2%20PV%5C%2FLPV.%20Only%205%5C%2F109%20women%20%284.6%25%29%20carried%20a%20PV%5C%2FLPV%20versus%2018%5C%2F85%20men%20%2821.2%25%29%20on%20these%20genes.%20FBC%20did%20not%20carry%20any%20PV%5C%2FLPV%20on%2011%20of%20these%20genes.%20Although%205.9%25%20of%20the%20MBC%20cohort%20carried%20PVs%5C%2FLPVs%20in%20PALLD%20and%20ERCC2%2C%20neither%20of%20these%20genes%20were%20altered%20in%20our%20FBC%20cohort.%20Our%20data%20suggest%20that%20in%20addition%20to%20BRCA1%5C%2FBRCA2%5C%2FPALB2%2C%20other%20genes%20involved%20in%20DNA%20repair%5C%2Fmaintenance%20or%20genomic%20stability%20as%20well%20as%20cell%20adhesion%20may%20form%20a%20specific%20MBC%20PV%5C%2FLPV%20signature.%22%2C%22date%22%3A%222023-09-20%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fijms241814348%22%2C%22ISSN%22%3A%221422-0067%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222023-09-28T12%3A28%3A54Z%22%7D%7D%2C%7B%22key%22%3A%224RRFLWH9%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Boumaza%20et%20al.%22%2C%22parsedDate%22%3A%222023-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBoumaza%2C%20Xavier%2C%20Margaux%20Lafaurie%2C%20Emmanuel%20Treiner%2C%20Ondine%20Walter%2C%20Gregory%20Pugnet%2C%20Guillaume%20Martin-Blondel%2C%20Damien%20Biotti%2C%20et%20al.%20%26%23x201C%3BInfectious%20Risk%20When%20Prescribing%20Rituximab%20in%20Patients%20with%20Hypogammaglobulinemia%20Acquired%20in%20the%20Setting%20of%20Autoimmune%20Diseases.%26%23x201D%3B%20%3Ci%3EInternational%20Immunopharmacology%3C%5C%2Fi%3E%20120%20%28July%202023%29%3A%20110342.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.intimp.2023.110342%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.intimp.2023.110342%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Infectious%20risk%20when%20prescribing%20rituximab%20in%20patients%20with%20hypogammaglobulinemia%20acquired%20in%20the%20setting%20of%20autoimmune%20diseases%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Boumaza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margaux%22%2C%22lastName%22%3A%22Lafaurie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Treiner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ondine%22%2C%22lastName%22%3A%22Walter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Pugnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Martin-Blondel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Biotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Constantin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tauber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Puisset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Moulis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Alric%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22Renaudineau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Chauveau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Sailler%22%7D%5D%2C%22abstractNote%22%3A%22We%20conducted%20a%20single-centre%20retrospective%20cohort%20study%20in%20a%20French%20University%20Hospital%20between%202010%20and%202018%20to%20describe%20the%20risk%20of%20severe%20infectious%20event%20%28SIE%29%20within%202%5Cu00a0years%20after%20the%20date%20of%20first%20rituximab%20infusion%20%28T0%29%20prescribed%20after%20the%20evidence%20of%20acquired%20hypogammaglobulinemia%20%28gamma%20globulins%20%5BGG%5D%5Cu00a0%5Cu2264%5Cu00a06%5Cu00a0g%5C%2FL%29%20in%20the%20setting%20of%20autoimmune%20diseases%20%28AID%29%20other%20than%20rheumatoid%20arthritis.%20SIE%20occurred%20in%2026%20out%20of%20121%20included%20patients.%20Two%20years%20cumulative%20incidence%20rates%20were%2012.7%5Cu00a0%25%20%2895%5Cu00a0%25%20CI%205.1-23.9%29%20in%20the%20multiple%20sclerosis%5C%2Fneuromyelitis%20optica%20spectrum%20disorder%20group%20%28n%5Cu00a0%3D%5Cu00a048%29%2C%2027.6%5Cu00a0%25%20%2895%5Cu00a0%25%20CI%2015.7-40.9%29%20in%20the%20ANCA-associated%20vasculitis%20group%20%28n%5Cu00a0%3D%5Cu00a048%29%20and%2030.6%5Cu00a0%25%20%2895%5Cu00a0%25%20CI%2013.1-50.3%29%20in%20the%20%27other%20AID%27%20group%20%28n%5Cu00a0%3D%5Cu00a025%29.%20Median%20GG%20level%20at%20T0%20was%205.3%5Cu00a0g%5C%2Fl%20%28IQR%204.1-5.6%29%20in%20the%20%27SIE%27%20group%20and%205.6%5Cu00a0g%5C%2Fl%20%28IQR%204.7-5.8%29%20in%20the%20%27no%20SIE%27%20group%20%28p%5Cu00a0%3D%5Cu00a00.04%29.%20In%20regression%20analysis%2C%20risk%20of%20SIE%20increased%20with%20Charlson%20comorbidity%20index%5Cu00a0%5Cu2265%5Cu00a03%20%28OR%202.77%3B%2095%5Cu00a0%25%20CI%201.01-7.57%29%2C%20lung%20disease%20%28OR%203.20%3B%2095%5Cu00a0%25%20CI%201.27-7.99%29%2C%20GG%5Cu00a0%3C%5Cu00a04%5Cu00a0g%5C%2FL%20%28OR%203.39%3B%2095%5Cu00a0%25%20CI%201.02-11.19%29%2C%20concomitant%20corticosteroid%20therapy%20%28OR%204.13%3B%2095%5Cu00a0%25%20CI%201.63-10.44%29%2C%20previous%20cyclophosphamide%20exposure%20%28OR%202.69%3B%2095%5Cu00a0%25%20CI%201.10-6.61%29%2C%20a%20lymphocyte%20count%5Cu00a0%3C%5Cu00a01000%20cells%5C%2F%5Cu00b5L%20%28OR%202.86%3B%2095%5Cu00a0%25%20CI%201.12-7.21%29%20and%20absence%20of%20pneumococcal%20vaccination%20%28OR%203.50%3B%2095%5Cu00a0%25%20CI%201.41-8.70%29.%20These%20results%20may%20help%20to%20inform%20clinical%20decision%20when%20considering%20a%20treatment%20by%20rituximab%20in%20immunosuppressed%20AID%20patients%20with%20hypogammaglobulinemia.%22%2C%22date%22%3A%222023-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.intimp.2023.110342%22%2C%22ISSN%22%3A%221878-1705%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222023-08-24T13%3A56%3A29Z%22%7D%7D%2C%7B%22key%22%3A%22YC9CWDF9%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Valentin%20et%20al.%22%2C%22parsedDate%22%3A%222023-06-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EValentin%2C%20Thibaud%2C%20Marie%20Lambert%2C%20L%26%23xE9%3Bonor%20Chaltiel%2C%20Ben%20Allal%2C%20Mourad%20Mseddi%2C%20Malika%20Yakoubi%2C%20Christine%20Chevreau%2C%20et%20al.%20%26%23x201C%3BPopulation%20Pharmacokinetic%20Analysis%20Reveals%20No%20Impact%20of%20Aprepitant%20on%20the%20Pharmacokinetics%20of%20Ifosfamide%2C%202-Dechloroifosfamide%2C%20and%203-Dechloroifosfamide.%26%23x201D%3B%20%3Ci%3EEuropean%20Journal%20of%20Pharmaceutical%20Sciences%3A%20Official%20Journal%20of%20the%20European%20Federation%20for%20Pharmaceutical%20Sciences%3C%5C%2Fi%3E%20185%20%28June%201%2C%202023%29%3A%20106420.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejps.2023.106420%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejps.2023.106420%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Population%20pharmacokinetic%20analysis%20reveals%20no%20impact%20of%20aprepitant%20on%20the%20pharmacokinetics%20of%20ifosfamide%2C%202-dechloroifosfamide%2C%20and%203-dechloroifosfamide%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaud%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Lambert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00e9onor%22%2C%22lastName%22%3A%22Chaltiel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ben%22%2C%22lastName%22%3A%22Allal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mourad%22%2C%22lastName%22%3A%22Mseddi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Malika%22%2C%22lastName%22%3A%22Yakoubi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Chevreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maud%22%2C%22lastName%22%3A%22Toulmonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nelly%22%2C%22lastName%22%3A%22Firmin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20Several%20case%20reports%20and%20retrospective%20series%20have%20clearly%20pointed%20to%20the%20role%20of%20aprepitant%2C%20an%20antiemetic%20drug%2C%20in%20the%20development%20of%20encephalopathy%20when%20used%20with%20ifosfamide.%20Described%20as%20an%20inhibitor%20of%20several%20CYP%20metabolic%20pathways%2C%20aprepitant%20is%20suspected%20of%20drug-drug-interaction%20on%20ifosfamide%20pharmacokinetics.%20The%20pharmacokinetics%20of%20ifosfamide%20and%20two%20of%20its%20metabolites%20%282-dechloroifosfamide%20and%203-dechloroifosfamide%29%20was%20studied%20in%20patients%20with%20soft%20tissue%20sarcomas%20to%20evaluate%20the%20impact%20of%20aprepitant%20administration.%5CnMETHODS%3A%20A%20population%20pharmacokinetic%20approach%20was%20applied%20to%20analyze%20data%20obtained%20in%2042%20patients%20at%20cycle%201%20%28without%20aprepitant%29%20and%20cycle%202%20%28with%20aprepitant%20for%2034%20of%20them%29.%5CnRESULTS%3A%20A%20previously%20published%20pharmacokinetic%20model%20including%20a%20time-dependency%20process%20well%20fit%20the%20data.%20Aprepitant%20had%20no%20impact%20on%20ifosfamide%20or%20its%20two%20metabolite%20pharmacokinetic%20parameters.%5CnCONCLUSION%3A%20This%20study%20suggests%20that%20aprepitant%20does%20not%20lead%20to%20a%20significant%20modification%20of%20ifosfamide%20metabolization%2C%20even%20though%20other%20metabolites%20such%20as%204%20hydroxyifosfamide%20and%20chloroacetaldehyde%20were%20not%20monitored%20in%20this%20study.%22%2C%22date%22%3A%222023-06-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ejps.2023.106420%22%2C%22ISSN%22%3A%221879-0720%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222023-08-24T13%3A53%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22YSSR4ZE3%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Royer%20et%20al.%22%2C%22parsedDate%22%3A%222023-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERoyer%2C%20B.%2C%20M.%20Launay%2C%20J.%20Ciccolini%2C%20L.%20Derain%2C%20F.%20Parant%2C%20F.%20Thomas%2C%20and%20J.%20Guitton.%20%26%23x201C%3BImpact%20of%20Renal%20Impairment%20on%20Dihydropyrimidine%20Dehydrogenase%20%28DPD%29%20Phenotyping.%26%23x201D%3B%20%3Ci%3EESMO%20Open%3C%5C%2Fi%3E%208%2C%20no.%203%20%28June%202023%29%3A%20101577.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.esmoop.2023.101577%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.esmoop.2023.101577%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20renal%20impairment%20on%20dihydropyrimidine%20dehydrogenase%20%28DPD%29%20phenotyping%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Royer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Launay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Ciccolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Derain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Parant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Guitton%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20chemotherapeutic%20agent%205-fluorouracil%20%285-FU%29%20is%20catabolized%20by%20dihydropyrimidine%20dehydrogenase%20%28DPD%29%2C%20the%20deficiency%20of%20which%20may%20lead%20to%20severe%20toxicity%20or%20death.%20Since%202019%2C%20DPD%20deficiency%20testing%2C%20based%20on%20uracilemia%2C%20is%20mandatory%20in%20France%20and%20recommended%20in%20Europe%20before%20initiating%20fluoropyrimidine-based%20regimens.%20However%2C%20it%20has%20been%20recently%20shown%20that%20renal%20impairment%20may%20impact%20uracil%20concentration%20and%20thus%20DPD%20phenotyping.%5CnPATIENTS%20AND%20METHODS%3A%20The%20impact%20of%20renal%20function%20on%20uracilemia%20and%20DPD%20phenotype%20was%20studied%20on%203039%20samples%20obtained%20from%20three%20French%20centers.%20We%20also%20explored%20the%20influence%20of%20dialysis%20and%20measured%20glomerular%20filtration%20rate%20%28mGFR%29%20on%20both%20parameters.%20Finally%2C%20using%20patients%20as%20their%20own%20controls%2C%20we%20assessed%20as%20to%20what%20extent%20modifications%20in%20renal%20function%20impacted%20uracilemia%20and%20DPD%20phenotyping.%5CnRESULTS%3A%20We%20observed%20that%20uracilemia%20and%20DPD-deficient%20phenotypes%20increased%20concomitantly%20to%20the%20severity%20of%20renal%20impairment%20based%20on%20the%20estimated%20GFR%2C%20independently%20and%20more%20critically%20than%20hepatic%20function.%20This%20observation%20was%20confirmed%20with%20the%20mGFR.%20The%20risk%20of%20being%20classified%20%27DPD%20deficient%27%20based%20on%20uracilemia%20was%20statistically%20higher%20in%20patients%20with%20renal%20impairment%20or%20dialyzed%20if%20uracilemia%20was%20measured%20before%20dialysis%20but%20not%20after.%20Indeed%2C%20the%20rate%20of%20DPD%20deficiency%20decreased%20from%2086.4%25%20before%20dialysis%20to%2013.7%25%20after.%20Moreover%2C%20for%20patients%20with%20transient%20renal%20impairment%2C%20the%20rate%20of%20DPD%20deficiency%20dropped%20dramatically%20from%2083.3%25%20to%2016.7%25%20when%20patients%20restored%20their%20renal%20function%2C%20especially%20in%20patients%20with%20an%20uracilemia%20close%20to%2016%20ng%5C%2Fml.%5CnCONCLUSIONS%3A%20DPD%20deficiency%20testing%20using%20uracilemia%20could%20be%20misleading%20in%20patients%20with%20renal%20impairment.%20When%20possible%2C%20uracilemia%20should%20be%20reassessed%20in%20case%20of%20transient%20renal%20impairment.%20For%20patients%20under%20dialysis%2C%20testing%20of%20DPD%20deficiency%20should%20be%20carried%20out%20on%20samples%20taken%20after%20dialysis.%20Hence%2C%205-FU%20therapeutic%20drug%20monitoring%20would%20be%20particularly%20helpful%20to%20guide%20dose%20adjustments%20in%20patients%20with%20elevated%20uracil%20and%20renal%20impairment.%22%2C%22date%22%3A%222023-06%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.esmoop.2023.101577%22%2C%22ISSN%22%3A%222059-7029%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222023-07-03T12%3A53%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22IUDL2EG7%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22de%20Jong%20et%20al.%22%2C%22parsedDate%22%3A%222023-03-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EJong%2C%20Loek%20A.%20W.%20de%2C%20Marie%20Lambert%2C%20Nielka%20P.%20van%20Erp%2C%20Lukas%20de%20Vries%2C%20Etienne%20Chatelut%2C%20and%20Petronella%20B.%20Ottevanger.%20%26%23x201C%3BSystemic%20Exposure%20to%20Cisplatin%20and%20Paclitaxel%20after%20Intraperitoneal%20Chemotherapy%20in%20Ovarian%20Cancer.%26%23x201D%3B%20%3Ci%3ECancer%20Chemotherapy%20and%20Pharmacology%3C%5C%2Fi%3E%2C%20March%209%2C%202023.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00280-023-04512-z%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00280-023-04512-z%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Systemic%20exposure%20to%20cisplatin%20and%20paclitaxel%20after%20intraperitoneal%20chemotherapy%20in%20ovarian%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loek%20A.%20W.%22%2C%22lastName%22%3A%22de%20Jong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Lambert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nielka%20P.%22%2C%22lastName%22%3A%22van%20Erp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lukas%22%2C%22lastName%22%3A%22de%20Vries%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Petronella%20B.%22%2C%22lastName%22%3A%22Ottevanger%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20To%20determine%20the%20systemic%20exposure%20to%20cisplatin%20and%20paclitaxel%20after%20adjuvant%20intraperitoneal%20administration%20in%20patients%20with%20advanced%20ovarian%20cancer%20who%20underwent%20primary%20debulking%20surgery.%20This%20could%20provide%20an%20explanation%20for%20the%20high%20incidence%20of%20systemic%20adverse%20events%20associated%20with%20this%20treatment%20regimen.%5CnMETHODS%3A%20This%20is%20a%20prospective%20pharmacokinetic%20study%20in%20patients%20with%20newly%20diagnosed%20advanced%20ovarian%20cancer%20who%20were%20treated%20with%20intraperitoneal%20administered%20cisplatin%20and%20paclitaxel.%20Plasma%20and%20peritoneal%20fluid%20samples%20were%20obtained%20during%20the%20first%20treatment%20cycle.%20The%20systemic%20exposure%20to%20cisplatin%20and%20paclitaxel%20was%20determined%20and%20compared%20to%20previously%20published%20exposure%20data%20after%20intravenous%20administration.%20An%20exploratory%20analysis%20was%20performed%20to%20investigate%20the%20relation%20between%20systemic%20exposure%20to%20cisplatin%20and%20the%20occurrence%20of%20adverse%20events.%5CnRESULTS%3A%20Pharmacokinetics%20of%20ultrafiltered%20cisplatin%20were%20studied%20in%20eleven%20evaluable%20patients.%20The%20geometric%20mean%20%5Brange%5D%20peak%20plasma%20concentration%20%28Cmax%29%20and%20area%20under%20the%20plasma-concentration%20time%20curve%20%28AUC0-24%5Cu00a0h%29%20for%20cisplatin%20was%202.2%20%5B1.8-2.7%5D%20mg%5C%2FL%20and%2010.1%20%5B9.0-12.6%5D%20mg%5Cu00a0h%5C%2FL%2C%20with%20a%20coefficient%20of%20variation%20%28CV%25%29%20of%2014%20and%2013.0%25%2C%20respectively.%20The%20geometric%20mean%20%5Brange%5D%20observed%20plasma%20concentration%20of%20paclitaxel%20was%200.06%20%5B0.04-0.08%5D%20mg%5C%2FL.%20No%20correlation%20was%20found%20between%20systemic%20exposure%20to%20ultrafiltered%20cisplatin%20and%20adverse%20events.%5CnCONCLUSION%3A%20Systemic%20exposure%20to%20ultrafiltered%20cisplatin%20after%20intraperitoneal%20administration%20is%20high.%20In%20addition%20to%20a%20local%20effect%2C%20this%20provides%20a%20pharmacological%20explanation%20for%20high%20incidence%20of%20adverse%20events%20seen%20after%20intraperitoneal%20administration%20of%20high-dose%20cisplatin.%20The%20study%20was%20registered%20at%20ClinicalTrials.gov%20under%20registration%20number%20NCT02861872.%22%2C%22date%22%3A%222023-03-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00280-023-04512-z%22%2C%22ISSN%22%3A%221432-0843%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222023-03-13T14%3A27%3A12Z%22%7D%7D%2C%7B%22key%22%3A%22Z49MW5GQ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Laloi%20et%20al.%22%2C%22parsedDate%22%3A%222023-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELaloi%2C%20Louise%2C%20Natacha%20Chaumard%20Billotey%2C%20Pierre-Yves%20Dumas%2C%20Franciane%20Paul%2C%20Alban%20Villate%2C%20C%26%23xE9%3Blestine%20Simand%2C%20Luc%20Fornecker%2C%20et%20al.%20%26%23x201C%3BRetrospective%2C%20Real-Life%20Study%20of%20Venetoclax%20plus%20Azacitidine%20or%20Low-Dose%20Cytarabine%20in%20French%20Patients%20with%20Acute%20Myeloid%20Leukemia%20Ineligible%20for%20Intensive%20Chemotherapy.%26%23x201D%3B%20%3Ci%3ECancer%20Medicine%3C%5C%2Fi%3E%2012%2C%20no.%206%20%28March%202023%29%3A%207175%26%23x2013%3B81.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcam4.5459%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcam4.5459%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Retrospective%2C%20real-life%20study%20of%20venetoclax%20plus%20azacitidine%20or%20low-dose%20cytarabine%20in%20French%20patients%20with%20acute%20myeloid%20leukemia%20ineligible%20for%20intensive%20chemotherapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louise%22%2C%22lastName%22%3A%22Laloi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natacha%20Chaumard%22%2C%22lastName%22%3A%22Billotey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Yves%22%2C%22lastName%22%3A%22Dumas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franciane%22%2C%22lastName%22%3A%22Paul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alban%22%2C%22lastName%22%3A%22Villate%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9lestine%22%2C%22lastName%22%3A%22Simand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Fornecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Puisset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Bertoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%20Boissard%22%2C%22lastName%22%3A%22Simonet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kamel%22%2C%22lastName%22%3A%22Laribi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dyhia%22%2C%22lastName%22%3A%22Houyou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alberto%22%2C%22lastName%22%3A%22Santagostino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabrielle%20Roth%22%2C%22lastName%22%3A%22Guepin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Guerineau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reza%22%2C%22lastName%22%3A%22Tabrizi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Hunault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lien%22%2C%22lastName%22%3A%22Giltat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22El%5Cu00e9onore%22%2C%22lastName%22%3A%22Kaphan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude%22%2C%22lastName%22%3A%22Bulabois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Cartet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9ment%22%2C%22lastName%22%3A%22Rocher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Lachenal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Morisset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22R%5Cu00e9cher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Pigneux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amine%22%2C%22lastName%22%3A%22Belhabri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mauricette%22%2C%22lastName%22%3A%22Michallet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Sophie%22%2C%22lastName%22%3A%22Michallet%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Recently%2C%20the%20combination%20of%20venetoclax%20plus%20a%20hypomethylating%20agent%20%28HMA%3B%20azacitidine%20ordecitabine%29%20or%20low-dose%20cytarabine%20%28LDAC%29%20showed%20promise%20in%20Phase%20III%20trials%20in%20previously%20untreated%20AML.%20In%20France%20at%20the%20time%20of%20this%20study%2C%20venetoclax%20was%20not%20yet%20approved%20for%20AML%20and%20there%20were%20therefore%20no%20formal%20usage%20recommendations.%20Here%20we%20report%20the%20first%20study%20in%20a%20French%20cohort%20that%20assessed%20venetoclax%20in%20combination%20with%20existing%20treatments%20for%20AML%20under%20real-life%20conditions.%5CnMETHOD%3A%20This%20retrospective%2C%20real-life%20study%20collected%20data%20on%20venetoclax%20use%20and%20management%20in%20a%20French%20cohort%20with%20acute%20myeloid%20leukemia%20%28AML%29%20ineligible%20for%20intensive%20chemotherapy.%5CnRESULT%3A%20Of%20118%20patients%2C%2081%20were%20in%20second%20line%5C%2Fbeyond%20%2871.6%25%20also%20hypomethylating%20agent%20%5BHMA%5D%3B%2023.5%25%20lowdose%20cytarabine%20%5BLDAC%5D%29%20and%2037%20in%20first%20line.%20For%20venetoclax%20initiation%2C%2057.3%25%20underwent%20ramp%20up%20and%2074.6%25%20were%20hospitalized.%20Median%20venetoclax%20duration%20was%202.5%20months%20%28range%200.03-16.2%29.%20With%20all%20treatment%20lines%20and%20regimens%2C%20most%20common%20grade%203%5C%2F4%20adverse%20events%20were%20hematologic%20%28overall%2096.4%25%20of%20patients%29%20and%20infections%20%2857.1%25%29.%20Dosage%20adjustments%20for%20drug%20interactions%20and%20safety%20varied%20between%20centers.%20In%20second-line%5C%2Fbeyond%2C%20median%20progression-free%20survival%20was%204.0%20months%20%2895%25%20confidence%20interval%20%5BCI%5D%202.7-12.8%29%20with%20venetoclax-HMA%20and%203.4%20months%20%281.3-8.9%29%20with%20venetoclax-LDAC%3B%20overall%20response%20rate%20was%2051.9%25%20and%2041.2%25%2C%20respectively.%20Thus%2C%20we%20showed%20that%20venetoclax-based%20treatment%20yields%20promising%20findings%20in%20patients%20with%20AML%2C%20but%20to%20address%20treatment%20complexity%2C%20practice%20harmonization%20is%20needed.%22%2C%22date%22%3A%222023-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fcam4.5459%22%2C%22ISSN%22%3A%222045-7634%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222023-08-24T13%3A55%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22WRJWJ74Q%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Poumeaud%20et%20al.%22%2C%22parsedDate%22%3A%222023-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPoumeaud%2C%20Fran%26%23xE7%3Bois%2C%20Florence%20Dalenc%2C%20Quentin%20Mathevet%2C%20Aur%26%23xE9%3Blie%20Brice%2C%20Audrey%20Eche-Gass%2C%20Eleonora%20De%20Maio%20D%26%23x2019%3BEsposito%2C%20Cl%26%23xE9%3Bmence%20Brac-de-la-Perriere%2C%20and%20Fabienne%20Thomas.%20%26%23x201C%3BPhenotype%5C%2FGenotype%20Discrepancy%20of%20DPD%20Deficiency%20Screening%20in%20a%20Patient%20With%20Severe%20Capecitabine%20Toxicity%3A%20A%20Case%20Report.%26%23x201D%3B%20%3Ci%3EJCO%20Precision%20Oncology%3C%5C%2Fi%3E%207%20%28March%202023%29%3A%20e2200508.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1200%5C%2FPO.22.00508%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1200%5C%2FPO.22.00508%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Phenotype%5C%2FGenotype%20Discrepancy%20of%20DPD%20Deficiency%20Screening%20in%20a%20Patient%20With%20Severe%20Capecitabine%20Toxicity%3A%20A%20Case%20Report%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Poumeaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Dalenc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Quentin%22%2C%22lastName%22%3A%22Mathevet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Brice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Eche-Gass%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eleonora%22%2C%22lastName%22%3A%22De%20Maio%20D%27Esposito%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Brac-de-la-Perriere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Thomas%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1200%5C%2FPO.22.00508%22%2C%22ISSN%22%3A%222473-4284%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222023-03-21T14%3A13%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22UW5LBI9E%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Puisset%20et%20al.%22%2C%22parsedDate%22%3A%222023-02-28%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPuisset%2C%20Florent%2C%20F%26%23xE9%3Blicien%20Le%20Louedec%2C%20Florence%20Dalenc%2C%20Lor%26%23xE8%3Bne%20Verguet%2C%20Eleonora%20De%20Maio%2C%20Jean%20Louis%20Lacaze%2C%20Marion%20Montastruc%2C%20et%20al.%20%26%23x201C%3BInvestigating%20the%20Clinical%20Impact%20of%20Dose-Banding%20for%20Weekly%20Paclitaxel%20in%20Patients%20with%20Breast%20Cancer%3A%20A%20Retrospective%20and%20Monocentric%20Study.%26%23x201D%3B%20%3Ci%3EBritish%20Journal%20of%20Clinical%20Pharmacology%3C%5C%2Fi%3E%2C%20February%2028%2C%202023.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbcp.15702%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbcp.15702%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Investigating%20the%20clinical%20impact%20of%20dose-banding%20for%20weekly%20paclitaxel%20in%20patients%20with%20breast%20cancer%3A%20a%20retrospective%20and%20monocentric%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Puisset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%5Cu00e9licien%22%2C%22lastName%22%3A%22Le%20Louedec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Dalenc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lor%5Cu00e8ne%22%2C%22lastName%22%3A%22Verguet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eleonora%22%2C%22lastName%22%3A%22De%20Maio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Louis%22%2C%22lastName%22%3A%22Lacaze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Montastruc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mony%22%2C%22lastName%22%3A%22Ung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Vinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Perriat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Pacher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lanie%20White%22%2C%22lastName%22%3A%22Koning%22%7D%5D%2C%22abstractNote%22%3A%22AIM%3A%20Dose-Banding%20%28DB%29%20consists%20in%20approximating%20the%20theoretical%20dose%20of%20anticancer%20drugs%20calculated%20according%20to%20the%20body%20surface%20area%20%28Dose-BSA%29%20of%20patients.%20This%20concept%20is%20supported%20by%20pharmacokinetic%20but%20not%20by%20clinical%20data.%20The%20aim%20of%20this%20study%20was%20to%20assess%20the%20clinical%20outcome%20of%20DB%20defined%20as%20dose-fitting%20up%20to%20%2B%5C%2F-10%25.%5CnMETHOD%3A%20This%20was%20a%20retrospective%20study%20conducted%20in%20patients%20receiving%20weekly%20paclitaxel%20in%20neoadjuvant%20%28NAT%29%20and%20metastatic%20%28M%2B%29%20settings.%20Three%20groups%20of%20patients%20were%20considered%20according%20to%20type%20of%20paclitaxel%20dosing%3A%20Dose-BSA%2C%20DB%20approximated%20down%20%28DB-Low%29%20and%20DB%20approximated%20up%20%28DB-High%29.%20Efficacy%20was%20evaluated%20by%20the%20rate%20of%20pathological%20complete%20response%20%28pCR%29%20for%20patients%20in%20NAT%20setting%20and%20by%20the%20median%20of%20progression%20free%20survival%20%28PFS%29%20plus%20overall%20survival%20%28OS%29%20for%20those%20in%20M%2B%20setting.%20Toxicity%20and%20efficacy%20were%20compared%20in%20the%203%20groups.%5CnRESULTS%3A%20A%20total%20of%20224%20and%20209%20patients%20were%20assessable%20in%20the%20M%2B%20and%20NAT%20settings%20respectively.%20A%20toxic%20event%20was%20observed%20for%2031.7%25%20and%2027.3%25%20in%20M%2B%20and%20NAT%20respectively.%20The%20rate%20of%20pCR%20was%2041.6%25%20in%20NAT.%20The%20median%20PFS%20was%205.2%20%5B4.1-5.8%5D%20and%20OS%20was%2016.3%20%5B14.6-18.4%5D%20months%20for%20patients%20in%20M%2B.%20Efficacy%20and%20toxicity%20were%20not%20different%20in%20DB-Low%20and%20DB-High%20group%20compared%20to%20Dose-BSA%20group.%5CnCONCLUSION%3A%20DB%20with%20approximated%20doses%20up%20to%20%2B%5C%2F-10%25%20does%20not%20seem%20to%20influence%20clinical%20outcome%20of%20patients%20treated%20with%20weekly%20paclitaxel.%20This%20is%20the%20first%20study%20to%20include%20clinical%20observations%20which%20lends%20support%20to%20DB%20as%20a%20safe%20and%20effective%20dosing%20method.%22%2C%22date%22%3A%222023-02-28%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fbcp.15702%22%2C%22ISSN%22%3A%221365-2125%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222023-03-03T09%3A43%3A28Z%22%7D%7D%2C%7B%22key%22%3A%22AE8FF3MU%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Overbeek%20et%20al.%22%2C%22parsedDate%22%3A%222023-02%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EOverbeek%2C%20J.%20K.%2C%20R.%20Ter%20Heine%2C%20H.%20M.%20W.%20Verheul%2C%20E.%20Chatelut%2C%20M.%20A.%20Rudek%2C%20H.%20Gurney%2C%20R.%20Plummer%2C%20et%20al.%20%26%23x201C%3BOff-Label%2C%20but%20on%20Target%3A%20The%20Evidence%20Needed%20to%20Implement%20Alternative%20Dosing%20Regimens%20of%20Anticancer%20Drugs.%26%23x201D%3B%20%3Ci%3EESMO%20Open%3C%5C%2Fi%3E%208%2C%20no.%201%20%28February%202023%29%3A%20100749.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.esmoop.2022.100749%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.esmoop.2022.100749%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Off-label%2C%20but%20on%20target%3A%20the%20evidence%20needed%20to%20implement%20alternative%20dosing%20regimens%20of%20anticancer%20drugs%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20K.%22%2C%22lastName%22%3A%22Overbeek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Ter%20Heine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20M.%20W.%22%2C%22lastName%22%3A%22Verheul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Rudek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Gurney%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Plummer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20C.%22%2C%22lastName%22%3A%22Gilbert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Buclin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20M.%22%2C%22lastName%22%3A%22Burger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20J.%22%2C%22lastName%22%3A%22Bloemendal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20P.%22%2C%22lastName%22%3A%22van%20Erp%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-02%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.esmoop.2022.100749%22%2C%22ISSN%22%3A%222059-7029%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222023-08-24T13%3A54%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22QVWVPNAL%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maillard%20et%20al.%22%2C%22parsedDate%22%3A%222023-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMaillard%2C%20Maud%2C%20Manon%20Launay%2C%20Bernard%20Royer%2C%20J%26%23xE9%3Br%26%23xF4%3Bme%20Guitton%2C%20Elodie%20Gautier-Veyret%2C%20Sophie%20Broutin%2C%20Camille%20Tron%2C%20et%20al.%20%26%23x201C%3BQuantitative%20Impact%20of%20Pre-Analytical%20Process%20on%20Plasma%20Uracil%20When%20Testing%20for%20Dihydropyrimidine%20Dehydrogenase%20Deficiency.%26%23x201D%3B%20%3Ci%3EBritish%20Journal%20of%20Clinical%20Pharmacology%3C%5C%2Fi%3E%2089%2C%20no.%202%20%28February%202023%29%3A%20762%26%23x2013%3B72.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbcp.15536%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbcp.15536%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Quantitative%20impact%20of%20pre-analytical%20process%20on%20plasma%20uracil%20when%20testing%20for%20dihydropyrimidine%20dehydrogenase%20deficiency%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maud%22%2C%22lastName%22%3A%22Maillard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manon%22%2C%22lastName%22%3A%22Launay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Royer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Guitton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Gautier-Veyret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Broutin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Tron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%5Cu00e9licien%22%2C%22lastName%22%3A%22Le%20Louedec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Ciccolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Richard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Alarcan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Haufroid%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Na%5Cu00efma%22%2C%22lastName%22%3A%22Tafzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonin%22%2C%22lastName%22%3A%22Schmitt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Christine%22%2C%22lastName%22%3A%22Etienne-Grimaldi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Narjoz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Groupe%20de%20Pharmacologie%20Clinique%20Oncologique%20%28GPCO%29%22%7D%5D%2C%22abstractNote%22%3A%22AIMS%3A%20Determining%20dihydropyrimidine%20dehydrogenase%20%28DPD%29%20activity%20by%20measuring%20patient%27s%20uracil%20%28U%29%20plasma%20concentration%20is%20mandatory%20before%20fluoropyrimidine%20%28FP%29%20administration%20in%20France.%20In%20this%20study%2C%20we%20aimed%20to%20refine%20the%20pre-analytical%20recommendations%20for%20determining%20U%20and%20dihydrouracil%20%28UH2%20%29%20concentrations%2C%20as%20they%20are%20essential%20in%20reliable%20DPD-deficiency%20testing.%5CnMETHODS%3A%20U%20and%20UH2%20concentrations%20were%20collected%20from%2014%20hospital%20laboratories.%20Stability%20in%20whole%20blood%20and%20plasma%20after%20centrifugation%2C%20the%20type%20of%20anticoagulant%20and%20long-term%20plasma%20storage%20were%20evaluated.%20The%20variation%20induced%20by%20time%20and%20temperature%20was%20calculated%20and%20compared%20to%20an%20acceptability%20range%20of%20%5Cu00b120%25.%20Inter-occasion%20variability%20%28IOV%29%20of%20U%20and%20UH2%20was%20assessed%20in%20573%20patients%20double%20sampled%20for%20DPD-deficiency%20testing.%5CnRESULTS%3A%20Storage%20of%20blood%20samples%20before%20centrifugation%20at%20room%20temperature%20%28RT%29%20should%20not%20exceed%201%5Cu00a0h%2C%20whereas%20cold%20%28%2B4%5Cu00b0C%29%20storage%20maintains%20the%20stability%20of%20uracil%20after%205%5Cu00a0hours.%20For%20patients%20correctly%20double%20sampled%2C%20IOV%20of%20U%20reached%2022.4%25%20for%20U%20%28SD%5Cu2009%3D%5Cu200917.9%25%2C%20range%5Cu2009%3D%5Cu20090-99%25%29.%20Notably%2C%2017%25%20of%20them%20were%20assigned%20with%20a%20different%20phenotype%20%28normal%20or%20DPD-deficient%29%20based%20on%20the%20analysis%20of%20their%20two%20samples.%20For%20those%20having%20at%20least%20one%20non-compliant%20sample%2C%20this%20percentage%20increased%20up%20to%2033.8%25.%20The%20moment%20of%20blood%20collection%20did%20not%20affect%20the%20DPD%20phenotyping%20result.%5CnCONCLUSION%3A%20Caution%20should%20be%20taken%20when%20interpreting%20U%20concentrations%20if%20the%20time%20before%20centrifugation%20exceeds%201%5Cu00a0hour%20at%20RT%2C%20since%20it%20rises%20significantly%20afterwards.%20Not%20respecting%20the%20pre-analytical%20conditions%20for%20DPD%20phenotyping%20increases%20the%20risk%20of%20DPD%20status%20misclassification.%22%2C%22date%22%3A%222023-02%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fbcp.15536%22%2C%22ISSN%22%3A%221365-2125%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222023-01-30T14%3A14%3A55Z%22%7D%7D%2C%7B%22key%22%3A%22WKIJU95Q%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Puisset%20et%20al.%22%2C%22parsedDate%22%3A%222023-01-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPuisset%2C%20Florent%2C%20Mourad%20Mseddi%2C%20Lo%26%23xEF%3Bc%20Mourey%2C%20Damien%20Pouessel%2C%20Benoit%20Blanchet%2C%20Etienne%20Chatelut%2C%20and%20Christine%20Chevreau.%20%26%23x201C%3BTherapeutic%20Drug%20Monitoring%20of%20Tyrosine%20Kinase%20Inhibitors%20in%20the%20Treatment%20of%20Advanced%20Renal%20Cancer.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2015%2C%20no.%201%20%28January%203%2C%202023%29%3A%20313.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers15010313%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers15010313%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Therapeutic%20Drug%20Monitoring%20of%20Tyrosine%20Kinase%20Inhibitors%20in%20the%20Treatment%20of%20Advanced%20Renal%20Cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Puisset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mourad%22%2C%22lastName%22%3A%22Mseddi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Mourey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Pouessel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Blanchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Chevreau%22%7D%5D%2C%22abstractNote%22%3A%22Seven%20tyrosine%20kinase%20inhibitor%20compounds%20with%20anti-angiogenic%20properties%20remain%20key%20drugs%20to%20treat%20advanced%20renal%20cell%20carcinoma.%20There%20is%20a%20strong%20rationale%20to%20develop%20therapeutic%20drug%20monitoring%20for%20these%20drugs.%20General%20considerations%20of%20such%20monitoring%20of%20the%20several%20groups%20of%20anticancer%20drugs%20are%20given%2C%20with%20a%20focus%20on%20oral%20therapy.%20Pharmacokinetics%20and%20the%20factors%20of%20inter-%20and%20intraindividual%20variabilities%20of%20these%20tyrosine%20kinase%20inhibitors%20are%20described%20together%20with%20an%20exhaustive%20presentation%20of%20their%20pharmacokinetic%5C%2Fpharmacodynamic%20relationships.%20The%20latter%20was%20observed%20in%20studies%20where%20every%20patient%20was%20treated%20with%20the%20same%20dose%2C%20and%20the%20results%20of%20several%20prospective%20studies%20based%20on%20dose%20individualization%20support%20the%20practice%20of%20increasing%20individual%20dosage%20in%20case%20of%20low%20observed%20plasma%20drug%20concentrations.%20Finally%2C%20the%20benefits%20and%20limits%20of%20therapeutic%20drug%20monitoring%20as%20a%20routine%20practice%20are%20discussed.%22%2C%22date%22%3A%222023-01-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers15010313%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222023-08-24T13%3A54%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22HKEK63JV%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Le%20Louedec%20et%20al.%22%2C%22parsedDate%22%3A%222023-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELe%20Louedec%2C%20F%26%23xE9%3Blicien%2C%20Florent%20Puisset%2C%20Etienne%20Chatelut%2C%20and%20Michel%20Tod.%20%26%23x201C%3BConsidering%20the%20Oral%20Bioavailability%20of%20Protein%20Kinase%20Inhibitors%3A%20Essential%20in%20Assessing%20the%20Extent%20of%20Drug-Drug%20Interaction%20and%20Improving%20Clinical%20Practice.%26%23x201D%3B%20%3Ci%3EClinical%20Pharmacokinetics%3C%5C%2Fi%3E%2062%2C%20no.%201%20%28January%202023%29%3A%2055%26%23x2013%3B66.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs40262-022-01200-8%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs40262-022-01200-8%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Considering%20the%20Oral%20Bioavailability%20of%20Protein%20Kinase%20Inhibitors%3A%20Essential%20in%20Assessing%20the%20Extent%20of%20Drug-Drug%20Interaction%20and%20Improving%20Clinical%20Practice%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%5Cu00e9licien%22%2C%22lastName%22%3A%22Le%20Louedec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Puisset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Tod%22%7D%5D%2C%22abstractNote%22%3A%22Protein%20kinase%20inhibitors%20share%20pharmacokinetic%20%28PK%29%20pathways%20among%20themselves.%20They%20are%20all%20metabolized%20by%20several%20cytochromes%20P450%20%28CYP%29.%20For%20most%20of%20them%2C%20CYP3A4%20is%20the%20predominant%20metabolic%20pathway.%20However%2C%20their%20oral%20bioavailability%20differs.%20For%20example%2C%20the%20oral%20bioavailability%20of%20imatinib%20has%20been%20estimated%20at%20nearly%20100%25%2C%20but%20that%20of%20ibrutinib%20averages%203%25%20due%20to%20its%20high%20hepatic%20first-pass%20effect.%20Overall%2C%20the%20smaller%20the%20oral%20bioavailability%2C%20the%20larger%20its%20interindividual%20PK%20variability.%20Indeed%2C%20for%20drugs%20with%20low%20oral%20bioavailability%2C%20the%20extent%20of%20their%20absorption%20is%20an%20additional%20cause%20%28along%20with%20elimination%20variability%29%20of%20differences%20in%20drug%20exposure%20among%20patients.%20The%20impact%20of%20drug-drug%20interaction%20%28DDI%29%20also%20differs%20between%20drugs%20with%20low%20or%20high%20oral%20bioavailability.%20We%20describe%20and%20explain%20why%20the%20impact%20of%20CYP3A4%20inhibitors%20and%20inducers%20is%20much%20greater%20for%20protein%20kinase%20inhibitors%20with%20low%20oral%20bioavailability.%20The%20effect%20of%20food%20on%20protein%20kinase%20inhibitors%20and%20DDIs%20corresponding%20to%20plasma%20protein%20binding%20will%20also%20be%20considered.%20Finally%2C%20the%20benefits%20of%20these%20concepts%20in%20clinical%20practice%20%28including%20therapeutic%20drug%20monitoring%29%20will%20be%20discussed.%20Overall%2C%20our%20main%20objective%20was%20to%20apply%20fundamental%20PK%20concepts%20to%20understanding%20the%20main%20clinical%20issues%20of%20these%20oral%20anticancer%20drugs.%22%2C%22date%22%3A%222023-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs40262-022-01200-8%22%2C%22ISSN%22%3A%221179-1926%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222023-08-24T13%3A54%3A05Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Ranchon, Florence, Étienne Chatelut, Juliette Lambert, Pierre Sesques, Constance Thibault, Isabelle Madelaine, Catherine Rioufol, Véronique Diéras, and Jean-Louis Cazin. “[Antibody drug conjugates (ADC) and bispecific antibodies in oncology - report of the 2022 Saint Louis day].” Bulletin Du Cancer<\/i>, October 10, 2023, S0007-4551(23)00345-4. https:\/\/doi.org\/10.1016\/j.bulcan.2023.07.009<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Al Saati, Ayman, Pierre Vande Perre, Julien Plenecassagnes, Julia Gilhodes, Nils Monselet, Bastien Cabarrou, Norbert Lignon, et al. “Multigene Panel Sequencing Identifies a Novel Germline Mutation Profile in Male Breast Cancer Patients.” International Journal of Molecular Sciences<\/i> 24, no. 18 (September 20, 2023): 14348. https:\/\/doi.org\/10.3390\/ijms241814348<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Boumaza, Xavier, Margaux Lafaurie, Emmanuel Treiner, Ondine Walter, Gregory Pugnet, Guillaume Martin-Blondel, Damien Biotti, et al. “Infectious Risk When Prescribing Rituximab in Patients with Hypogammaglobulinemia Acquired in the Setting of Autoimmune Diseases.” International Immunopharmacology<\/i> 120 (July 2023): 110342. https:\/\/doi.org\/10.1016\/j.intimp.2023.110342<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Valentin, Thibaud, Marie Lambert, Léonor Chaltiel, Ben Allal, Mourad Mseddi, Malika Yakoubi, Christine Chevreau, et al. “Population Pharmacokinetic Analysis Reveals No Impact of Aprepitant on the Pharmacokinetics of Ifosfamide, 2-Dechloroifosfamide, and 3-Dechloroifosfamide.” European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences<\/i> 185 (June 1, 2023): 106420. https:\/\/doi.org\/10.1016\/j.ejps.2023.106420<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Royer, B., M. Launay, J. Ciccolini, L. Derain, F. Parant, F. Thomas, and J. Guitton. “Impact of Renal Impairment on Dihydropyrimidine Dehydrogenase (DPD) Phenotyping.” ESMO Open<\/i> 8, no. 3 (June 2023): 101577. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101577<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Jong, Loek A. W. de, Marie Lambert, Nielka P. van Erp, Lukas de Vries, Etienne Chatelut, and Petronella B. Ottevanger. “Systemic Exposure to Cisplatin and Paclitaxel after Intraperitoneal Chemotherapy in Ovarian Cancer.” Cancer Chemotherapy and Pharmacology<\/i>, March 9, 2023. https:\/\/doi.org\/10.1007\/s00280-023-04512-z<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Laloi, Louise, Natacha Chaumard Billotey, Pierre-Yves Dumas, Franciane Paul, Alban Villate, Célestine Simand, Luc Fornecker, et al. “Retrospective, Real-Life Study of Venetoclax plus Azacitidine or Low-Dose Cytarabine in French Patients with Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy.” Cancer Medicine<\/i> 12, no. 6 (March 2023): 7175–81. https:\/\/doi.org\/10.1002\/cam4.5459<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Poumeaud, François, Florence Dalenc, Quentin Mathevet, Aurélie Brice, Audrey Eche-Gass, Eleonora De Maio D’Esposito, Clémence Brac-de-la-Perriere, and Fabienne Thomas. “Phenotype\/Genotype Discrepancy of DPD Deficiency Screening in a Patient With Severe Capecitabine Toxicity: A Case Report.” JCO Precision Oncology<\/i> 7 (March 2023): e2200508. https:\/\/doi.org\/10.1200\/PO.22.00508<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Puisset, Florent, Félicien Le Louedec, Florence Dalenc, Lorène Verguet, Eleonora De Maio, Jean Louis Lacaze, Marion Montastruc, et al. “Investigating the Clinical Impact of Dose-Banding for Weekly Paclitaxel in Patients with Breast Cancer: A Retrospective and Monocentric Study.” British Journal of Clinical Pharmacology<\/i>, February 28, 2023. https:\/\/doi.org\/10.1111\/bcp.15702<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Overbeek, J. K., R. Ter Heine, H. M. W. Verheul, E. Chatelut, M. A. Rudek, H. Gurney, R. Plummer, et al. “Off-Label, but on Target: The Evidence Needed to Implement Alternative Dosing Regimens of Anticancer Drugs.” ESMO Open<\/i> 8, no. 1 (February 2023): 100749. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100749<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Maillard, Maud, Manon Launay, Bernard Royer, Jérôme Guitton, Elodie Gautier-Veyret, Sophie Broutin, Camille Tron, et al. “Quantitative Impact of Pre-Analytical Process on Plasma Uracil When Testing for Dihydropyrimidine Dehydrogenase Deficiency.” British Journal of Clinical Pharmacology<\/i> 89, no. 2 (February 2023): 762–72. https:\/\/doi.org\/10.1111\/bcp.15536<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Puisset, Florent, Mourad Mseddi, Loïc Mourey, Damien Pouessel, Benoit Blanchet, Etienne Chatelut, and Christine Chevreau. “Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer.” Cancers<\/i> 15, no. 1 (January 3, 2023): 313. https:\/\/doi.org\/10.3390\/cancers15010313<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Le Louedec, Félicien, Florent Puisset, Etienne Chatelut, and Michel Tod. “Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug-Drug Interaction and Improving Clinical Practice.” Clinical Pharmacokinetics<\/i> 62, no. 1 (January 2023): 55–66. https:\/\/doi.org\/10.1007\/s40262-022-01200-8<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][et_pb_toggle title=”PUBLICATIONS 2022″ open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_text_color=”#505659″ closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.19.0″ _module_preset=”default” title_text_color=”#ffffff” title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_font=”|600|||||||” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” global_colors_info=”{}”]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\tNMTDPBH9<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2022<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 38370<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-39c161ef3e8fe8e763d39eb041806c37%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22XDLEKZKK%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Etienne-Grimaldi%20et%20al.%22%2C%22parsedDate%22%3A%222022-12-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EEtienne-Grimaldi%2C%20Marie-Christine%2C%20Nicolas%20Pallet%2C%20Val%26%23xE9%3Brie%20Boige%2C%20Joseph%20Ciccolini%2C%20Laurent%20Chouchana%2C%20Chantal%20Barin-Le%20Guellec%2C%20Aziz%20Zaanan%2C%20et%20al.%20%26%23x201C%3BCurrent%20Diagnostic%20and%20Clinical%20Issues%20of%20Screening%20for%20Dihydropyrimidine%20Dehydrogenase%20Deficiency.%26%23x201D%3B%20%3Ci%3EEuropean%20Journal%20of%20Cancer%20%28Oxford%2C%20England%3A%201990%29%3C%5C%2Fi%3E%20181%20%28December%209%2C%202022%29%3A%203%26%23x2013%3B17.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejca.2022.11.028%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejca.2022.11.028%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Current%20diagnostic%20and%20clinical%20issues%20of%20screening%20for%20dihydropyrimidine%20dehydrogenase%20deficiency%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Christine%22%2C%22lastName%22%3A%22Etienne-Grimaldi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Pallet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Boige%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Ciccolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Chouchana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Barin-Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aziz%22%2C%22lastName%22%3A%22Zaanan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Narjoz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Taieb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Anne%22%2C%22lastName%22%3A%22Loriot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Francophone%20Network%20of%20Pharmacogenetics%20%28RNPGx%29%20and%20the%20French%20Clinical%20Oncopharmacology%20Group%20%28GPCO%29-UNICANCER%22%7D%5D%2C%22abstractNote%22%3A%22Fluoropyrimidine%20drugs%20%28FP%29%20are%20the%20backbone%20of%20many%20chemotherapy%20protocols%20for%20treating%20solid%20tumours.%20The%20rate-limiting%20step%20of%20fluoropyrimidine%20catabolism%20is%20dihydropyrimidine%20dehydrogenase%20%28DPD%29%2C%20and%20deficiency%20in%20DPD%20activity%20can%20result%20in%20severe%20and%20even%20fatal%20toxicity.%20In%20this%20review%2C%20we%20survey%20the%20evidence-based%20pharmacogenetics%20and%20therapeutic%20recommendations%20regarding%20DPYD%20%28the%20gene%20encoding%20DPD%29%20genotyping%20and%20DPD%20phenotyping%20to%20prevent%20toxicity%20and%20optimize%20dosing%20adaptation%20before%20FP%20administration.%20The%20French%20experience%20of%20mandatory%20DPD-deficiency%20screening%20prior%20to%20initiating%20FP%20is%20discussed.%22%2C%22date%22%3A%222022-12-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ejca.2022.11.028%22%2C%22ISSN%22%3A%221879-0852%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222023-01-16T11%3A43%3A10Z%22%7D%7D%2C%7B%22key%22%3A%22ZNUUM692%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Thomas%20et%20al.%22%2C%22parsedDate%22%3A%222022-11-22%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EThomas%2C%20Fabienne%2C%20Manon%20Launay%2C%20J%26%23xE9%3Br%26%23xF4%3Bme%20Guitton%2C%20Marie-Anne%20Loriot%2C%20Jean-Christophe%20Boyer%2C%20Vincent%20Haufroid%2C%20Marie-Christine%20Etienne-Grimaldi%2C%20Bernard%20Royer%2C%20and%20GPCO-UNICANCER%20Group.%20%26%23x201C%3BPlasma%20Uracil%20as%20a%20DPD%20Phenotyping%20Test%3A%20Pre-Analytical%20Handling%20Matters%21%26%23x201D%3B%20%3Ci%3EClinical%20Pharmacology%20and%20Therapeutics%3C%5C%2Fi%3E%2C%20November%2022%2C%202022.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcpt.2772%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcpt.2772%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Plasma%20Uracil%20as%20a%20DPD%20Phenotyping%20Test%3A%20Pre-Analytical%20Handling%20Matters%21%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manon%22%2C%22lastName%22%3A%22Launay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Guitton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Anne%22%2C%22lastName%22%3A%22Loriot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Christophe%22%2C%22lastName%22%3A%22Boyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Haufroid%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Christine%22%2C%22lastName%22%3A%22Etienne-Grimaldi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Royer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22GPCO-UNICANCER%20Group%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-11-22%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fcpt.2772%22%2C%22ISSN%22%3A%221532-6535%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222022-11-23T16%3A28%3A24Z%22%7D%7D%2C%7B%22key%22%3A%226CXAWUUU%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maillard%20et%20al.%22%2C%22parsedDate%22%3A%222022-09-11%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMaillard%2C%20Maud%2C%20C%26%23xE9%3Bcile%20Arellano%2C%20Christelle%20Vachoux%2C%20Christine%20Chevreau%2C%20Nicolas%20J.%20Cabaton%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Pont%2C%20Nathalie%20Saint-Laurent%2C%20Thierry%20Lafont%2C%20Etienne%20Chatelut%2C%20and%20Fabienne%20Thomas.%20%26%23x201C%3BBiological%20Role%20of%20Pazopanib%20and%20Sunitinib%20Aldehyde%20Derivatives%20in%20Drug-Induced%20Liver%20Injury.%26%23x201D%3B%20%3Ci%3EMetabolites%3C%5C%2Fi%3E%2012%2C%20no.%209%20%28September%2011%2C%202022%29%3A%20852.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fmetabo12090852%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fmetabo12090852%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Biological%20Role%20of%20Pazopanib%20and%20Sunitinib%20Aldehyde%20Derivatives%20in%20Drug-Induced%20Liver%20Injury%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maud%22%2C%22lastName%22%3A%22Maillard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Arellano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christelle%22%2C%22lastName%22%3A%22Vachoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Chevreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%20J.%22%2C%22lastName%22%3A%22Cabaton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Pont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Saint-Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Lafont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Thomas%22%7D%5D%2C%22abstractNote%22%3A%22Tyrosine%20kinase%20inhibitors%20pazopanib%20and%20sunitinib%20are%20both%20used%20to%20treat%20advanced%20renal%20cell%20carcinoma%20but%20expose%20patients%20to%20an%20increased%20risk%20of%20hepatotoxicity.%20We%20have%20previously%20identified%20two%20aldehyde%20derivatives%20for%20pazopanib%20and%20sunitinib%20%28P-CHO%20and%20S-CHO%2C%20respectively%29%20in%20liver%20microsomes.%20In%20this%20study%2C%20we%20aimed%20to%20decipher%20their%20role%20in%20hepatotoxicity%20by%20treating%20HepG2%20and%20HepaRG%20hepatic%20cell%20lines%20with%20these%20derivatives%20and%20evaluating%20cell%20viability%2C%20mitochondrial%20dysfunction%2C%20and%20oxidative%20stress%20accumulation.%20Additionally%2C%20plasma%20concentrations%20of%20P-CHO%20were%20assessed%20in%20a%20cohort%20of%20patients%20treated%20with%20pazopanib.%20Results%20showed%20that%20S-CHO%20slightly%20decreased%20the%20viability%20of%20HepG2%2C%20but%20to%20a%20lesser%20extent%20than%20sunitinib%2C%20and%20affected%20the%20maximal%20respiratory%20capacity%20of%20the%20mitochondrial%20chain.%20P-CHO%20decreased%20viability%20and%20ATP%20production%20in%20HepG2.%20Traces%20of%20P-CHO%20were%20detected%20in%20the%20plasma%20of%20patients%20treated%20with%20pazopanib.%20Overall%2C%20these%20results%20showed%20that%20P-CHO%20and%20S-CHO%20affect%20hepatocyte%20integrity%20and%20could%20be%20involved%20in%20the%20pazopanib%20and%20sunitinib%20hepatotoxicity.%22%2C%22date%22%3A%222022-09-11%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fmetabo12090852%22%2C%22ISSN%22%3A%222218-1989%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222022-09-26T08%3A26%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22EAWN3R6E%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22de%20Jong%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-22%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EJong%2C%20Loek%20A.%20W.%20de%2C%20Fortun%26%23xE9%3B%20M.%20K.%20Elekonawo%2C%20Marie%20Lambert%2C%20Jan%20Marie%20de%20Gooyer%2C%20Henk%20M.%20W.%20Verheul%2C%20David%20M.%20Burger%2C%20Johannes%20H.%20W.%20de%20Wilt%2C%20et%20al.%20%26%23x201C%3BCorrection%20to%3A%20Wide%20Variation%20in%20Tissue%2C%20Systemic%2C%20and%20Drain%20Fluid%20Exposure%20after%20Oxaliplatin%26%23x2011%3Bbased%20HIPEC%3A%20Results%20of%20the%20GUTOX%20Study.%26%23x201D%3B%20%3Ci%3ECancer%20Chemotherapy%20and%20Pharmacology%3C%5C%2Fi%3E%2C%20June%2022%2C%202022.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00280-022-04450-2%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00280-022-04450-2%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Correction%20to%3A%20Wide%20variation%20in%20tissue%2C%20systemic%2C%20and%20drain%20fluid%20exposure%20after%20oxaliplatin%5Cu2011based%20HIPEC%3A%20results%20of%20the%20GUTOX%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loek%20A.%20W.%22%2C%22lastName%22%3A%22de%20Jong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fortun%5Cu00e9%20M.%20K.%22%2C%22lastName%22%3A%22Elekonawo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Lambert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%20Marie%22%2C%22lastName%22%3A%22de%20Gooyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Henk%20M.%20W.%22%2C%22lastName%22%3A%22Verheul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20M.%22%2C%22lastName%22%3A%22Burger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johannes%20H.%20W.%22%2C%22lastName%22%3A%22de%20Wilt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rob%22%2C%22lastName%22%3A%22Ter%20Heine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philip%20R.%22%2C%22lastName%22%3A%22de%20Reuver%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andre%20J.%20A.%22%2C%22lastName%22%3A%22Bremers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nielka%20P.%22%2C%22lastName%22%3A%22van%20Erp%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-06-22%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00280-022-04450-2%22%2C%22ISSN%22%3A%221432-0843%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222022-06-28T07%3A43%3A34Z%22%7D%7D%2C%7B%22key%22%3A%225EHLFWJB%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maillard%20et%20al.%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMaillard%2C%20Maud%2C%20Baptiste%20Louveau%2C%20Paul%20Vilquin%2C%20Lauriane%20Goldwirt%2C%20Fabienne%20Thomas%2C%20and%20Samia%20Mourah.%20%26%23x201C%3BPharmacogenomics%20in%20Solid%20Cancers%20and%20Hematologic%20Malignancies%3A%20Improving%20Personalized%20Drug%20Prescription.%26%23x201D%3B%20%3Ci%3ETherapie%3C%5C%2Fi%3E%2077%2C%20no.%202%20%28April%202022%29%3A%20171%26%23x2013%3B83.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.therap.2021.11.003%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.therap.2021.11.003%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pharmacogenomics%20in%20solid%20cancers%20and%20hematologic%20malignancies%3A%20Improving%20personalized%20drug%20prescription%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maud%22%2C%22lastName%22%3A%22Maillard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Baptiste%22%2C%22lastName%22%3A%22Louveau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Vilquin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauriane%22%2C%22lastName%22%3A%22Goldwirt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samia%22%2C%22lastName%22%3A%22Mourah%22%7D%5D%2C%22abstractNote%22%3A%22The%20discovery%20of%20molecular%20alterations%20involved%20in%20oncogenesis%20is%20evolving%20rapidly%20and%20has%20led%20to%20the%20development%20of%20new%20innovative%20targeted%20therapies%20in%20oncology.%20High-throughput%20sequencing%20techniques%20help%20to%20identify%20genomic%20targets%20and%20to%20provide%20predictive%20molecular%20biomarkers%20of%20response%20to%20guide%20alternative%20therapeutic%20strategies.%20Besides%20the%20emergence%20of%20these%20theranostic%20markers%20for%20the%20new%20targeted%20treatments%2C%20pharmacogenetic%20markers%20%28corresponding%20to%20genetic%20variants%20existing%20in%20the%20constitutional%20DNA%2C%20i.e.%2C%20the%20host%20genome%29%20can%20help%20to%20optimize%20the%20use%20of%20chemotherapy.%20In%20this%20review%2C%20we%20present%20the%20current%20clinical%20applications%20of%20constitutional%20PG%20and%20the%20recent%20concepts%20and%20advances%20in%20pharmacogenomics%2C%20a%20rapidly%20evolving%20field%20that%20focuses%20on%20various%20molecular%20alterations%20identified%20on%20constitutional%20or%20somatic%20%28tumor%29%20genome.%22%2C%22date%22%3A%222022-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.therap.2021.11.003%22%2C%22ISSN%22%3A%221958-5578%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A11%3A20Z%22%7D%7D%2C%7B%22key%22%3A%22YEZHMPZ4%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Krache%20et%20al.%22%2C%22parsedDate%22%3A%222022-01-31%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKrache%2C%20Anis%2C%20Charlotte%20Fontan%2C%20Carine%20Pestourie%2C%20Manuel%20Bardi%26%23xE8%3Bs%2C%20Yann%20Bouvet%2C%20Pierre%20Payoux%2C%20Etienne%20Chatelut%2C%20Melanie%20White-Koning%2C%20and%20Anne-Sophie%20Salabert.%20%26%23x201C%3BPreclinical%20Pharmacokinetics%20and%20Dosimetry%20of%20an%2089Zr%20Labelled%20Anti-PDL1%20in%20an%20Orthotopic%20Lung%20Cancer%20Murine%20Model.%26%23x201D%3B%20%3Ci%3EFrontiers%20in%20Medicine%3C%5C%2Fi%3E%208%20%28January%2031%2C%202022%29%3A%20741855.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffmed.2021.741855%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffmed.2021.741855%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Preclinical%20Pharmacokinetics%20and%20Dosimetry%20of%20an%2089Zr%20Labelled%20Anti-PDL1%20in%20an%20Orthotopic%20Lung%20Cancer%20Murine%20Model%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anis%22%2C%22lastName%22%3A%22Krache%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Fontan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Pestourie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manuel%22%2C%22lastName%22%3A%22Bardi%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22Bouvet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Payoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melanie%22%2C%22lastName%22%3A%22White-Koning%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Sophie%22%2C%22lastName%22%3A%22Salabert%22%7D%5D%2C%22abstractNote%22%3A%22Anti-PDL1%20is%20a%20monoclonal%20antibody%20targeting%20the%20programmed%20death-cell%20ligand%20%28PD-L1%29%20by%20blocking%20the%20programmed%20death-cell%20%28PD-1%29%5C%2FPD-L1%20axis.%20It%20restores%20the%20immune%20system%20response%20in%20several%20tumours%2C%20such%20as%20non-small%20cell%20lung%20cancer%20%28NSCLC%29.%20Anti-PDL1%20or%20anti-PD1%20treatments%20rely%20on%20PD-L1%20tumoural%20expression%20assessed%20by%20immunohistochemistry%20on%20biopsy%20tissue.%20However%2C%20depending%20on%20the%20biopsy%20extraction%20site%2C%20PD-L1%20expression%20can%20vary%20greatly.%20Non-invasive%20imaging%20enables%20whole-body%20mapping%20of%20PD-L1%20sites%20and%20could%20improve%20the%20assessment%20of%20tumoural%20PD-L1%20expression.%5CnMethods%3A%20Pharmacokinetics%20%28PK%29%2C%20biodistribution%20and%20dosimetry%20of%20a%20murine%20anti-PDL1%20radiolabelled%20with%20zirconium-89%2C%20were%20evaluated%20in%20both%20healthy%20mice%20and%20immunocompetent%20mice%20with%20lung%20cancer.%20Preclinical%20PET%20%28%5Cu03bcPET%29%20imaging%20was%20used%20to%20analyse%20%5B89Zr%5DDFO-Anti-PDL1%20distribution%20in%20both%20groups%20of%20mice.%20Non-compartmental%20%28NCA%29%20and%20compartmental%20%28CA%29%20PK%20analyses%20were%20performed%20in%20order%20to%20describe%20PK%20parameters%20and%20assess%20area%20under%20the%20concentration-time%20curve%20%28AUC%29%20for%20dosimetry%20evaluation%20in%20humans.%5CnResults%3A%20Organ%20distribution%20was%20correctly%20estimated%20using%20PK%20modelling%20in%20both%20healthy%20mice%20and%20mice%20with%20lung%20cancer.%20Tumoural%20uptake%20occurred%20within%2024%20h%20post-injection%20of%20%5B89Zr%5DDFO-Anti-PDL1%2C%20and%20the%20best%20imaging%20time%20was%20at%2048%20h%20according%20to%20the%20signal-to-noise%20ratio%20%28SNR%29%20and%20image%20quality.%20An%20in%20vivo%20blocking%20study%20confirmed%20that%20%5B89Zr%5DDFO-anti-PDL1%20specifically%20targeted%20PD-L1%20in%20CMT167%20lung%20tumours%20in%20mice.%20AUC%20in%20organs%20was%20estimated%20using%20a%201-compartment%20PK%20model%20and%20extrapolated%20to%20human%20%28using%20allometric%20scaling%29%20in%20order%20to%20estimate%20the%20radiation%20exposure%20in%20human.%20Human-estimated%20effective%20dose%20was%20131%20%5Cu03bcSv%5C%2FMBq.%5CnConclusion%3A%20The%20predicted%20dosimetry%20was%20similar%20or%20lower%20than%20other%20antibodies%20radiolabelled%20with%20zirconium-89%20for%20immunoPET%20imaging.%22%2C%22date%22%3A%222022-01-31%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3389%5C%2Ffmed.2021.741855%22%2C%22ISSN%22%3A%222296-858X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A12%3A34Z%22%7D%7D%2C%7B%22key%22%3A%223WHCTDU9%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Grand%20et%20al.%22%2C%22parsedDate%22%3A%222022-01-06%22%2C%22numChildren%22%3A8%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGrand%2C%20Ana%26%23xEF%3Bs%2C%20Jean-Baptiste%20Desbouges%2C%20Coralie%20Guillemot%2C%20Coline%20Spinau%2C%20and%20Florent%20Puisset.%20%26%23x201C%3BStill%20Some%20Constraints%20Before%20Generalization%20of%20Remote%20Clinical%20Trial%20Monitoring%3A%20A%20Pharmacist%26%23x2019%3Bs%20Point%20of%20View%20of%20the%20Lessons%20From%20the%20COVID-19%20Pandemic.%26%23x201D%3B%20%3Ci%3EJCO%20Oncology%20Practice%3C%5C%2Fi%3E%2C%20January%206%2C%202022%2C%20OP2100749.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1200%5C%2FOP.21.00749%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1200%5C%2FOP.21.00749%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Still%20Some%20Constraints%20Before%20Generalization%20of%20Remote%20Clinical%20Trial%20Monitoring%3A%20A%20Pharmacist%27s%20Point%20of%20View%20of%20the%20Lessons%20From%20the%20COVID-19%20Pandemic%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%5Cu00efs%22%2C%22lastName%22%3A%22Grand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Baptiste%22%2C%22lastName%22%3A%22Desbouges%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Coralie%22%2C%22lastName%22%3A%22Guillemot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Coline%22%2C%22lastName%22%3A%22Spinau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Puisset%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-01-06%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1200%5C%2FOP.21.00749%22%2C%22ISSN%22%3A%222688-1535%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%2C%223U3NWA3K%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A10%3A48Z%22%7D%7D%2C%7B%22key%22%3A%22ZQKFUE7M%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lambert%20et%20al.%22%2C%22parsedDate%22%3A%222022%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELambert%2C%20Marie%2C%20Lawrence%20Dierickx%2C%20S%26%23xE9%3Bverine%20Brillouet%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Courbon%2C%20and%20Etienne%20Chatelut.%20%26%23x201C%3BComparison%20of%20Two%20Types%20of%20Amino%20Acid%20Solutions%20on%20177Lu-Dotatate%20Pharmacokinetics%20and%20Pharmacodynamics%20in%20Patients%20with%20Metastatic%20Gastroenteropancreatic%20Neuroendocrine%20Tumors.%26%23x201D%3B%20%3Ci%3ECurrent%20Radiopharmaceuticals%3C%5C%2Fi%3E%2015%2C%20no.%202%20%282022%29%3A%20164%26%23x2013%3B72.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.2174%5C%2F1874471015666211228123525%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.2174%5C%2F1874471015666211228123525%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Comparison%20of%20Two%20Types%20of%20Amino%20Acid%20Solutions%20on%20177Lu-Dotatate%20Pharmacokinetics%20and%20Pharmacodynamics%20in%20Patients%20with%20Metastatic%20Gastroenteropancreatic%20Neuroendocrine%20Tumors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Lambert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lawrence%22%2C%22lastName%22%3A%22Dierickx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9verine%22%2C%22lastName%22%3A%22Brillouet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Courbon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20177Lu-Dotatate%20is%20used%20in%20the%20treatment%20of%20somatostatin-receptor-positive%20inoperable%20progressive%20gastroenteropancreatic%20neuroendocrine%20tumors.%20A%20co-infusion%20of%20amino%20acids%20%28AAs%29%20is%20administered%20to%20prevent%20renal%20toxicity.%5CnOBJECTIVE%3A%20This%20study%20aimed%20to%20quantify%20the%20impact%20of%20two%20types%20of%20AA%20cocktails%20on%20the%20pharmacokinetics%20and%20toxicity%20of%20177Lu-Dotatate.%5CnMETHODS%3A%20Four%20injections%20of%207400%20MBq%20177Lu-Dotatate%20were%20given%20per%20patient%20with%20administration%20of%20either%20Primene%5Cu00ae%2010%25%20%28containing%20a%20cocktail%20of%2020%20AAs%20with%2022g%20of%20Lysine%20and%2016.8%20g%20of%20Arginine%29%20or%20Lysakare%5Cu00ae%20%28containing%2025%20g%20of%20Lysine%20and%2025%20g%20of%20Arginine%29.%20Nine%20blood%20samples%20were%20collected%20at%20each%20cycle.%20Radioactivity-time%20data%20were%20analyzed%20according%20to%20a%20population-based%20model%20using%20NONMEM%20%28version%207.4.1%29.%20Renal%20and%20hematological%20toxicity%20was%20evaluated%20after%20each%20cycle.%5CnRESULTS%3A%201%2C678%20177Lu-Dotatate%20plasma%20concentrations%20versus%20time%20were%20analyzed%20from%2083%20consecutive%20patients%20with%20Primene%5Cu00ae%20%28n%3D%2045%20pts%29%20or%20Lysakare%5Cu00ae%20%28n%3D%2036%20pts%29.%20Population%20pharmacokinetic%20analysis%20showed%20that%20Primene%5Cu00ae%20significantly%20increased%20the%20elimination%20rate%20constant%20of%20177Lu-Dotatate%20as%20opposed%20to%20Lysakare%5Cu00ae.%20Primene%5Cu00ae%20also%20significantly%20lowered%20Lutathera%5Cu00ae%20plasma%20exposure%20%28AUC%29%20by%2034%25%2C%20whereas%20Lysakare%5Cu00ae%20increased%20AUC%20by%207%25.%20There%20was%20no%20renal%20toxicity%20in%20either%20case.%20Lymphopenia%20significantly%20correlated%20with%20AUC%20%28p%3D0.021%29%20with%20a%20trend%20towards%20higher%20toxicity%20with%20Lysakare%5Cu00ae.%5CnCONCLUSION%3A%20Unlike%20Primene%5Cu00ae%2C%20Lysakare%5Cu00ae%20does%20not%20increase%20177Lu-Dotatate%20elimination.%20This%20difference%20is%20associated%20with%20a%20significant%20impact%20on%20AUC.%20The%20latter%20parameter%20has%20a%20high%20interpatient%20variability%20but%20a%20low%20intrapatient%20variability%2C%20which%20could%20have%20important%20clinical%20implications%20for%20treatment%20tailoring.%22%2C%22date%22%3A%222022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.2174%5C%2F1874471015666211228123525%22%2C%22ISSN%22%3A%221874-4729%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%2C%22S3JJUU84%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A09%3A52Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Etienne-Grimaldi, Marie-Christine, Nicolas Pallet, Valérie Boige, Joseph Ciccolini, Laurent Chouchana, Chantal Barin-Le Guellec, Aziz Zaanan, et al. “Current Diagnostic and Clinical Issues of Screening for Dihydropyrimidine Dehydrogenase Deficiency.” European Journal of Cancer (Oxford, England: 1990)<\/i> 181 (December 9, 2022): 3–17. https:\/\/doi.org\/10.1016\/j.ejca.2022.11.028<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Thomas, Fabienne, Manon Launay, Jérôme Guitton, Marie-Anne Loriot, Jean-Christophe Boyer, Vincent Haufroid, Marie-Christine Etienne-Grimaldi, Bernard Royer, and GPCO-UNICANCER Group. “Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!” Clinical Pharmacology and Therapeutics<\/i>, November 22, 2022. https:\/\/doi.org\/10.1002\/cpt.2772<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Maillard, Maud, Cécile Arellano, Christelle Vachoux, Christine Chevreau, Nicolas J. Cabaton, Frédéric Pont, Nathalie Saint-Laurent, Thierry Lafont, Etienne Chatelut, and Fabienne Thomas. “Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury.” Metabolites<\/i> 12, no. 9 (September 11, 2022): 852. https:\/\/doi.org\/10.3390\/metabo12090852<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Jong, Loek A. W. de, Fortuné M. K. Elekonawo, Marie Lambert, Jan Marie de Gooyer, Henk M. W. Verheul, David M. Burger, Johannes H. W. de Wilt, et al. “Correction to: Wide Variation in Tissue, Systemic, and Drain Fluid Exposure after Oxaliplatin‑based HIPEC: Results of the GUTOX Study.” Cancer Chemotherapy and Pharmacology<\/i>, June 22, 2022. https:\/\/doi.org\/10.1007\/s00280-022-04450-2<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Maillard, Maud, Baptiste Louveau, Paul Vilquin, Lauriane Goldwirt, Fabienne Thomas, and Samia Mourah. “Pharmacogenomics in Solid Cancers and Hematologic Malignancies: Improving Personalized Drug Prescription.” Therapie<\/i> 77, no. 2 (April 2022): 171–83. https:\/\/doi.org\/10.1016\/j.therap.2021.11.003<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Krache, Anis, Charlotte Fontan, Carine Pestourie, Manuel Bardiès, Yann Bouvet, Pierre Payoux, Etienne Chatelut, Melanie White-Koning, and Anne-Sophie Salabert. “Preclinical Pharmacokinetics and Dosimetry of an 89Zr Labelled Anti-PDL1 in an Orthotopic Lung Cancer Murine Model.” Frontiers in Medicine<\/i> 8 (January 31, 2022): 741855. https:\/\/doi.org\/10.3389\/fmed.2021.741855<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Grand, Anaïs, Jean-Baptiste Desbouges, Coralie Guillemot, Coline Spinau, and Florent Puisset. “Still Some Constraints Before Generalization of Remote Clinical Trial Monitoring: A Pharmacist’s Point of View of the Lessons From the COVID-19 Pandemic.” JCO Oncology Practice<\/i>, January 6, 2022, OP2100749. https:\/\/doi.org\/10.1200\/OP.21.00749<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Lambert, Marie, Lawrence Dierickx, Séverine Brillouet, Frédéric Courbon, and Etienne Chatelut. “Comparison of Two Types of Amino Acid Solutions on 177Lu-Dotatate Pharmacokinetics and Pharmacodynamics in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors.” Current Radiopharmaceuticals<\/i> 15, no. 2 (2022): 164–72. https:\/\/doi.org\/10.2174\/1874471015666211228123525<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][et_pb_toggle title=”PUBLICATIONS 2021″ open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_text_color=”#505659″ closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.16″ _module_preset=”default” title_text_color=”#ffffff” title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_font=”|600|||||||” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” global_colors_info=”{}”]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\tNMTDPBH9<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2021<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 38370<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-fb11e98cdb60f37d86c1f84344f64769%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%226TJHA58S%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Malier%20et%20al.%22%2C%22parsedDate%22%3A%222021-12-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMalier%2C%20Marie%2C%20Khaldoun%20Gharzeddine%2C%20Marie-H%26%23xE9%3Bl%26%23xE8%3Bne%20Laverriere%2C%20Sabrina%20Marsili%2C%20Fabienne%20Thomas%2C%20Thomas%20Decaens%2C%20Gael%20Roth%2C%20and%20Arnaud%20Millet.%20%26%23x201C%3BHypoxia%20Drives%20Dihydropyrimidine%20Dehydrogenase%20Expression%20in%20Macrophages%20and%20Confers%20Chemoresistance%20in%20Colorectal%20Cancer.%26%23x201D%3B%20%3Ci%3ECancer%20Research%3C%5C%2Fi%3E%2081%2C%20no.%2023%20%28December%201%2C%202021%29%3A%205963%26%23x2013%3B76.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F0008-5472.CAN-21-1572%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F0008-5472.CAN-21-1572%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Hypoxia%20Drives%20Dihydropyrimidine%20Dehydrogenase%20Expression%20in%20Macrophages%20and%20Confers%20Chemoresistance%20in%20Colorectal%20Cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Malier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Khaldoun%22%2C%22lastName%22%3A%22Gharzeddine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Laverriere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabrina%22%2C%22lastName%22%3A%22Marsili%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Decaens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gael%22%2C%22lastName%22%3A%22Roth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Millet%22%7D%5D%2C%22abstractNote%22%3A%22Colorectal%20adenocarcinoma%20is%20a%20leading%20cause%20of%20death%20worldwide%2C%20and%20immune%20infiltration%20in%20colorectal%20tumors%20has%20been%20recognized%20recently%20as%20an%20important%20pathophysiologic%20event.%20In%20this%20context%2C%20tumor-associated%20macrophages%20%28TAM%29%20have%20been%20related%20to%20chemoresistance%20to%205-fluorouracil%20%285-FU%29%2C%20the%20first-line%20chemotherapeutic%20agent%20used%20in%20treating%20colorectal%20cancers.%20Nevertheless%2C%20the%20details%20of%20this%20chemoresistance%20mechanism%20are%20still%20poorly%20elucidated.%20In%20the%20current%20study%2C%20we%20report%20that%20macrophages%20specifically%20overexpress%20dihydropyrimidine%20dehydrogenase%20%28DPD%29%20in%20hypoxia%2C%20leading%20to%20macrophage-induced%20chemoresistance%20to%205-FU%20via%20inactivation%20of%20the%20drug.%20Hypoxia-induced%20macrophage%20DPD%20expression%20was%20controlled%20by%20HIF2%5Cu03b1.%20TAMs%20constituted%20the%20main%20contributors%20to%20DPD%20activity%20in%20human%20colorectal%20primary%20or%20secondary%20tumors%2C%20while%20cancer%20cells%20did%20not%20express%20significant%20levels%20of%20DPD.%20In%20addition%2C%20contrary%20to%20humans%2C%20macrophages%20in%20mice%20do%20not%20express%20DPD.%20Together%2C%20these%20findings%20shed%20light%20on%20the%20role%20of%20TAMs%20in%20promoting%20chemoresistance%20in%20colorectal%20cancers%20and%20identify%20potential%20new%20therapeutic%20targets.%20SIGNIFICANCE%3A%20Hypoxia%20induces%20HIF2%5Cu03b1-mediated%20overexpression%20of%20dihydropyrimidine%20dehydrogenase%20in%20TAMs%2C%20leading%20to%20chemoresistance%20to%205-FU%20in%20colon%20cancers.%22%2C%22date%22%3A%222021-12-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1158%5C%2F0008-5472.CAN-21-1572%22%2C%22ISSN%22%3A%221538-7445%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222022-01-14T16%3A46%3A56Z%22%7D%7D%2C%7B%22key%22%3A%228WRAJAEH%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Clarke%20et%20al.%22%2C%22parsedDate%22%3A%222021-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EClarke%2C%20William%20A.%2C%20Etienne%20Chatelut%2C%20Alan%20K.%20Fotoohi%2C%20Richard%20A.%20Larson%2C%20Jennifer%20H.%20Martin%2C%20Ron%20H.%20J.%20Mathijssen%2C%20and%20Salvatore%20J.%20Salamone.%20%26%23x201C%3BTherapeutic%20Drug%20Monitoring%20in%20Oncology%3A%20International%20Association%20of%20Therapeutic%20Drug%20Monitoring%20and%20Clinical%20Toxicology%20Consensus%20Guidelines%20for%20Imatinib%20Therapy.%26%23x201D%3B%20%3Ci%3EEuropean%20Journal%20of%20Cancer%20%28Oxford%2C%20England%3A%201990%29%3C%5C%2Fi%3E%20157%20%28November%202021%29%3A%20428%26%23x2013%3B40.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejca.2021.08.033%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejca.2021.08.033%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Therapeutic%20drug%20monitoring%20in%20oncology%3A%20International%20Association%20of%20Therapeutic%20Drug%20Monitoring%20and%20Clinical%20Toxicology%20consensus%20guidelines%20for%20imatinib%20therapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%20A.%22%2C%22lastName%22%3A%22Clarke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alan%20K.%22%2C%22lastName%22%3A%22Fotoohi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20A.%22%2C%22lastName%22%3A%22Larson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%20H.%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ron%20H.%20J.%22%2C%22lastName%22%3A%22Mathijssen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salvatore%20J.%22%2C%22lastName%22%3A%22Salamone%22%7D%5D%2C%22abstractNote%22%3A%22Although%20therapeutic%20drug%20monitoring%20%28TDM%29%20is%20an%20important%20tool%20in%20guiding%20drug%20dosing%20for%20other%20areas%20of%20medicine%20including%20infectious%20diseases%2C%20cardiology%2C%20psychiatry%20and%20transplant%20medicine%2C%20it%20has%20not%20gained%20wide%20acceptance%20in%20oncology.%20For%20imatinib%20and%20other%20tyrosine%20kinase%20inhibitors%2C%5Cu00a0a%20flat%20dosing%20approach%20is%20utilised%20for%20management%20of%20oral%20chemotherapy.%20There%20are%20many%20published%20studies%20examining%20the%20correlation%20of%20blood%20concentrations%20with%20clinical%20effects%20of%20imatinib.%20The%20International%20Association%20of%20Therapeutic%20Drug%20Monitoring%20and%20Clinical%20Toxicology%20%28IATDMCT%29%20determined%20that%20there%20was%20a%20need%20to%20examine%20the%20published%20literature%20regarding%20utility%20of%20TDM%20in%20imatinib%20therapy%5Cu00a0and%20to%20develop%20consensus%20guidelines%20for%20TDM%20based%20on%20the%20available%20data.%20This%20article%20summarises%20the%20scientific%20evidence%20regarding%20TDM%20of%20imatinib%2C%20as%20well%20as%20the%20consensus%20guidelines%20developed%20by%20the%20IATDMCT.%22%2C%22date%22%3A%222021-11%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ejca.2021.08.033%22%2C%22ISSN%22%3A%221879-0852%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222022-01-14T15%3A48%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22Q9DDR9CF%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Le%20Louedec%20et%20al.%22%2C%22parsedDate%22%3A%222021-10%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELe%20Louedec%2C%20F%26%23xE9%3Blicien%2C%20Florent%20Puisset%2C%20Fabienne%20Thomas%2C%20%26%23xC9%3Btienne%20Chatelut%2C%20and%20M%26%23xE9%3Blanie%20White-Koning.%20%26%23x201C%3BEasy%20and%20Reliable%20Maximum%20a%20Posteriori%20Bayesian%20Estimation%20of%20Pharmacokinetic%20Parameters%20with%20the%20Open-Source%20R%20Package%20Mapbayr.%26%23x201D%3B%20%3Ci%3ECPT%3A%20Pharmacometrics%20%26amp%3B%20Systems%20Pharmacology%3C%5C%2Fi%3E%2010%2C%20no.%2010%20%28October%202021%29%3A%201208%26%23x2013%3B20.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fpsp4.12689%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fpsp4.12689%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Easy%20and%20reliable%20maximum%20a%20posteriori%20Bayesian%20estimation%20of%20pharmacokinetic%20parameters%20with%20the%20open-source%20R%20package%20mapbayr%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%5Cu00e9licien%22%2C%22lastName%22%3A%22Le%20Louedec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Puisset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c9tienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lanie%22%2C%22lastName%22%3A%22White-Koning%22%7D%5D%2C%22abstractNote%22%3A%22Pharmacokinetic%20%28PK%29%20parameter%20estimation%20is%20a%20critical%20and%20complex%20step%20in%20the%20model-informed%20precision%20dosing%20%28MIPD%29%20approach.%20The%20mapbayr%20package%20was%20developed%20to%20perform%20maximum%20a%20posteriori%20Bayesian%20estimation%20%28MAP-BE%29%20in%20R%20from%20any%20population%20PK%20model%20coded%20in%20mrgsolve.%20The%20performances%20of%20mapbayr%20were%20assessed%20using%20two%20approaches.%20First%2C%20%5C%22test%5C%22%20models%20with%20different%20features%20were%20coded%2C%20for%20example%2C%20first-order%20and%20zero-order%20absorption%2C%20lag%20time%2C%20time-varying%20covariates%2C%20Michaelis-Menten%20elimination%2C%20combined%20and%20exponential%20residual%20error%2C%20parent%20drug%20and%20metabolite%2C%20and%20small%20or%20large%20inter-individual%20variability%20%28IIV%29.%20A%20total%20of%204000%20PK%20profiles%20%28combining%20single%5C%2Fmultiple%20dosing%20and%20rich%5C%2Fsparse%20sampling%29%20were%20simulated%20from%20each%20test%20model%2C%20and%20MAP-BE%20of%20parameters%20was%20performed%20in%20both%20mapbayr%20and%20NONMEM.%20Second%2C%20a%20similar%20procedure%20was%20conducted%20with%20seven%20%5C%22real%5C%22%20previously%20published%20models%20to%20compare%20mapbayr%20and%20NONMEM%20on%20a%20PK%20outcome%20used%20in%20MIPD.%20For%20the%20test%20models%2C%2098%25%20of%20mapbayr%20estimations%20were%20identical%20to%20those%20given%20by%20NONMEM.%20Some%20discordances%20could%20be%20observed%20when%20dose-related%20parameters%20were%20estimated%20or%20when%20models%20with%20large%20IIV%20were%20used.%20The%20exploration%20of%20objective%20function%20values%20suggested%20that%20mapbayr%20might%20outdo%20NONMEM%20in%20specific%20cases.%20For%20the%20real%20models%2C%20a%20concordance%20close%20to%20100%25%20on%20PK%20outcomes%20was%20observed.%20The%20mapbayr%20package%20provides%20a%20reliable%20solution%20to%20perform%20MAP-BE%20of%20PK%20parameters%20in%20R.%20It%20also%20includes%20functions%20dedicated%20to%20data%20formatting%20and%20reporting%20and%20enables%20the%20creation%20of%20standalone%20Shiny%20web%20applications%20dedicated%20to%20MIPD%2C%20whatever%20the%20model%20or%20the%20clinical%20protocol%20and%20without%20additional%20software%20other%20than%20R.%22%2C%22date%22%3A%222021-10%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fpsp4.12689%22%2C%22ISSN%22%3A%222163-8306%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-10-29T14%3A22%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22KWJ4UNWZ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gallais%20et%20al.%22%2C%22parsedDate%22%3A%222021-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGallais%2C%20Fanny%2C%20Lo%26%23xEF%3Bc%20Ysebaert%2C%20Fabien%20Despas%2C%20Sandra%20De%20Barros%2C%20Lucie%20Ob%26%23xE9%3Bric%2C%20Ben%20Allal%2C%20Etienne%20Chatelut%2C%20and%20M%26%23xE9%3Blanie%20White-Koning.%20%26%23x201C%3BPopulation%20PK-PD%20Modeling%20of%20Circulating%20Lymphocyte%20Dynamics%20in%20Chronic%20Lymphocytic%20Leukemia%20Patients%20Under%20Ibrutinib%20Treatment.%26%23x201D%3B%20%3Ci%3EClinical%20Pharmacology%20and%20Therapeutics%3C%5C%2Fi%3E%20110%2C%20no.%201%20%28July%202021%29%3A%20220%26%23x2013%3B28.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcpt.2189%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcpt.2189%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Population%20PK-PD%20Modeling%20of%20Circulating%20Lymphocyte%20Dynamics%20in%20Chronic%20Lymphocytic%20Leukemia%20Patients%20Under%20Ibrutinib%20Treatment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fanny%22%2C%22lastName%22%3A%22Gallais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Despas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22De%20Barros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Ob%5Cu00e9ric%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ben%22%2C%22lastName%22%3A%22Allal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lanie%22%2C%22lastName%22%3A%22White-Koning%22%7D%5D%2C%22abstractNote%22%3A%22Ibrutinib%20is%20indicated%20for%20the%20treatment%20of%20chronic%20lymphocytic%20leukemia%20%28CLL%29.%20Absolute%20lymphocyte%20count%20%28ALC%29%20is%20a%20clinical%20criterion%20used%20for%20the%20monitoring%20of%20CLL.%20Ibrutinib%20has%20several%20effects%20on%20lymphocytes%2C%20and%20has%20highly%20variable%20pharmacokinetics%20%28PK%29.%20The%20objective%20of%20this%20work%20was%20to%20build%20a%20PK-pharmacodynamic%20%28PD%29%20model%20describing%20ALC%20dynamics%20under%20ibrutinib%20treatment%20in%20patients%20with%20CLL.%20ALC%20observations%20before%20and%20after%20ibrutinib%20treatment%20initiation%20in%20patients%20with%20CLL%20were%20included%20in%20the%20analysis.%20A%20population%20PK-PD%20model%20was%20developed%20based%20on%20physio-pharmacological%20knowledge.%20Individual%20PK%20concentrations%20at%20each%20hospital%20visit%20were%20included%20in%20the%20model.%20The%20association%20between%20PD%20parameters%20and%20lymphocytosis%2C%20and%20between%20PD%20parameters%20and%20response%20to%20treatment%20were%20assessed.%20A%20total%20of%2094%20patients%2C%20658%20ALC%20and%201%2C501%20PK%20observations%20were%20included%20in%20model%20development.%20The%20final%20PK-PD%20model%20accurately%20described%20ALC%20dynamics%20for%20different%20patient%20profiles.%20It%20consisted%20in%20two%20compartments%20%28tissues%20and%20blood%20circulation%29%20with%20ibrutinib%20plasmatic%20concentration%20inducing%20two%20drug%20effects%3A%20stimulation%20of%20lymphocyte%20redistribution%20and%20death.%20Patients%20with%20hyperlymphocytosis%20had%20significantly%20higher%20tissues%20to%20circulation%20baseline%20lymphocyte%20count%20ratio%2C%20and%20lower%20death%20effect.%20Patients%20who%20progressed%20under%20ibrutinib%20had%20significantly%20lower%20baseline%20lymphocyte%20counts%20in%20tissues%20%282-fold%20lower%29%20and%20blood%20%283-fold%20lower%29.%20The%20first%20PK-PD%20model%20for%20ALC%20in%20patients%20with%20CLL%20under%20ibrutinib%20treatment%20was%20developed.%20This%20model%20suggests%20that%20estimated%20lymphocyte%20counts%20in%20tissues%20and%20blood%20could%20be%20used%20as%20an%20early%20predictor%20of%20response%20in%20patients%20with%20CLL.%22%2C%22date%22%3A%222021-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fcpt.2189%22%2C%22ISSN%22%3A%221532-6535%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-10-12T10%3A50%3A39Z%22%7D%7D%2C%7B%22key%22%3A%226M5QYW58%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22White-Koning%20et%20al.%22%2C%22parsedDate%22%3A%222021-07%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EWhite-Koning%2C%20Melanie%2C%20Marie%20No%26%23xEB%3Blle%20Paludetto%2C%20F%26%23xE9%3Blicien%20Le%20Louedec%2C%20Laurence%20Gladieff%2C%20Christine%20Chevreau%2C%20Etienne%20Chatelut%2C%20and%20Florent%20Puisset.%20%26%23x201C%3BCorrection%20to%3A%20Formulae%20Recently%20Proposed%20to%20Estimate%20Renal%20Glomerular%20Filtration%20Rate%20Improve%20the%20Prediction%20of%20Carboplatin%20Clearance.%26%23x201D%3B%20%3Ci%3ECancer%20Chemotherapy%20and%20Pharmacology%3C%5C%2Fi%3E%2088%2C%20no.%201%20%28July%202021%29%3A%20171.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00280-021-04268-4%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00280-021-04268-4%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Correction%20to%3A%20Formulae%20recently%20proposed%20to%20estimate%20renal%20glomerular%20filtration%20rate%20improve%20the%20prediction%20of%20carboplatin%20clearance%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melanie%22%2C%22lastName%22%3A%22White-Koning%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20No%5Cu00eblle%22%2C%22lastName%22%3A%22Paludetto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%5Cu00e9licien%22%2C%22lastName%22%3A%22Le%20Louedec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Gladieff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Chevreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Puisset%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222021-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00280-021-04268-4%22%2C%22ISSN%22%3A%221432-0843%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-10-12T10%3A51%3A20Z%22%7D%7D%2C%7B%22key%22%3A%22FJGWANBI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Thomas%20et%20al.%22%2C%22parsedDate%22%3A%222021-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EThomas%2C%20F.%2C%20M.%20Maillard%2C%20M.%20Launay%2C%20C.%20Tron%2C%20M.-C.%20Etienne-Grimaldi%2C%20E.%20Gautier-Veyret%2C%20V.%20Haufroid%2C%20et%20al.%20%26%23x201C%3BArtificial%20Increase%20of%20Uracilemia%20during%20Fluoropyrimidine%20Treatment%20Can%20Lead%20to%20DPD%20Deficiency%20Misinterpretation.%26%23x201D%3B%20%3Ci%3EAnnals%20of%20Oncology%3A%20Official%20Journal%20of%20the%20European%20Society%20for%20Medical%20Oncology%3C%5C%2Fi%3E%2032%2C%20no.%206%20%28June%202021%29%3A%20810%26%23x2013%3B11.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annonc.2021.02.020%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annonc.2021.02.020%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Artificial%20increase%20of%20uracilemia%20during%20fluoropyrimidine%20treatment%20can%20lead%20to%20DPD%20deficiency%20misinterpretation%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Maillard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Launay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Tron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.-C.%22%2C%22lastName%22%3A%22Etienne-Grimaldi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Gautier-Veyret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Haufroid%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Pallet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Royer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Narjoz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Schmitt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Groupe%20de%20Pharmacologie%20Clinique%20Oncologique%20%28GPCO-UNICANCER%29%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222021-06%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.annonc.2021.02.020%22%2C%22ISSN%22%3A%221569-8041%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-07-22T11%3A12%3A52Z%22%7D%7D%2C%7B%22key%22%3A%22D5GQBKCV%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mourey%20et%20al.%22%2C%22parsedDate%22%3A%222021-06%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMourey%2C%20Lo%26%23xEF%3Bc%2C%20F%26%23xE9%3Blicien%20Le%20Louedec%2C%20Alain%20Ravaud%2C%20Marie-No%26%23xEB%3Blle%20Paludetto%2C%20Laurence%20Digue%2C%20Carlos%20Alberto%20Gomez-Roca%2C%20Thibaud%20Valentin%2C%20et%20al.%20%26%23x201C%3BVOTRAGE%20Study%3A%20Phase%20I%20Dose-Escalation%20Study%20of%20Pazopanib%20in%20Unfit%20Older%20Patients.%26%23x201D%3B%20%3Ci%3EJournal%20of%20Geriatric%20Oncology%3C%5C%2Fi%3E%2012%2C%20no.%205%20%28June%202021%29%3A%20759%26%23x2013%3B64.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jgo.2021.02.006%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jgo.2021.02.006%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22VOTRAGE%20study%3A%20Phase%20I%20dose-escalation%20study%20of%20pazopanib%20in%20unfit%20older%20patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Mourey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%5Cu00e9licien%22%2C%22lastName%22%3A%22Le%20Louedec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Ravaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-No%5Cu00eblle%22%2C%22lastName%22%3A%22Paludetto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Digue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%20Alberto%22%2C%22lastName%22%3A%22Gomez-Roca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaud%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Balardy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Olivier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Cabarrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Pazopanib%20is%20a%20tyrosine%20kinase%20inhibitor%20given%20at%20the%20approved%20dose%20of%20800%5Cu00a0mg%20orally%20once%20daily%20%28OD%29%2C%20but%20often%20requiring%20individual%20dose%20adjustment%20due%20to%20toxicity.%20Limited%20data%20is%20available%20to%20guide%20prescription%20in%20older%20patients%20especially%20the%20unfit%20according%20to%20geriatric%20assessment.%5CnPATIENTS%20AND%20METHODS%3A%20VOTRAGE%20is%20a%203%5Cu00a0%2B%5Cu00a03%20dose-escalation%2C%20open-label%20phase%20I%20trial%20of%20continuous%20OD%20oral%20administration%20of%20pazopanib%20to%20evaluate%20safety%2C%20PK%20and%20PD%20data%20in%20unfit%20older%20patients%20with%20advanced%20solid%20tumors.%20The%20primary%20objective%20was%20to%20determine%20the%20maximum%20tolerated%20dose%20%28MTD%29.%20PK%20data%20were%20compared%20with%20those%20obtained%20in%20younger%20adult%20patients%20in%20a%20population%20PK%20analysis.%5CnRESULTS%3A%20Eighteen%20patients%20with%20a%20median%20age%20of%2082.5%5Cu00a0years%20%28range%2075-91%29%20were%20included%20in%20three%20dosing%20cohorts%20%28400%2C%20600%2C%20and%20800%5Cu00a0mg%20daily%29.%20Three%20dose-limiting%20toxicities%20%28DLT%29%20were%20observed%20in%20five%20patients%20at%20800%5Cu00a0mg%20and%20one%20DLT%20at%20600%5Cu00a0mg%20in%20six%20evaluable%20patients.%20MTD%20was%20defined%20as%20level%202%20dose%20%28600%5Cu00a0mg%29.%20Individual%20oral%20clearance%20was%20not%20correlated%20with%20age.%20A%20relationship%20was%20observed%20between%20the%20occurrence%20of%20DLT%20and%20pazopanib%20plasma%20exposure.%20Decreased%20oral%20bioavailability%20of%20pazopanib%20when%20given%20with%20proton-pump%20inhibitors%20was%20confirmed%20in%20this%20group%20of%20patients.%5CnCONCLUSION%3A%20We%20recommend%20performing%20geriatric%20assessment%20in%20patients%20older%20than%2075%20and%20starting%20pazopanib%20at%20600%5Cu00a0mg%20per%20day%20in%20unfit%20older%20patients.%20Therapeutic%20drug%20monitoring%20appears%20very%20helpful%20in%20this%20population.%22%2C%22date%22%3A%222021-06%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jgo.2021.02.006%22%2C%22ISSN%22%3A%221879-4076%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-10-12T10%3A51%3A12Z%22%7D%7D%2C%7B%22key%22%3A%22NMGHD84D%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Puszkiel%20et%20al.%22%2C%22parsedDate%22%3A%222021-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPuszkiel%2C%20Alicja%2C%20C%26%23xE9%3Bcile%20Arellano%2C%20Christelle%20Vachoux%2C%20Alexandre%20Evrard%2C%20Val%26%23xE9%3Brie%20Le%20Morvan%2C%20Jean-Christophe%20Boyer%2C%20Jacques%20Robert%2C%20et%20al.%20%26%23x201C%3BModel-Based%20Quantification%20of%20Impact%20of%20Genetic%20Polymorphisms%20and%20Co-Medications%20on%20Pharmacokinetics%20of%20Tamoxifen%20and%20Six%20Metabolites%20in%20Breast%20Cancer.%26%23x201D%3B%20%3Ci%3EClinical%20Pharmacology%20and%20Therapeutics%3C%5C%2Fi%3E%20109%2C%20no.%205%20%28May%202021%29%3A%201244%26%23x2013%3B55.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcpt.2077%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcpt.2077%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Model-Based%20Quantification%20of%20Impact%20of%20Genetic%20Polymorphisms%20and%20Co-Medications%20on%20Pharmacokinetics%20of%20Tamoxifen%20and%20Six%20Metabolites%20in%20Breast%20Cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alicja%22%2C%22lastName%22%3A%22Puszkiel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Arellano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christelle%22%2C%22lastName%22%3A%22Vachoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Evrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Le%20Morvan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Christophe%22%2C%22lastName%22%3A%22Boyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Delmas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Dalenc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Debled%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Venat-Bouvet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%22%2C%22lastName%22%3A%22Jacot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Dohollou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Bernard-Marty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hortense%22%2C%22lastName%22%3A%22Laharie-Mineur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Henri%22%2C%22lastName%22%3A%22Roch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melanie%22%2C%22lastName%22%3A%22White-Koning%22%7D%5D%2C%22abstractNote%22%3A%22Variations%20in%20clinical%20response%20to%20tamoxifen%20%28TAM%29%20may%20be%20related%20to%20polymorphic%20cytochromes%20P450%20%28CYPs%29%20involved%20in%20forming%20its%20active%20metabolite%20endoxifen%20%28ENDO%29.%20We%20developed%20a%20population%20pharmacokinetic%20%28PopPK%29%20model%20for%20tamoxifen%20and%20six%20metabolites%20to%20determine%20clinically%20relevant%20factors%20of%20ENDO%20exposure.%20Concentration-time%20data%20for%20TAM%20and%206%20metabolites%20come%20from%20a%20prospective%2C%20multicenter%2C%203-year%20follow-up%20study%20of%20adjuvant%20TAM%20%2820%5Cu00a0mg%5C%2Fday%29%20in%20patients%20with%20breast%20cancer%2C%20with%20plasma%20samples%20drawn%20every%206%5Cu00a0months%2C%20and%20genotypes%20for%2063%20genetic%20polymorphisms%20%28PHACS%20study%2C%20NCT01127295%29.%20Concentration%20data%20for%20TAM%20and%206%20metabolites%20from%20928%20patients%20%28n%5Cu00a0%3D%5Cu00a027%2C433%20concentrations%29%20were%20analyzed%20simultaneously%20with%20a%207-compartment%20PopPK%20model.%20CYP2D6%20phenotype%20%28poor%20metabolizer%20%28PM%29%2C%20intermediate%20metabolizer%20%28IM%29%2C%20normal%20metabolizer%20%28NM%29%2C%20and%20ultra-rapid%20metabolizer%20%28UM%29%29%2C%20CYP3A4%2A22%2C%20CYP2C19%2A2%2C%20and%20CYP2B6%2A6%20genotypes%2C%20concomitant%20CYP2D6%20inhibitors%2C%20age%2C%20and%20body%20weight%20had%20a%20significant%20impact%20on%20TAM%20metabolism.%20Formation%20of%20ENDO%20from%20N-desmethyltamoxifen%20was%20decreased%20by%2084%25%20%28relative%20standard%20error%20%28RSE%29%5Cu00a0%3D%5Cu00a014%25%29%20in%20PM%20patients%20and%20by%2047%25%20%28RSE%5Cu00a0%3D%5Cu00a09%25%29%20in%20IM%20patients%20and%20increased%20in%20UM%20patients%20by%2027%25%20%28RSE%5Cu00a0%3D%5Cu00a012%25%29%20compared%20with%20NM%20patients.%20Dose-adjustment%20simulations%20support%20an%20increase%20from%2020%5Cu00a0mg%5C%2Fday%20to%2040%20and%2080%5Cu00a0mg%5C%2Fday%20in%20IM%20patients%20and%20PM%20patients%2C%20respectively%2C%20to%20reach%20ENDO%20levels%20similar%20to%20those%20in%20NM%20patients.%20However%2C%20when%20considering%20Antiestrogenic%20Activity%20Score%20%28AAS%29%2C%20a%20dose%20increase%20to%2060%5Cu00a0mg%5C%2Fday%20in%20PM%20patients%20seems%20sufficient.%20This%20PopPK%20model%20can%20be%20used%20as%20a%20tool%20to%20predict%20ENDO%20levels%20or%20AAS%20according%20to%20the%20patient%27s%20CYP2D6%20phenotype%20for%20TAM%20dose%20adaptation.%22%2C%22date%22%3A%222021-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fcpt.2077%22%2C%22ISSN%22%3A%221532-6535%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-06-16T13%3A50%3A39Z%22%7D%7D%2C%7B%22key%22%3A%2266QID6ER%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maillard%20et%20al.%22%2C%22parsedDate%22%3A%222021-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMaillard%2C%20Maud%2C%20Audrey%20Eche-Gass%2C%20Mony%20Ung%2C%20Aur%26%23xE9%3Blie%20Brice%2C%20Sabrina%20Marsili%2C%20Marion%20Montastruc%2C%20Florent%20Puisset%2C%20and%20Fabienne%20Thomas.%20%26%23x201C%3BSevere%20Toxicity%20of%20Capecitabine%20in%20a%20Patient%20with%20DPD%20Deficiency%20after%20a%20Safe%20FEC-100%20Experience%3A%20Why%20We%20Should%20Test%20DPD%20Deficiency%20in%20All%20Patients%20before%20High-Dose%20Fluoropyrimidines.%26%23x201D%3B%20%3Ci%3ECancer%20Chemotherapy%20and%20Pharmacology%3C%5C%2Fi%3E%2087%2C%20no.%204%20%28April%202021%29%3A%20579%26%23x2013%3B83.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00280-021-04233-1%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00280-021-04233-1%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Severe%20toxicity%20of%20capecitabine%20in%20a%20patient%20with%20DPD%20deficiency%20after%20a%20safe%20FEC-100%20experience%3A%20why%20we%20should%20test%20DPD%20deficiency%20in%20all%20patients%20before%20high-dose%20fluoropyrimidines%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maud%22%2C%22lastName%22%3A%22Maillard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Eche-Gass%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mony%22%2C%22lastName%22%3A%22Ung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Brice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabrina%22%2C%22lastName%22%3A%22Marsili%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Montastruc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Puisset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Thomas%22%7D%5D%2C%22abstractNote%22%3A%22We%20report%20the%20case%20of%20a%2044-year-old%20patient%20who%20experienced%20severe%20toxicity%20while%20being%20treated%20with%20capecitabine%20at%20standard%20dose%20for%20metastatic%20breast%20cancer.%20As%20the%20patient%20had%20already%20received%205-FU%20within%20the%20FEC%20protocol%20%285-FU%20500%5Cu00a0mg%5C%2Fm2%2C%20epirubicin%20100%5Cu00a0mg%5C%2Fm2%2C%20and%20cyclophosphamide%20500%5Cu00a0mg%5C%2Fm2%29%2010%5Cu00a0years%20ago%20without%20experiencing%20any%20severe%20adverse%20event%2C%20no%20DPD%20deficiency%20testing%20was%20performed%20before%20capecitabine%20treatment.%20Nevertheless%2C%20she%20experienced%20severe%20diarrhea%20and%20grade%202%20hand-foot%20syndrome%20from%20the%20first%20cycle%2C%20forcing%20her%20to%20stop%20the%20treatment.%20Phenotypic%20and%20genotypic%20investigation%20of%20DPD%20activity%20revealed%20that%20the%20patient%20had%20a%20partial%20deficiency%20and%20had%20therefore%20been%20exposed%20to%20a%20higher%20risk%20of%20developing%20severe%20toxicities%20on%20fluoropyrimidines.%20This%20case%20proves%20that%20tolerance%20to%20low-dose%20fluoropyrimidines%20does%20not%20preclude%20DPD%20deficiency%20and%20the%20occurrence%20of%20severe%20toxicities%20if%20higher%20doses%20of%20fluoropyrimidines%20are%20used%20as%20a%20second-line%20treatment.%20It%20emphasizes%20the%20role%20of%20DPD%20phenotyping%20testing%20based%20on%20uracilemia%20in%20patients%20scheduled%20for%20fluoropyrimidine%20drugs%2C%20even%20if%20previous%20courses%20with%20low-dose%205-FU%20were%20safely%20administered.%22%2C%22date%22%3A%222021-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00280-021-04233-1%22%2C%22ISSN%22%3A%221432-0843%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-11-15T17%3A46%3A31Z%22%7D%7D%2C%7B%22key%22%3A%22VKTFXBTB%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chevreau%20et%20al.%22%2C%22parsedDate%22%3A%222021-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EChevreau%2C%20Christine%2C%20Christophe%20Massard%2C%20Aude%20Flechon%2C%20R%26%23xE9%3Bmy%20Delva%2C%20Gwena%26%23xEB%3Blle%20Gravis%2C%20Jean-Pierre%20Lotz%2C%20Jacques-Olivier%20Bay%2C%20et%20al.%20%26%23x201C%3BMulticentric%20Phase%20II%20Trial%20of%20TI-CE%20High-Dose%20Chemotherapy%20with%20Therapeutic%20Drug%20Monitoring%20of%20Carboplatin%20in%20Patients%20with%20Relapsed%20Advanced%20Germ%20Cell%20Tumors.%26%23x201D%3B%20%3Ci%3ECancer%20Medicine%3C%5C%2Fi%3E%2010%2C%20no.%207%20%28April%202021%29%3A%202250%26%23x2013%3B58.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcam4.3687%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcam4.3687%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Multicentric%20phase%20II%20trial%20of%20TI-CE%20high-dose%20chemotherapy%20with%20therapeutic%20drug%20monitoring%20of%20carboplatin%20in%20patients%20with%20relapsed%20advanced%20germ%20cell%20tumors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Chevreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Massard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aude%22%2C%22lastName%22%3A%22Flechon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%5Cu00e9my%22%2C%22lastName%22%3A%22Delva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwena%5Cu00eblle%22%2C%22lastName%22%3A%22Gravis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Lotz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques-Olivier%22%2C%22lastName%22%3A%22Bay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Gross-Goupil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karim%22%2C%22lastName%22%3A%22Fizazi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Mourey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angelo%22%2C%22lastName%22%3A%22Paci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Guitton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9n%5Cu00e9dicte%22%2C%22lastName%22%3A%22Leli%5Cu00e8vre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Ciccolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sotheara%22%2C%22lastName%22%3A%22Moeung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yohan%22%2C%22lastName%22%3A%22Gallois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Olivier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Culine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20High-dose%20chemotherapy%20%28HDCT%29%20with%20TI-CE%20regimen%20is%20a%20valid%20option%20for%20the%20treatment%20of%20relapsed%20advanced%20germ%20cell%20tumors%20%28GCT%29.%20We%20report%20a%20phase%20II%20trial%20with%20therapeutic%20drug%20monitoring%20of%20carboplatin%20for%20optimizing%20area%20under%20the%20curve%20%28AUC%29%20of%20this%20drug.%5CnMETHODS%3A%20Patients%20with%20unfavorable%20relapsed%20GCT%20were%20treated%20according%20to%20TI-CE%20regimen%3A%20two%20cycles%20combining%20paclitaxel%20and%20ifosfamide%20followed%20by%20three%20cycles%20of%20HD%20carboplatin%20plus%20etoposide%20administered%20on%203%5Cu00a0days.%20Carboplatin%20dose%20was%20adapted%20on%20day%203%20based%20on%20carboplatin%20clearance%20%28CL%29%20at%20day%201%20in%20order%20to%20reach%20a%20target%20AUC%20of%2024%5Cu00a0mg.min%5C%2FmL%20per%20cycle.%20The%20primary%20endpoint%20was%20the%20complete%20response%20%28CR%29%20rate.%5CnRESULTS%3A%20Eighty-nine%20patients%20who%20received%20HDCT%20were%20included%20in%20the%20modified%20intent-to-treat%20%28mITT%29%20analysis.%20Measured%20mean%20AUC%20was%2024.4%5Cu00a0mg.min%5C%2FmL%20per%20cycle%20%2822.4%20and%2026.8%5Cu00a0mg.min%5C%2FmL%20for%2010th%20and%2090th%20percentiles%29.%20Thirty-five%20%2844.3%25%29%20patients%20achieved%20a%20CR%20with%20or%20without%20surgery%20of%20residual%20masses%20and%2020%20patients%20achieved%20a%20partial%20response%20with%20negative%20tumor%20markers.%20With%20a%20median%20follow-up%20of%2044%5Cu00a0months%20%28m%29%2C%20median%20PFS%20was%2012.3%5Cu00a0m%20%2895%25%20CI%3A%207.5-25.9%29%20and%20OS%20was%2046.3%5Cu00a0m%20%2895%25%20CI%3A%2018.6-not%20reached%29.%20For%20high-%20and%20very%20high-risk%20patients%2C%20according%20to%20the%20International%20Prognostic%20Score%20at%20first%20relapse%20or%20treated%20after%20at%20least%20one%20salvage%20treatment%20%28n%5Cu00a0%3D%5Cu00a051%29%2C%202-year%20PFS%20rate%20was%2041.1%25.%5CnCONCLUSION%3A%20The%20rates%20of%20complete%20and%20favorable%20responses%20were%20clinically%20relevant%20in%20this%20very%20poor%20risk%20population.%20Individual%20monitoring%20of%20carboplatin%20plasma%20concentration%20permitted%20to%20control%20more%20accurately%20the%20target%20AUC%20and%20avoided%20both%20underexposure%20and%20overexposure%20to%20the%20drug.%22%2C%22date%22%3A%222021-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fcam4.3687%22%2C%22ISSN%22%3A%222045-7634%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-06-16T10%3A50%3A41Z%22%7D%7D%2C%7B%22key%22%3A%22M4KTLFY2%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Medrano%20et%20al.%22%2C%22parsedDate%22%3A%222021-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMedrano%2C%20Chlo%26%23xE9%3B%2C%20Lucie%20Oberic%2C%20Florent%20Puisset%2C%20Christian%20Recher%2C%20Delphine%20Larrieu-Ciron%2C%20Lo%26%23xEF%3Bc%20Ysebaert%2C%20Caroline%20Protin%2C%20et%20al.%20%26%23x201C%3BLife-Threatening%20Complications%20after%20High-Dose%20Methotrexate%20and%20the%20Benefits%20of%20Glucarpidase%20as%20Salvage%20Therapy%3A%20A%20Cohort%20Study%20of%20468%20Patients.%26%23x201D%3B%20%3Ci%3ELeukemia%20%26amp%3B%20Lymphoma%3C%5C%2Fi%3E%2062%2C%20no.%204%20%28April%202021%29%3A%20846%26%23x2013%3B53.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F10428194.2020.1846733%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F10428194.2020.1846733%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Life-threatening%20complications%20after%20high-dose%20methotrexate%20and%20the%20benefits%20of%20glucarpidase%20as%20salvage%20therapy%3A%20a%20cohort%20study%20of%20468%20patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chlo%5Cu00e9%22%2C%22lastName%22%3A%22Medrano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Oberic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Puisset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Recher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Larrieu-Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Protin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Picard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Perriat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Bertoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Huguet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Tavitian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stanislas%22%2C%22lastName%22%3A%22Faguer%22%7D%5D%2C%22abstractNote%22%3A%22The%20aims%20of%20this%20study%20were%20to%20characterize%20the%20incidence%20and%20outcomes%20of%20severe%20toxicities%20following%20the%20administration%20of%20high-dose%20methotrexate%20%28HD-MTX%3B%20%5Cu22651%5Cu2009g%5C%2Fm2%29.%20Among%20the%20468%20patients%20included%20in%20the%20study%2C%2069%20%2814.9%25%29%20developed%20at%20least%20one%20episode%20of%20acute%20kidney%20injury%20%28AKI%3B%20138%5C%2F1264%5Cu2009HD-MTX%20administrations%29%2C%20including%2034%20%287.2%25%29%20who%20developed%20KDIGO%20stage%202-3%20AKI.%20The%20three%20baseline%20factors%20independently%20associated%20with%20the%20risk%20of%20developing%20AKI%20were%20age%2C%20body%20mass%20index%20and%20a%20diagnosis%20of%20acute%20lymphoblastic%20leukemia.%20Higher%20plasma%20MTX%20concentration%20was%20associated%20with%20AKI%20and%20extra-renal%20toxicities.%20Notwithstanding%20potentially%20confounding%20factors%2C%20most%20patients%20with%20AKI%20who%20received%20glucarpidase%20%28n%5Cu2009%3D%5Cu200941%29%20developed%20extra-renal%20toxicity%20%28leading%20to%20the%20death%20of%20two%20patients%29%20despite%20early%20administration.%20Thus%2C%20severe%20toxicity%20and%20death%20can%20occur%20whether%20or%20not%20glucarpidase%20is%20administered%2C%20which%20confirms%20the%20need%20for%20further%20interventional%20studies%20to%20provide%20greater%20precision%20on%20its%20role%20in%20the%20management%20of%20HD-MTX%20toxicity.%22%2C%22date%22%3A%222021-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1080%5C%2F10428194.2020.1846733%22%2C%22ISSN%22%3A%221029-2403%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-06-16T13%3A51%3A56Z%22%7D%7D%2C%7B%22key%22%3A%22SSNIJ9H6%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chatelut%20et%20al.%22%2C%22parsedDate%22%3A%222021-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EChatelut%2C%20Etienne%2C%20Jeroen%20J.%20M.%20A.%20Hendrikx%2C%20Jennifer%20Martin%2C%20Joseph%20Ciccolini%2C%20and%20Dirk%20Jan%20A.%20R.%20Moes.%20%26%23x201C%3BUnraveling%20the%20Complexity%20of%20Therapeutic%20Drug%20Monitoring%20for%20Monoclonal%20Antibody%20Therapies%20to%20Individualize%20Dose%20in%20Oncology.%26%23x201D%3B%20%3Ci%3EPharmacology%20Research%20%26amp%3B%20Perspectives%3C%5C%2Fi%3E%209%2C%20no.%202%20%28April%202021%29%3A%20e00757.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fprp2.757%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fprp2.757%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Unraveling%20the%20complexity%20of%20therapeutic%20drug%20monitoring%20for%20monoclonal%20antibody%20therapies%20to%20individualize%20dose%20in%20oncology%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeroen%20J.%20M.%20A.%22%2C%22lastName%22%3A%22Hendrikx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Ciccolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dirk%20Jan%20A.%20R.%22%2C%22lastName%22%3A%22Moes%22%7D%5D%2C%22abstractNote%22%3A%22Monoclonal%20antibodies%20%28Mabs%29%20have%20become%20key%20drugs%20in%20cancer%20treatment%2C%20either%20as%20targeted%20therapies%20or%20more%20recently%20as%20immune%20checkpoint%20inhibitors%20%28ICIs%29.%20The%20fact%20that%20only%20some%20patients%20benefit%20from%20these%20drugs%20poses%20the%20usual%20question%20in%20the%20field%20of%20onco-hematology%3A%20that%20of%20the%20benefit%20of%20individual%20dosing%20and%20the%20potential%20of%20therapeutic%20drug%20monitoring%20%28TDM%29%20to%20carry%20out%20this%20individualization.%20However%2C%20Mabs%20present%20unique%20pharmacological%20characteristics%20for%20TDM%2C%20and%20the%20pharmacokinetic-pharmacodynamic%20relationship%20observed%20should%20be%20interpreted%20differently%20than%20that%20observed%20for%20conventional%20drugs%20and%20small%20molecules.%20This%20pharmacology%20practice%20review%20has%20been%20summarized%20from%20a%20public%20debate%20between%20the%20authors%20at%20the%20International%20TDM%20and%20Clinical%20Toxicology%20meeting%20in%20Banff%2C%202020%2C%20regarding%20the%20potential%20roles%20of%20TDM%20in%20the%20Mab%5C%2FICI%20setting.%22%2C%22date%22%3A%222021-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fprp2.757%22%2C%22ISSN%22%3A%222052-1707%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-06-16T10%3A50%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22A9CDJ975%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Le%20Louedec%20et%20al.%22%2C%22parsedDate%22%3A%222021-02-18%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELe%20Louedec%2C%20F%26%23xE9%3Blicien%2C%20Fanny%20Gallais%2C%20Fabienne%20Thomas%2C%20M%26%23xE9%3Blanie%20White-Koning%2C%20Ben%20Allal%2C%20Caroline%20Protin%2C%20Lo%26%23xEF%3Bc%20Ysebaert%2C%20%26%23xC9%3Btienne%20Chatelut%2C%20and%20Florent%20Puisset.%20%26%23x201C%3BLimited%20Sampling%20Strategy%20for%20Determination%20of%20Ibrutinib%20Plasma%20Exposure%3A%20Joint%20Analyses%20with%20Metabolite%20Data.%26%23x201D%3B%20%3Ci%3EPharmaceuticals%20%28Basel%2C%20Switzerland%29%3C%5C%2Fi%3E%2014%2C%20no.%202%20%28February%2018%2C%202021%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fph14020162%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fph14020162%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Limited%20Sampling%20Strategy%20for%20Determination%20of%20Ibrutinib%20Plasma%20Exposure%3A%20Joint%20Analyses%20with%20Metabolite%20Data%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%5Cu00e9licien%22%2C%22lastName%22%3A%22Le%20Louedec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fanny%22%2C%22lastName%22%3A%22Gallais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lanie%22%2C%22lastName%22%3A%22White-Koning%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ben%22%2C%22lastName%22%3A%22Allal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Protin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c9tienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Puisset%22%7D%5D%2C%22abstractNote%22%3A%22Therapeutic%20drug%20monitoring%20of%20ibrutinib%20is%20based%20on%20the%20area%20under%20the%20curve%20of%20concentration%20vs.%20time%20%28AUCIBRU%29%20instead%20of%20trough%20concentration%20%28Cmin%2Css%29%20because%20of%20a%20limited%20accumulation%20in%20plasma.%20Our%20objective%20was%20to%20identify%20a%20limited%20sampling%20strategy%20%28LSS%29%20to%20estimate%20AUCIBRU%20associated%20with%20Bayesian%20estimation.%20The%20actual%20AUCIBRU%20of%2085%20patients%20was%20determined%20by%20the%20Bayesian%20analysis%20of%20the%20full%20pharmacokinetic%20profile%20of%20ibrutinib%20concentrations%20%28pre-dose%20T0%20and%200.5%2C%201%2C%202%2C%204%20and%206%20h%20post-dose%29%20and%20experimental%20AUCIBRU%20were%20derived%20considering%20combinations%20of%20one%20to%20four%20sampling%20times.%20The%20T0-1-2-4%20design%20was%20the%20most%20accurate%20LSS%20%28root-mean-square%20error%20RMSE%20%3D%2011.0%25%29%2C%20and%20three-point%20strategies%20removing%20the%201%20h%20or%202%20h%20points%20%28RMSE%20%3D%2022.7%25%20and%2014.5%25%2C%20respectively%29%20also%20showed%20good%20accuracy.%20The%20correlation%20between%20the%20actual%20AUCIBRU%20and%20Cmin%2Css%20was%20poor%20%28r2%20%3D%200.25%29.%20The%20joint%20analysis%20of%20dihydrodiol-ibrutinib%20metabolite%20concentrations%20did%20not%20improve%20the%20predictive%20performance%20of%20AUCIBRU.%20These%20results%20were%20confirmed%20in%20a%20prospective%20validation%20cohort%20%28n%20%3D%2027%20patients%29.%20At%20least%20three%20samples%2C%20within%20the%20pre-dose%20and%204%20h%20post-dose%20period%2C%20are%20necessary%20to%20estimate%20ibrutinib%20exposure%20accurately.%22%2C%22date%22%3A%222021-02-18%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fph14020162%22%2C%22ISSN%22%3A%221424-8247%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-06-16T11%3A54%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22STD84G8U%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Larroque-Lombard%20et%20al.%22%2C%22parsedDate%22%3A%222021-02-16%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELarroque-Lombard%2C%20Anne-Laure%2C%20Etienne%20Chatelut%2C%20Jean-Pierre%20Delord%2C%20Diane-Charlotte%20Imbs%2C%20Philippe%20Rochaix%2C%20Bertrand%20Jean-Claude%2C%20and%20Ben%20Allal.%20%26%23x201C%3BDesign%20and%20Mechanism%20of%20Action%20of%20a%20New%20Prototype%20of%20Combi-Molecule%20%26%23x2018%3BProgramed%26%23x2019%3B%20to%20Release%20Bioactive%20Species%20at%20a%20PH%20Range%20Akin%20to%20That%20of%20the%20Tumor%20Microenvironment.%26%23x201D%3B%20%3Ci%3EPharmaceuticals%20%28Basel%2C%20Switzerland%29%3C%5C%2Fi%3E%2014%2C%20no.%202%20%28February%2016%2C%202021%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fph14020160%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fph14020160%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Design%20and%20Mechanism%20of%20Action%20of%20a%20New%20Prototype%20of%20Combi-Molecule%20%5C%22Programed%5C%22%20to%20Release%20Bioactive%20Species%20at%20a%20pH%20Range%20Akin%20to%20That%20of%20the%20Tumor%20Microenvironment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Laure%22%2C%22lastName%22%3A%22Larroque-Lombard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diane-Charlotte%22%2C%22lastName%22%3A%22Imbs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Rochaix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Jean-Claude%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ben%22%2C%22lastName%22%3A%22Allal%22%7D%5D%2C%22abstractNote%22%3A%22The%20clinical%20use%20of%20cytotoxic%20agents%20is%20plagued%20by%20systemic%20toxicity.%20We%20report%20a%20novel%20approach%20that%20seeks%20to%20design%20a%20%5C%22combi-molecule%5C%22%20to%20behave%20as%20an%20alkylating%20agent%20on%20its%20own%20and%20to%20undergo%20acid-catalyzed%20conversion%20to%20two%20bioactive%20species%20at%20a%20pH%20range%20akin%20to%20that%20of%20a%20tumor%20microenvironment%3A%20an%20AL530%20prototype%20was%20synthesized%20and%20we%20studied%20its%20ability%20to%20release%20a%20chlorambucil%20analogue%20%28CBL-A%29%20plus%20a%20potent%20mitogen-activated%20protein%5C%2Fextracellular%20signal-regulated%20kinase%20kinase%20%28MEK%29%20inhibitor%20%28PD98059%29%20at%20different%20pHs%20in%20buffered%20solutions%2C%20plasma%20and%20tumors.%20Its%20potency%20was%20compared%20in%20vitro%20with%20CBL%2BPD98059%20%28SRB%20assay%29%20and%20in%20vivo%20in%20a%20xenograft%20model.%20Its%20target%20modulation%20was%20studied%20by%20western%20blotting%20and%20immunohistochemistry.%20AL530%20released%20PD98059%2BCBL-A%20at%20mild%20acidic%20pH%20and%20in%20vitro%20was%20fivefold%20more%20potent%20than%20CBL%20and%20three-to-fivefold%20more%20potent%20than%20CBL%2BPD98059.%20In%20vivo%20it%20released%20high%20levels%20of%20PD98059%20in%20tumors%20with%20a%20tumor%5C%2Fplasma%20ratio%20of%20five.%20It%20induced%20%5Cu03b3-H2AX%20phosphorylation%20and%20blocked%20pErk1%2C2%2C%20indirectly%20indicating%20its%20ability%20to%20damage%20DNA%20and%20modulate%20MEK.%20It%20induced%20significant%20tumor%20delay%20and%20less%20toxicity%20at%20unachievable%20doses%20for%20CBL%20and%20CBL%2BPD98059.%20We%20demonstrated%20the%20feasibility%20of%20a%20pH-labile%20combi-molecule%20capable%20of%20delivering%20high%20MEK%20inhibitor%20concentration%20in%20tumors%2C%20damaging%20DNA%20therein%2C%20and%20inducing%20tumor%20growth%20delay.%22%2C%22date%22%3A%222021-02-16%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fph14020160%22%2C%22ISSN%22%3A%221424-8247%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-06-16T11%3A53%3A51Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Malier, Marie, Khaldoun Gharzeddine, Marie-Hélène Laverriere, Sabrina Marsili, Fabienne Thomas, Thomas Decaens, Gael Roth, and Arnaud Millet. “Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer.” Cancer Research<\/i> 81, no. 23 (December 1, 2021): 5963–76. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-1572<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Clarke, William A., Etienne Chatelut, Alan K. Fotoohi, Richard A. Larson, Jennifer H. Martin, Ron H. J. Mathijssen, and Salvatore J. Salamone. “Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Consensus Guidelines for Imatinib Therapy.” European Journal of Cancer (Oxford, England: 1990)<\/i> 157 (November 2021): 428–40. https:\/\/doi.org\/10.1016\/j.ejca.2021.08.033<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Le Louedec, Félicien, Florent Puisset, Fabienne Thomas, Étienne Chatelut, and Mélanie White-Koning. “Easy and Reliable Maximum a Posteriori Bayesian Estimation of Pharmacokinetic Parameters with the Open-Source R Package Mapbayr.” CPT: Pharmacometrics & Systems Pharmacology<\/i> 10, no. 10 (October 2021): 1208–20. https:\/\/doi.org\/10.1002\/psp4.12689<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Gallais, Fanny, Loïc Ysebaert, Fabien Despas, Sandra De Barros, Lucie Obéric, Ben Allal, Etienne Chatelut, and Mélanie White-Koning. “Population PK-PD Modeling of Circulating Lymphocyte Dynamics in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment.” Clinical Pharmacology and Therapeutics<\/i> 110, no. 1 (July 2021): 220–28. https:\/\/doi.org\/10.1002\/cpt.2189<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
White-Koning, Melanie, Marie Noëlle Paludetto, Félicien Le Louedec, Laurence Gladieff, Christine Chevreau, Etienne Chatelut, and Florent Puisset. “Correction to: Formulae Recently Proposed to Estimate Renal Glomerular Filtration Rate Improve the Prediction of Carboplatin Clearance.” Cancer Chemotherapy and Pharmacology<\/i> 88, no. 1 (July 2021): 171. https:\/\/doi.org\/10.1007\/s00280-021-04268-4<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Thomas, F., M. Maillard, M. Launay, C. Tron, M.-C. Etienne-Grimaldi, E. Gautier-Veyret, V. Haufroid, et al. “Artificial Increase of Uracilemia during Fluoropyrimidine Treatment Can Lead to DPD Deficiency Misinterpretation.” Annals of Oncology: Official Journal of the European Society for Medical Oncology<\/i> 32, no. 6 (June 2021): 810–11. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.020<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Mourey, Loïc, Félicien Le Louedec, Alain Ravaud, Marie-Noëlle Paludetto, Laurence Digue, Carlos Alberto Gomez-Roca, Thibaud Valentin, et al. “VOTRAGE Study: Phase I Dose-Escalation Study of Pazopanib in Unfit Older Patients.” Journal of Geriatric Oncology<\/i> 12, no. 5 (June 2021): 759–64. https:\/\/doi.org\/10.1016\/j.jgo.2021.02.006<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Puszkiel, Alicja, Cécile Arellano, Christelle Vachoux, Alexandre Evrard, Valérie Le Morvan, Jean-Christophe Boyer, Jacques Robert, et al. “Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer.” Clinical Pharmacology and Therapeutics<\/i> 109, no. 5 (May 2021): 1244–55. https:\/\/doi.org\/10.1002\/cpt.2077<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Maillard, Maud, Audrey Eche-Gass, Mony Ung, Aurélie Brice, Sabrina Marsili, Marion Montastruc, Florent Puisset, and Fabienne Thomas. “Severe Toxicity of Capecitabine in a Patient with DPD Deficiency after a Safe FEC-100 Experience: Why We Should Test DPD Deficiency in All Patients before High-Dose Fluoropyrimidines.” Cancer Chemotherapy and Pharmacology<\/i> 87, no. 4 (April 2021): 579–83. https:\/\/doi.org\/10.1007\/s00280-021-04233-1<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Chevreau, Christine, Christophe Massard, Aude Flechon, Rémy Delva, Gwenaëlle Gravis, Jean-Pierre Lotz, Jacques-Olivier Bay, et al. “Multicentric Phase II Trial of TI-CE High-Dose Chemotherapy with Therapeutic Drug Monitoring of Carboplatin in Patients with Relapsed Advanced Germ Cell Tumors.” Cancer Medicine<\/i> 10, no. 7 (April 2021): 2250–58. https:\/\/doi.org\/10.1002\/cam4.3687<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Medrano, Chloé, Lucie Oberic, Florent Puisset, Christian Recher, Delphine Larrieu-Ciron, Loïc Ysebaert, Caroline Protin, et al. “Life-Threatening Complications after High-Dose Methotrexate and the Benefits of Glucarpidase as Salvage Therapy: A Cohort Study of 468 Patients.” Leukemia & Lymphoma<\/i> 62, no. 4 (April 2021): 846–53. https:\/\/doi.org\/10.1080\/10428194.2020.1846733<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Chatelut, Etienne, Jeroen J. M. A. Hendrikx, Jennifer Martin, Joseph Ciccolini, and Dirk Jan A. R. Moes. “Unraveling the Complexity of Therapeutic Drug Monitoring for Monoclonal Antibody Therapies to Individualize Dose in Oncology.” Pharmacology Research & Perspectives<\/i> 9, no. 2 (April 2021): e00757. https:\/\/doi.org\/10.1002\/prp2.757<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Le Louedec, Félicien, Fanny Gallais, Fabienne Thomas, Mélanie White-Koning, Ben Allal, Caroline Protin, Loïc Ysebaert, Étienne Chatelut, and Florent Puisset. “Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite Data.” Pharmaceuticals (Basel, Switzerland)<\/i> 14, no. 2 (February 18, 2021). https:\/\/doi.org\/10.3390\/ph14020162<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Larroque-Lombard, Anne-Laure, Etienne Chatelut, Jean-Pierre Delord, Diane-Charlotte Imbs, Philippe Rochaix, Bertrand Jean-Claude, and Ben Allal. “Design and Mechanism of Action of a New Prototype of Combi-Molecule ‘Programed’ to Release Bioactive Species at a PH Range Akin to That of the Tumor Microenvironment.” Pharmaceuticals (Basel, Switzerland)<\/i> 14, no. 2 (February 16, 2021). https:\/\/doi.org\/10.3390\/ph14020160<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][et_pb_toggle title=”PUBLICATIONS 2020″ open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.16″ _module_preset=”default” title_text_color=”#505659″ title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_font=”|600|||||||” closed_title_text_align=”center” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” global_colors_info=”{}”]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\tNMTDPBH9<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2020<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 38370<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-f524fb00f95315a31ad07640cbfb0ea4%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22WB2WMVSN%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maillard%20et%20al.%22%2C%22parsedDate%22%3A%222020-12-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMaillard%2C%20Maud%2C%20Christine%20Chevreau%2C%20F%26%23xE9%3Blicien%20Le%20Louedec%2C%20Manon%20Cassou%2C%20Caroline%20Delmas%2C%20Laure%20Gourdain%2C%20Jean-Yves%20Blay%2C%20et%20al.%20%26%23x201C%3BPharmacogenetic%20Study%20of%20Trabectedin-Induced%20Severe%20Hepatotoxicity%20in%20Patients%20with%20Advanced%20Soft%20Tissue%20Sarcoma.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2012%2C%20no.%2012%20%28December%204%2C%202020%29%3A%203647.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12123647%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12123647%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pharmacogenetic%20Study%20of%20Trabectedin-Induced%20Severe%20Hepatotoxicity%20in%20Patients%20with%20Advanced%20Soft%20Tissue%20Sarcoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maud%22%2C%22lastName%22%3A%22Maillard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Chevreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%5Cu00e9licien%22%2C%22lastName%22%3A%22Le%20Louedec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manon%22%2C%22lastName%22%3A%22Cassou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Delmas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Gourdain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Yves%22%2C%22lastName%22%3A%22Blay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Cupissol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Bompas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Italiano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Isambert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Delcambre-Lair%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Penel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Bertucci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Guillemet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Plenecassagnes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Foulon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c9tienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Axel%22%2C%22lastName%22%3A%22Le%20Cesne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Thomas%22%7D%5D%2C%22abstractNote%22%3A%22Hepatotoxicity%20is%20an%20important%20concern%20for%20nearly%2040%25%20of%20the%20patients%20treated%20with%20trabectedin%20for%20advanced%20soft%20tissue%20sarcoma%20%28ASTS%29.%20The%20mechanisms%20underlying%20these%20liver%20damages%20have%20not%20yet%20been%20elucidated%20but%20they%20have%20been%20suggested%20to%20be%20related%20to%20the%20production%20of%20reactive%20metabolites.%20The%20aim%20of%20this%20pharmacogenetic%20study%20was%20to%20identify%20genetic%20variants%20of%20pharmacokinetic%20genes%20such%20as%20CYP450%20and%20ABC%20drug%20transporters%20that%20could%20impair%20the%20trabectedin%20metabolism%20in%20hepatocytes.%20Sixty-three%20patients%20with%20ASTS%20from%20the%20TSAR%20clinical%20trial%20%28NCT02672527%29%20were%20genotyped%20by%20next-generation%20sequencing%20for%2011%20genes%2C%20and%20genotype%5Cu2013toxicity%20association%20analyses%20were%20performed%20with%20R%20package%20SNPassoc.%20Among%20the%20results%2C%20ABCC2%20c.1249A%20allele%20%28rs2273697%29%20and%20ABCG2%20intron%20variant%20c.-15994T%20%28rs7699188%29%20were%20associated%20with%20an%20increased%20risk%20of%20severe%20cytolysis%2C%20whereas%20ABCC2%20c.3563A%20allele%20had%20a%20protective%20effect%2C%20as%20well%20as%20ABCB1%20variants%20rs2032582%20and%20rs1128503%20%28p-value%20%3C%200.05%29.%20Furthermore%2C%20CYP3A5%2A1%20rs776746%20%28c.6986A%20%3E%20G%29%20increased%20the%20risk%20of%20severe%20overall%20hepatotoxicity%20%28p%20%3D%200.012%2C%20odds%20ratio%20%28OR%29%20%3D%205.75%29%2C%20suggesting%20the%20implication%20of%20metabolites%20in%20the%20hepatotoxicity.%20However%2C%20these%20results%20did%20not%20remain%20significant%20after%20multiple%20analysis%20correction.%20These%20findings%20need%20to%20be%20validated%20on%20larger%20cohorts%20of%20patients%2C%20with%20mechanistic%20studies%20potentially%20being%20able%20to%20validate%20the%20functional%20consequences%20of%20these%20variants.%22%2C%22date%22%3A%222020-12-04%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers12123647%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2072-6694%5C%2F12%5C%2F12%5C%2F3647%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A22%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22LXJP9TV3%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Le%20Louedec%20et%20al.%22%2C%22parsedDate%22%3A%222020-10-31%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELe%20Louedec%2C%20F%26%23xE9%3Blicien%2C%20Fanny%20Leenhardt%2C%20Cl%26%23xE9%3Bmence%20Marin%2C%20%26%23xC9%3Btienne%20Chatelut%2C%20Alexandre%20Evrard%2C%20and%20Joseph%20Ciccolini.%20%26%23x201C%3BCancer%20Immunotherapy%20Dosing%3A%20A%20Pharmacokinetic%5C%2FPharmacodynamic%20Perspective.%26%23x201D%3B%20%3Ci%3EVaccines%3C%5C%2Fi%3E%208%2C%20no.%204%20%28October%2031%2C%202020%29%3A%20632.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fvaccines8040632%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fvaccines8040632%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cancer%20Immunotherapy%20Dosing%3A%20A%20Pharmacokinetic%5C%2FPharmacodynamic%20Perspective%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%5Cu00e9licien%22%2C%22lastName%22%3A%22Le%20Louedec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fanny%22%2C%22lastName%22%3A%22Leenhardt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Marin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c9tienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Evrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Ciccolini%22%7D%5D%2C%22abstractNote%22%3A%22Immune%20check-point%20inhibitors%20are%20drugs%20that%20are%20markedly%20different%20from%20other%20anticancer%20drugs%20because%20of%20their%20indirect%20mechanisms%20of%20antitumoral%20action%20and%20their%20apparently%20random%20effect%20in%20terms%20of%20efficacy%20and%20toxicity.%20This%20marked%20pharmacodynamics%20variability%20in%20patients%20calls%20for%20reconsidering%20to%20what%20extent%20approved%20dosing%20used%20in%20clinical%20practice%20are%20optimal%20or%20whether%20they%20should%20require%20efforts%20for%20customization%20in%20outlier%20patients.%20To%20better%20understand%20whether%20or%20not%20dosing%20could%20be%20an%20actionable%20item%20in%20oncology%2C%20in%20this%20review%2C%20preclinical%20and%20clinical%20development%20of%20immune%20checkpoint%20inhibitors%20are%20described%2C%20particularly%20from%20the%20angle%20of%20dose%20finding%20studies.%20Other%20issues%20in%20connection%20with%20dosing%20issues%20are%20developed%2C%20such%20as%20the%20flat%20dosing%20alternative%2C%20the%20putative%20role%20therapeutic%20drug%20monitoring%20could%20play%2C%20the%20rise%20of%20combinatorial%20strategies%2C%20and%20pharmaco-economic%20aspects.%22%2C%22date%22%3A%222020-10-31%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fvaccines8040632%22%2C%22ISSN%22%3A%222076-393X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2076-393X%5C%2F8%5C%2F4%5C%2F632%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22QFBTT6K4%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lambert%20et%20al.%22%2C%22parsedDate%22%3A%222020-10-15%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELambert%2C%20Marie%2C%20Melanie%20White%26%23x2010%3BKoning%2C%20Mathieu%20Alonso%2C%20Arnaud%20Garnier%2C%20Gwennaelle%20Alphonsa%2C%20Chlo%26%23xE9%3B%20Puiseux%2C%20Caroline%20Munzer%2C%20et%20al.%20%26%23x201C%3BPlasma%20Cystatin%20C%20Is%20a%20Marker%20of%20Renal%20Glomerular%20Injury%20in%20Children%20Treated%20with%20Cisplatin%20or%20Ifosfamide.%26%23x201D%3B%20%3Ci%3EPediatric%20Blood%20%26amp%3B%20Cancer%3C%5C%2Fi%3E%2C%20October%2015%2C%202020.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fpbc.28747%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fpbc.28747%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Plasma%20cystatin%20C%20is%20a%20marker%20of%20renal%20glomerular%20injury%20in%20children%20treated%20with%20cisplatin%20or%20ifosfamide%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Lambert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melanie%22%2C%22lastName%22%3A%22White%5Cu2010Koning%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Alonso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Garnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwennaelle%22%2C%22lastName%22%3A%22Alphonsa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chlo%5Cu00e9%22%2C%22lastName%22%3A%22Puiseux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Munzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Berthier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Malard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marl%5Cu00e8ne%22%2C%22lastName%22%3A%22Pasquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-10-15%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1002%5C%2Fpbc.28747%22%2C%22ISSN%22%3A%221545-5009%2C%201545-5017%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2F10.1002%5C%2Fpbc.28747%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22W555H2QD%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Le%20Louedec%20and%20Chatelut%22%2C%22parsedDate%22%3A%222020-10-12%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELe%20Louedec%2C%20F%26%23xE9%3Blicien%2C%20and%20Etienne%20Chatelut.%20%26%23x201C%3BCorrelation%20between%20Bevacizumab%20Exposure%20and%20Survival%20Does%20Not%20Necessarily%20Imply%20Causality.%20Letter%20to%20the%20Editor.%26%23x201D%3B%20%3Ci%3EThe%20Oncologist%3C%5C%2Fi%3E%2C%20October%2012%2C%202020%2C%20onco.13564.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fonco.13564%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fonco.13564%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Correlation%20between%20Bevacizumab%20Exposure%20and%20Survival%20does%20not%20necessarily%20imply%20Causality.%20Letter%20to%20the%20Editor%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%5Cu00e9licien%22%2C%22lastName%22%3A%22Le%20Louedec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-10-12%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1002%5C%2Fonco.13564%22%2C%22ISSN%22%3A%221083-7159%2C%201549-490X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2F10.1002%5C%2Fonco.13564%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A45Z%22%7D%7D%2C%7B%22key%22%3A%22QJXTYVZ4%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maillard%20et%20al.%22%2C%22parsedDate%22%3A%222020-10-05%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMaillard%2C%20Maud%2C%20F%26%23xE9%3Blicien%20Le%20Louedec%2C%20Fabienne%20Thomas%2C%20and%20Etienne%20Chatelut.%20%26%23x201C%3BDiversity%20of%20Dose-Individualization%20and%20Therapeutic%20Drug%20Monitoring%20Practices%20of%20Platinum%20Compounds%3A%20A%20Review.%26%23x201D%3B%20%3Ci%3EExpert%20Opinion%20on%20Drug%20Metabolism%20%26amp%3B%20Toxicology%3C%5C%2Fi%3E%2C%20October%205%2C%202020%2C%201%26%23x2013%3B19.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F17425255.2020.1789590%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F17425255.2020.1789590%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Diversity%20of%20dose-individualization%20and%20therapeutic%20drug%20monitoring%20practices%20of%20platinum%20compounds%3A%20a%20review%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maud%22%2C%22lastName%22%3A%22Maillard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%5Cu00e9licien%22%2C%22lastName%22%3A%22Le%20Louedec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-10-05%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1080%5C%2F17425255.2020.1789590%22%2C%22ISSN%22%3A%221742-5255%2C%201744-7607%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.tandfonline.com%5C%2Fdoi%5C%2Ffull%5C%2F10.1080%5C%2F17425255.2020.1789590%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22D562T6KQ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gallais%20et%20al.%22%2C%22parsedDate%22%3A%222020-09-10%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGallais%2C%20Fanny%2C%20Lucie%20Oberic%2C%20Stanislas%20Faguer%2C%20Suzanne%20Tavitian%2C%20Thierry%20Lafont%2C%20Sabrina%20Marsili%2C%20Aur%26%23xE9%3Blie%20Brice%2C%20Etienne%20Chatelut%2C%20and%20Florent%20Puisset.%20%26%23x201C%3BBody%20Surface%20Area%20Dosing%20of%20High-Dose%20Methotrexate%20Should%20Be%20Reconsidered%2C%20Particularly%20in%20Overweight%2C%20Adult%20Patients.%26%23x201D%3B%20%3Ci%3ETherapeutic%20Drug%20Monitoring%3C%5C%2Fi%3E%20Publish%20Ahead%20of%20Print%20%28September%2010%2C%202020%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FFTD.0000000000000813%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FFTD.0000000000000813%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Body%20Surface%20Area%20Dosing%20of%20High-Dose%20Methotrexate%20Should%20be%20Reconsidered%2C%20Particularly%20in%20Overweight%2C%20Adult%20Patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fanny%22%2C%22lastName%22%3A%22Gallais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Oberic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stanislas%22%2C%22lastName%22%3A%22Faguer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Tavitian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Lafont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabrina%22%2C%22lastName%22%3A%22Marsili%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Brice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Puisset%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-09-10%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1097%5C%2FFTD.0000000000000813%22%2C%22ISSN%22%3A%220163-4356%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjournals.lww.com%5C%2F10.1097%5C%2FFTD.0000000000000813%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A41Z%22%7D%7D%2C%7B%22key%22%3A%22RJ7D838C%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gallais%20et%20al.%22%2C%22parsedDate%22%3A%222020-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGallais%2C%20Fanny%2C%20Lo%26%23xEF%3Bc%20Ysebaert%2C%20Fabien%20Despas%2C%20Sandra%20De%20Barros%2C%20Lo%26%23xEF%3Bc%20Dupr%26%23xE9%3B%2C%20Anne%20Quillet-Mary%2C%20Caroline%20Protin%2C%20et%20al.%20%26%23x201C%3BPopulation%20Pharmacokinetics%20of%20Ibrutinib%20and%20Its%20Dihydrodiol%20Metabolite%20in%20Patients%20with%20Lymphoid%20Malignancies.%26%23x201D%3B%20%3Ci%3EClinical%20Pharmacokinetics%3C%5C%2Fi%3E%2059%2C%20no.%209%20%28September%202020%29%3A%201171%26%23x2013%3B83.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs40262-020-00884-0%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs40262-020-00884-0%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Population%20Pharmacokinetics%20of%20Ibrutinib%20and%20Its%20Dihydrodiol%20Metabolite%20in%20Patients%20with%20Lymphoid%20Malignancies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fanny%22%2C%22lastName%22%3A%22Gallais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Despas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22De%20Barros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Dupr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Quillet-Mary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Protin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Ob%5Cu00e9ric%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ben%22%2C%22lastName%22%3A%22Allal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lanie%22%2C%22lastName%22%3A%22White-Koning%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVE%3A%20Ibrutinib%20is%20used%20for%20the%20treatment%20of%20chronic%20lymphocytic%20leukemia%20and%20other%20lymphoid%20malignancies.%20The%20aim%20of%20this%20work%20is%20to%20develop%20a%20population%20pharmacokinetic%20model%20for%20ibrutinib%20and%20its%20dihydrodiol%20metabolite%20to%20quantify%20pharmacokinetic%20inter-%20and%20intra-individual%20variability%2C%20to%20evaluate%20the%20impact%20of%20several%20covariates%20on%20ibrutinib%20pharmacokinetic%20parameters%2C%20and%20to%20examine%20the%20relationship%20between%20exposure%20and%20clinical%20outcome.%5CnMETHODS%3A%20Patients%20treated%20with%20ibrutinib%20were%20included%20in%20the%20study%20and%20followed%20up%20for%202%5Cu00a0years.%20Pharmacokinetic%20blood%20samples%20were%20taken%20from%20months%201%20to%2012%20after%20inclusion.%20Ibrutinib%20and%20dihydrodiol-ibrutinib%20concentrations%20were%20assessed%20using%20ultra-performance%20liquid%20chromatography%20tandem%20mass%20spectrometry.%20A%20population%20pharmacokinetic%20model%20was%20developed%20using%20NONMEM%20version%207.4.%5CnRESULTS%3A%20A%20total%20of%2089%20patients%20and%201501%20plasma%20concentrations%20were%20included%20in%20the%20pharmacokinetic%20analysis.%20The%20best%20model%20consisted%20in%20two%20compartments%20for%20each%20molecule.%20Absorption%20was%20described%20by%20a%20sequential%20zero%20first-order%20process%20and%20a%20lag%20time.%20Ibrutinib%20was%20either%20metabolised%20into%20dihydrodiol-ibrutinib%20or%20excreted%20through%20other%20elimination%20routes.%20A%20link%20between%20the%20dosing%20compartment%20and%20the%20dihydrodiol-ibrutinib%20central%20compartment%20was%20added%20to%20assess%20for%20high%20first-pass%20hepatic%20metabolism.%20Ibrutinib%20clearance%20had%2067%25%20and%2047%25%20inter-%20and%20intra-individual%20variability%2C%20respectively%2C%20while%20dihydrodiol-ibrutinib%20clearance%20had%2051%25%20and%2026%25%20inter-%20and%20intra-individual%20variability%2C%20respectively.%20Observed%20ibrutinib%20exposure%20is%20significantly%20higher%20in%20patients%20carrying%20one%20copy%20of%20the%20cytochrome%20P450%203A4%2A22%20variant%20%281167%20ng.h%5C%2FmL%20vs%20743%20ng.h%5C%2FmL%2C%20respectively%2C%20p%20%3D%200.024%29.%20However%2C%20no%20covariates%20with%20a%20clinically%20relevant%20effect%20on%20ibrutinib%20or%20dihydrodiol-ibrutinib%20exposure%20were%20identified%20in%20the%20PK%20model.%20An%20external%20evaluation%20of%20the%20model%20was%20performed.%20Clinical%20outcome%20was%20expressed%20as%20the%20continuation%20or%20discontinuation%20of%20ibrutinib%20therapy%201%5Cu00a0year%20after%20treatment%20initiation.%20Patients%20who%20had%20treatment%20discontinuation%20because%20of%20toxicity%20had%20significantly%20higher%20ibrutinib%20area%20under%20the%20curve%20%28p%5Cu2009%3D%5Cu20090.047%29.%20No%20association%20was%20found%20between%20cessation%20of%20therapy%20due%20to%20disease%20progression%20and%20ibrutinib%20area%20under%20the%20curve%20in%20patients%20with%20chronic%20lymphocytic%20leukemia.%20For%20the%20seven%20patients%20with%20mantle%20cell%20lymphoma%20studied%2C%20an%20association%20trend%20was%20observed%20between%20disease%20progression%20and%20low%20exposure%20to%20ibrutinib.%5CnCONCLUSIONS%3A%20We%20present%20the%20first%20population%20pharmacokinetic%20model%20describing%20ibrutinib%20and%20dihydrodiol-ibrutinib%20concentrations%20simultaneously.%20Large%20inter-individual%20variability%20and%20substantial%20intra-individual%20variability%20were%20estimated%20and%20could%20not%20be%20explained%20by%20any%20covariate.%20Higher%20plasma%20exposure%20to%20ibrutinib%20is%20associated%20with%20cessation%20of%20therapy%20due%20to%20the%20occurrence%20of%20adverse%20events%20within%20the%20first%20year%20of%20treatment.%20The%20association%20between%20disease%20progression%20and%20ibrutinib%20exposure%20in%20patients%20with%20mantle%20cell%20lymphoma%20should%20be%20further%20investigated.%5CnTRIAL%20REGISTRATION%3A%20ClinicalTrials.gov%20no.%20NCT02824159.%22%2C%22date%22%3A%222020-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs40262-020-00884-0%22%2C%22ISSN%22%3A%221179-1926%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%2C%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222022-01-27T15%3A12%3A26Z%22%7D%7D%2C%7B%22key%22%3A%223VFQT6JT%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22White-Koning%20et%20al.%22%2C%22parsedDate%22%3A%222020-01-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EWhite-Koning%2C%20Melanie%2C%20Marie%20No%26%23xEB%3Blle%20Paludetto%2C%20F%26%23xE9%3Blicien%20Le%20Louedec%2C%20Laurence%20Gladieff%2C%20Christine%20Chevreau%2C%20Etienne%20Chatelut%2C%20and%20Florent%20Puisset.%20%26%23x201C%3BFormulae%20Recently%20Proposed%20to%20Estimate%20Renal%20Glomerular%20Filtration%20Rate%20Improve%20the%20Prediction%20of%20Carboplatin%20Clearance.%26%23x201D%3B%20%3Ci%3ECancer%20Chemotherapy%20and%20Pharmacology%3C%5C%2Fi%3E%2C%20January%209%2C%202020.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00280-019-04020-z%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00280-019-04020-z%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Formulae%20recently%20proposed%20to%20estimate%20renal%20glomerular%20filtration%20rate%20improve%20the%20prediction%20of%20carboplatin%20clearance%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melanie%22%2C%22lastName%22%3A%22White-Koning%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20No%5Cu00eblle%22%2C%22lastName%22%3A%22Paludetto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%5Cu00e9licien%22%2C%22lastName%22%3A%22Le%20Louedec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Gladieff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Chevreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Puisset%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20While%20doses%20of%20carboplatin%20are%20mostly%20individualized%20according%20to%20the%20Calvert%20equation%20based%20on%20estimated%20Glomerular%20Filtration%20Rate%20%28eGFR%29%2C%20there%20is%20still%20uncertainty%20regarding%20the%20best%20formula%20to%20predict%20GFR.%20Since%20Janowitz%20et%20al.%20recently%20proposed%20a%20new%20equation%20predicting%20GFR%20in%20cancer%20patients%2C%20we%20aimed%20to%20compare%20this%20equation%20to%20other%20carboplatin%20clearance%20%28carboCL%29%20predicting%20formulae.%5CnMETHODS%3A%20The%20actual%20carboCL%20of%20491%20patients%20was%20compared%20to%20predicted%20carboCL%20according%20to%20the%20Calvert%20formula%20using%20several%20equations%20to%20predict%20GFR%20%28Janowitz%2C%20Cockcroft-Gault%2C%20MDRD%2C%20CKD-EPI%2C%20CKD-EPI%20with%20cystatin%20C%20%28CKD-EPI-cysC%29%29%3B%20and%20according%20to%20two%20others%20that%20directly%20predict%20carboCL%20%28Chatelut%20and%20Thomas%29.%20The%20formulae%20were%20compared%20on%20Mean%20Percentage%20Error%20%28MPE%29%2C%20Mean%20Absolute%20Percentage%20Error%20%28MAPE%29%20and%20percentage%20of%20patients%20with%20a%20prediction%20error%20above%2020%25%20%28P20%29.%5CnRESULTS%3A%20The%20MPE%2C%20MAPE%20and%20P20%20were%2C%20respectively%2C%20within%20the%20ranges%20-%5Cu20095.2%20to%20%2B%5Cu20095.9%25%3B%2014.0-21.2%25%20and%2023-46%25.%20The%20MAPE%20and%20P20%20of%20Calvert-CKD-EPI-cysC%20were%20the%20lowest.%20The%20performance%20of%20Calvert-CKD-EPI%20was%20better%20than%20that%20of%20other%20creatinine-based%20formulae%20although%20not%20significantly%20different%20from%20the%20Calvert-Janowitz%20formula.%20Among%20formulae%20based%20on%20creatinine%20only%2C%20Calvert-CKD-EPI%20and%20Calvert-Janowitz%20are%20the%20least%20influenced%20by%20patient%20characteristics.%5CnCONCLUSION%3A%20Whereas%20CysC%20improves%20carboplatin%20CL%20prediction%2C%20the%20Calvert-CKD-EPI%20equation%20seems%20the%20most%20suitable%20creatinine-based%20formula%20to%20predict%20carboCL%20homogeneously%20in%20all%20subgroups%20of%20patients.%22%2C%22date%22%3A%22Jan%2009%2C%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00280-019-04020-z%22%2C%22ISSN%22%3A%221432-0843%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22LPWFRFBC%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Metsu%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMetsu%2C%20David%2C%20Thomas%20Lanot%2C%20Fran%26%23xE7%3Bois%20Fraissinet%2C%20Didier%20Concordet%2C%20V%26%23xE9%3Bronique%20Gayrard%2C%20Manon%20Averseng%2C%20Alice%20Ressault%2C%20et%20al.%20%26%23x201C%3BComparing%20Ultrafiltration%20and%20Equilibrium%20Dialysis%20to%20Measure%20Unbound%20Plasma%20Dolutegravir%20Concentrations%20Based%20on%20a%20Design%20of%20Experiment%20Approach.%26%23x201D%3B%20%3Ci%3EScientific%20Reports%3C%5C%2Fi%3E%2010%2C%20no.%201%20%282020%29%3A%2012265.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-020-69102-y%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-020-69102-y%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Comparing%20ultrafiltration%20and%20equilibrium%20dialysis%20to%20measure%20unbound%20plasma%20dolutegravir%20concentrations%20based%20on%20a%20design%20of%20experiment%20approach%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Metsu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Lanot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Fraissinet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Concordet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Gayrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manon%22%2C%22lastName%22%3A%22Averseng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22Ressault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Martin-Blondel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22F%5Cu00e9vrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Delobel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peggy%22%2C%22lastName%22%3A%22Gandia%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2212%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-020-69102-y%22%2C%22ISSN%22%3A%222045-2322%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41598-020-69102-y%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A15Z%22%7D%7D%2C%7B%22key%22%3A%22ZRRYZ6ER%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22de%20Jong%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EJong%2C%20Loek%20A.%20W.%20de%2C%20Fortun%26%23xE9%3B%20M.%20K.%20Elekonawo%2C%20Marie%20Lambert%2C%20Jan%20Marie%20de%20Gooyer%2C%20Henk%20M.%20W.%20Verheul%2C%20David%20M.%20Burger%2C%20Johannes%20H.%20W.%20de%20Wilt%2C%20et%20al.%20%26%23x201C%3BWide%20Variation%20in%20Tissue%2C%20Systemic%2C%20and%20Drain%20Fluid%20Exposure%20after%20Oxaliplatin-Based%20HIPEC%3A%20Results%20of%20the%20GUTOX%20Study.%26%23x201D%3B%20%3Ci%3ECancer%20Chemotherapy%20and%20Pharmacology%3C%5C%2Fi%3E%2086%2C%20no.%201%20%282020%29%3A%20141%26%23x2013%3B50.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00280-020-04107-y%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00280-020-04107-y%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Wide%20variation%20in%20tissue%2C%20systemic%2C%20and%20drain%20fluid%20exposure%20after%20oxaliplatin-based%20HIPEC%3A%20results%20of%20the%20GUTOX%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loek%20A.%20W.%22%2C%22lastName%22%3A%22de%20Jong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fortun%5Cu00e9%20M.%20K.%22%2C%22lastName%22%3A%22Elekonawo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Lambert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%20Marie%22%2C%22lastName%22%3A%22de%20Gooyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Henk%20M.%20W.%22%2C%22lastName%22%3A%22Verheul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20M.%22%2C%22lastName%22%3A%22Burger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johannes%20H.%20W.%22%2C%22lastName%22%3A%22de%20Wilt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rob%22%2C%22lastName%22%3A%22ter%20Heine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philip%20R.%22%2C%22lastName%22%3A%22de%20Reuver%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andre%20J.%20A.%22%2C%22lastName%22%3A%22Bremers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nielka%20P.%22%2C%22lastName%22%3A%22van%20Erp%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%227%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00280-020-04107-y%22%2C%22ISSN%22%3A%220344-5704%2C%201432-0843%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Flink.springer.com%5C%2F10.1007%5C%2Fs00280-020-04107-y%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A19Z%22%7D%7D%2C%7B%22key%22%3A%226RPG3DAI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Moeung%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMoeung%2C%20Sotheara%2C%20Christine%20Chevreau%2C%20Sabrina%20Marsili%2C%20Christophe%20Massart%2C%20Aude%20Fl%26%23xE9%3Bchon%2C%20R%26%23xE9%3Bmy%20Delva%2C%20Gwena%26%23xEB%3Blle%20Gravis%2C%20et%20al.%20%26%23x201C%3BPharmacokinetic%20and%20Pharmacogenetic%20Study%20of%20Etoposide%20in%20High-Dose%20Protocol%20%28TI-CE%29%20for%20Advanced%20Germ%20Cell%20Tumors.%26%23x201D%3B%20%3Ci%3EPharmaceutical%20Research%3C%5C%2Fi%3E%2037%2C%20no.%207%20%282020%29%3A%20147.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs11095-020-02861-5%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs11095-020-02861-5%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pharmacokinetic%20and%20Pharmacogenetic%20Study%20of%20Etoposide%20in%20High-Dose%20Protocol%20%28TI-CE%29%20for%20Advanced%20Germ%20Cell%20Tumors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sotheara%22%2C%22lastName%22%3A%22Moeung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Chevreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabrina%22%2C%22lastName%22%3A%22Marsili%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Massart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aude%22%2C%22lastName%22%3A%22Fl%5Cu00e9chon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%5Cu00e9my%22%2C%22lastName%22%3A%22Delva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwena%5Cu00eblle%22%2C%22lastName%22%3A%22Gravis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Lotz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques-Olivier%22%2C%22lastName%22%3A%22Bay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Gross-Goupil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Delmas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Lafont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Thomas%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%227%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1007%5C%2Fs11095-020-02861-5%22%2C%22ISSN%22%3A%220724-8741%2C%201573-904X%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Flink.springer.com%5C%2F10.1007%5C%2Fs11095-020-02861-5%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22H9ZDCQ2D%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chatelut%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EChatelut%2C%20Etienne%2C%20F%26%23xE9%3Blicien%20Le%20Louedec%2C%20and%20G%26%23xE9%3Brard%20Milano.%20%26%23x201C%3BSetting%20the%20Dose%20of%20Checkpoint%20Inhibitors%3A%20The%20Role%20of%20Clinical%20Pharmacology.%26%23x201D%3B%20%3Ci%3EClinical%20Pharmacokinetics%3C%5C%2Fi%3E%2059%2C%20no.%203%20%282020%29%3A%20287%26%23x2013%3B96.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs40262-019-00837-2%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs40262-019-00837-2%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Setting%20the%20Dose%20of%20Checkpoint%20Inhibitors%3A%20The%20Role%20of%20Clinical%20Pharmacology%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%5Cu00e9licien%22%2C%22lastName%22%3A%22Le%20Louedec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00e9rard%22%2C%22lastName%22%3A%22Milano%22%7D%5D%2C%22abstractNote%22%3A%22Cancer%20immunotherapy%20is%20based%20on%20checkpoint%20inhibitors%20%28CPIs%29%20that%20significantly%20improve%20the%20clinical%20outcome%20of%20several%20malignant%20diseases.%20These%20inhibitors%20are%20monoclonal%20antibodies%20%28mAbs%29%20directed%20at%20cytotoxic%20T%5Cu00a0lymphocyte-associated%20protein%5Cu00a04%20%28CTLA-4%29%2C%20programmed%20cell%20death%5Cu00a01%20%28PD-1%29%2C%20or%20programmed%20death-ligand%201%20%28PD-L1%29%2C%20sharing%20most%20of%20the%20clinical%20pharmacokinetic%20characteristics%20of%20mAb%20targeted%20therapies%2C%20all%20of%20which%20differ%20from%20those%20of%20cytotoxics%20and%20small%20molecules.%20Establishing%20the%20labeled%20dose%20of%20mAbs%2C%20and%20particularly%20of%20the%20CPIs%2C%20represents%20a%20true%20challenge.%20This%20review%20therefore%20examines%20the%20main%20criteria%20used%20for%20dose%20selection%2C%20along%20with%20their%20limits.%20The%20relationships%20between%20CPI%20pharmacokinetic%20parameters%20and%20treatment%20outcome%20%28efficacy%20and%5C%2For%20toxicity%29%20differ%20somewhat%20among%20the%20various%20drugs%2C%20but%20general%20features%20can%20be%20identified.%20Nevertheless%2C%20the%20interpretation%20of%20these%20relationships%20remains%20quite%20controversial.%20A%20first%20interpretation%20asserts%20that%20inter-individual%20pharmacokinetic%20variability%20in%20clearance%20has%20an%20impact%20on%20outcome%20and%20should%20be%20taken%20into%20consideration%20for%20dosing%20individualization.%20The%20second%20considers%20that%20higher%20clearance%20values%20observed%20in%20some%20patients%20result%20from%20characteristics%20associated%20with%20poor%20predictive%20factors%20of%20efficacy.%20Finally%2C%20the%20schedule%2C%20and%20particularly%20its%20frequency%20of%20administration%2C%20merits%20rethinking.%22%2C%22date%22%3A%2203%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs40262-019-00837-2%22%2C%22ISSN%22%3A%221179-1926%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-07-22T11%3A27%3A02Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Maillard, Maud, Christine Chevreau, Félicien Le Louedec, Manon Cassou, Caroline Delmas, Laure Gourdain, Jean-Yves Blay, et al. “Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma.” Cancers<\/i> 12, no. 12 (December 4, 2020): 3647. https:\/\/doi.org\/10.3390\/cancers12123647<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Le Louedec, Félicien, Fanny Leenhardt, Clémence Marin, Étienne Chatelut, Alexandre Evrard, and Joseph Ciccolini. “Cancer Immunotherapy Dosing: A Pharmacokinetic\/Pharmacodynamic Perspective.” Vaccines<\/i> 8, no. 4 (October 31, 2020): 632. https:\/\/doi.org\/10.3390\/vaccines8040632<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Lambert, Marie, Melanie White‐Koning, Mathieu Alonso, Arnaud Garnier, Gwennaelle Alphonsa, Chloé Puiseux, Caroline Munzer, et al. “Plasma Cystatin C Is a Marker of Renal Glomerular Injury in Children Treated with Cisplatin or Ifosfamide.” Pediatric Blood & Cancer<\/i>, October 15, 2020. https:\/\/doi.org\/10.1002\/pbc.28747<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Le Louedec, Félicien, and Etienne Chatelut. “Correlation between Bevacizumab Exposure and Survival Does Not Necessarily Imply Causality. Letter to the Editor.” The Oncologist<\/i>, October 12, 2020, onco.13564. https:\/\/doi.org\/10.1002\/onco.13564<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Maillard, Maud, Félicien Le Louedec, Fabienne Thomas, and Etienne Chatelut. “Diversity of Dose-Individualization and Therapeutic Drug Monitoring Practices of Platinum Compounds: A Review.” Expert Opinion on Drug Metabolism & Toxicology<\/i>, October 5, 2020, 1–19. https:\/\/doi.org\/10.1080\/17425255.2020.1789590<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Gallais, Fanny, Lucie Oberic, Stanislas Faguer, Suzanne Tavitian, Thierry Lafont, Sabrina Marsili, Aurélie Brice, Etienne Chatelut, and Florent Puisset. “Body Surface Area Dosing of High-Dose Methotrexate Should Be Reconsidered, Particularly in Overweight, Adult Patients.” Therapeutic Drug Monitoring<\/i> Publish Ahead of Print (September 10, 2020). https:\/\/doi.org\/10.1097\/FTD.0000000000000813<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Gallais, Fanny, Loïc Ysebaert, Fabien Despas, Sandra De Barros, Loïc Dupré, Anne Quillet-Mary, Caroline Protin, et al. “Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies.” Clinical Pharmacokinetics<\/i> 59, no. 9 (September 2020): 1171–83. https:\/\/doi.org\/10.1007\/s40262-020-00884-0<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
White-Koning, Melanie, Marie Noëlle Paludetto, Félicien Le Louedec, Laurence Gladieff, Christine Chevreau, Etienne Chatelut, and Florent Puisset. “Formulae Recently Proposed to Estimate Renal Glomerular Filtration Rate Improve the Prediction of Carboplatin Clearance.” Cancer Chemotherapy and Pharmacology<\/i>, January 9, 2020. https:\/\/doi.org\/10.1007\/s00280-019-04020-z<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Metsu, David, Thomas Lanot, François Fraissinet, Didier Concordet, Véronique Gayrard, Manon Averseng, Alice Ressault, et al. “Comparing Ultrafiltration and Equilibrium Dialysis to Measure Unbound Plasma Dolutegravir Concentrations Based on a Design of Experiment Approach.” Scientific Reports<\/i> 10, no. 1 (2020): 12265. https:\/\/doi.org\/10.1038\/s41598-020-69102-y<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Jong, Loek A. W. de, Fortuné M. K. Elekonawo, Marie Lambert, Jan Marie de Gooyer, Henk M. W. Verheul, David M. Burger, Johannes H. W. de Wilt, et al. “Wide Variation in Tissue, Systemic, and Drain Fluid Exposure after Oxaliplatin-Based HIPEC: Results of the GUTOX Study.” Cancer Chemotherapy and Pharmacology<\/i> 86, no. 1 (2020): 141–50. https:\/\/doi.org\/10.1007\/s00280-020-04107-y<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Moeung, Sotheara, Christine Chevreau, Sabrina Marsili, Christophe Massart, Aude Fléchon, Rémy Delva, Gwenaëlle Gravis, et al. “Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors.” Pharmaceutical Research<\/i> 37, no. 7 (2020): 147. https:\/\/doi.org\/10.1007\/s11095-020-02861-5<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Chatelut, Etienne, Félicien Le Louedec, and Gérard Milano. “Setting the Dose of Checkpoint Inhibitors: The Role of Clinical Pharmacology.” Clinical Pharmacokinetics<\/i> 59, no. 3 (2020): 287–96. https:\/\/doi.org\/10.1007\/s40262-019-00837-2<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][et_pb_toggle title=”PUBLICATIONS 2019″ open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_text_color=”#505659″ closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.16″ _module_preset=”default” title_text_color=”#505659″ title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_text_align=”center” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” global_colors_info=”{}”]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\tNMTDPBH9<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2019<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 38370<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-53ac568489f1ffed71946cf3c7d596b7%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%222CRYSXT8%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Paludetto%20et%20al.%22%2C%22parsedDate%22%3A%222019-09-26%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPaludetto%2C%20Marie-No%26%23xEB%3Blle%2C%20Jean-Luc%20Stigliani%2C%20Anne%20Robert%2C%20Vania%20Bernardes-G%26%23xE9%3Bnisson%2C%20Etienne%20Chatelut%2C%20Florent%20Puisset%2C%20and%20C%26%23xE9%3Bcile%20Arellano.%20%26%23x201C%3BInvolvement%20of%20Pazopanib%20and%20Sunitinib%20Aldehyde%20Reactive%20Metabolites%20in%20Toxicity%20and%20Drug-Drug%20Interactions%20in%20Vitro%20and%20in%20Patient%20Samples.%26%23x201D%3B%20%3Ci%3EChemical%20Research%20in%20Toxicology%3C%5C%2Fi%3E%2C%20September%2026%2C%202019.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1021%5C%2Facs.chemrestox.9b00205%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1021%5C%2Facs.chemrestox.9b00205%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Involvement%20of%20Pazopanib%20and%20Sunitinib%20Aldehyde%20Reactive%20Metabolites%20in%20Toxicity%20and%20Drug-Drug%20Interactions%20in%20Vitro%20and%20in%20Patient%20Samples%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-No%5Cu00eblle%22%2C%22lastName%22%3A%22Paludetto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Luc%22%2C%22lastName%22%3A%22Stigliani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vania%22%2C%22lastName%22%3A%22Bernardes-G%5Cu00e9nisson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Puisset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Arellano%22%7D%5D%2C%22abstractNote%22%3A%22Tyrosine%20kinase%20inhibitors%20%28TKI%29%20are%20targeted%20anticancer%20drugs%20that%20have%20been%20successfully%20developed%20over%20the%20past%202%20decades.%20To%20date%2C%20many%20of%20them%20%28around%2070%25%29%20require%20warnings%20for%20liver%20injury%20and%20five%20of%20them%2C%20including%20pazopanib%20and%20sunitinib%2C%20have%20Black%20Box%20Warning%20%28BBW%29%20labels.%20Although%20TKI-induced%20hepatotoxicity%20is%20the%20first%20cause%20of%20drug%20failures%20in%20clinical%20trials%2C%20BBW%20labels%2C%20and%20market%20withdrawals%2C%20the%20underlying%20mechanisms%20remain%20unclear.%20However%2C%20the%20recent%20discovery%20of%20new%20reactive%20metabolites%20%28RM%29%20with%20aldehyde%20structures%20during%20pazopanib%20and%20sunitinib%20metabolism%20offers%20new%20perspectives%20for%20investigating%20their%20involvement%20in%20the%20toxicity%20of%20these%20two%20TKI.%20These%20hard%20electrophiles%20have%20a%20high%20reactivity%20potential%20toward%20proteins%20and%20are%20thought%20to%20be%20responsible%20for%20cytochrome%20P450%20inactivation%2C%20drug-drug%20interactions%20%28DDI%29%2C%20and%20liver%20toxicity.%20We%20report%20here%2C%20for%20the%20first%20time%2C%20the%20presence%20of%20these%20aldehyde%20RM%20in%20human%20plasma%20samples%20obtained%20during%20drug%20monitoring.%20Docking%20experiments%20in%20the%20CYP3A4%20active%20site%20were%20performed%20and%20showed%20that%20pazopanib%20and%20sunitinib%20fitting%20in%20the%20catalytic%20site%20are%20in%20accordance%20with%20their%20regioselective%20oxidation%20to%20aldehydes.%20They%20also%20suggested%20that%20aldehyde%20RM%20may%20react%20with%20lysine%20and%20arginine%20residues.%20Based%20on%20these%20results%2C%20we%20studied%20the%20reactivity%20of%20the%20aldehyde%20RM%20toward%20lysine%20and%20arginine%20residues%20as%20potential%20targets%20on%20the%20protein%20framework%20to%20better%20understand%20how%20these%20RM%20could%20be%20involved%20in%20liver%20toxicity%20and%20drug-drug%20interactions.%20Adduct%20formation%20with%20different%20hepatic%20and%20plasma%20proteins%20was%20investigated%20by%20LC-MS%5C%2FMS%2C%20and%20adducts%20between%20pazopanib%20or%20sunitinib%20aldehyde%20derivatives%20and%20lysine%20residues%20on%20both%20CYP3A4%20and%20plasma%20proteins%20were%20indeed%20shown%20for%20the%20first%20time.%22%2C%22date%22%3A%22Sep%2026%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1021%5C%2Facs.chemrestox.9b00205%22%2C%22ISSN%22%3A%221520-5010%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A38Z%22%7D%7D%2C%7B%22key%22%3A%2283J2QESF%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Soul%5Cu00e8s%20et%20al.%22%2C%22parsedDate%22%3A%222019-08-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESoul%26%23xE8%3Bs%2C%20R%26%23xE9%3Bgis%2C%20Fabien%20Audouard-Combe%2C%20Emilie%20Huc-Claustre%2C%20Philippe%20de%20Medina%2C%20Arnaud%20Rives%2C%20Etienne%20Chatelut%2C%20Florence%20Dalenc%2C%20et%20al.%20%26%23x201C%3BA%20Fast%20UPLC-HILIC%20Method%20for%20an%20Accurate%20Quanti%26%23xFB01%3Bcation%20of%20Dendrogenin%20A%20in%20Human%20Tissues.%26%23x201D%3B%20%3Ci%3EThe%20Journal%20of%20Steroid%20Biochemistry%20and%20Molecular%20Biology%3C%5C%2Fi%3E%20194%20%28August%2012%2C%202019%29%3A%20105447.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jsbmb.2019.105447%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jsbmb.2019.105447%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20fast%20UPLC-HILIC%20method%20for%20an%20accurate%20quanti%5Cufb01cation%20of%20dendrogenin%20A%20in%20human%20tissues%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%5Cu00e9gis%22%2C%22lastName%22%3A%22Soul%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Audouard-Combe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Huc-Claustre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22de%20Medina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Rives%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Dalenc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Franchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Silvente-Poirot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Poirot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ben%22%2C%22lastName%22%3A%22Allal%22%7D%5D%2C%22abstractNote%22%3A%22Dendrogenin%20A%20%28DDA%29%20is%20a%20newly-discovered%20steroidal%20alkaloid%2C%20which%20remains%20to%20date%20the%20first%20ever%20found%20in%20mammals.%20DDA%20is%20a%20cholesterol%20metabolites%20that%20induces%20cancer%20cell%20differentiation%20and%20death%20in%20vitro%20and%20in%20vivo%2C%20and%20thus%20behave%20like%20a%20tumor%20suppressor%20metabolite.%20Preliminary%20studies%20performed%20on%2010%20patients%20with%20estrogen%20receptor%20positive%20breast%20cancers%20%28ER%28%2B%29BC%29%20showed%20a%20strong%20decrease%20in%20DDA%20levels%20between%20normal%20matched%20tissue%20and%20tumors.%20This%20suggests%20that%20a%20deregulation%20on%20DDA%20metabolism%20is%20associated%20with%20breast%20carcinogenesis.%20To%20further%20investigate%20DDA%20metabolism%20on%20large%20cohorts%20of%20patients%20we%20have%20developed%20an%20ultra-high%20performance%20liquid%20chromatography-tandem%20mass%20spectrometry%20%28UPLC-MS%29%20procedure%20for%20the%20quantification%20of%20DDA%20in%20liquid%20and%20in%20solid%20tissues.%20This%20method%20enabled%20the%20identification%20of%20DDA%20analogues%20such%20as%20its%20geometric%20isomer%20C17%20and%20dendrogenin%20B%20%28C26%29%20in%20human%20samples%20showing%20that%20other%205%2C6%5Cu03b1-epoxycholesterol%20conjugation%20products%20with%20biogenic%20amines%20exist%20as%20endogenous%20metabolites%20.%20We%20report%20here%20the%20first%20complete%20method%20of%20quantification%20of%20DDA%20in%20liquid%20and%20solid%20tissues%20using%20hydrophilic%20interaction%20liquid%20chromatography%20%28HILIC%29.%20Two%20different%20methods%20of%20extraction%20using%20either%20a%20Bligh%20and%20Dyer%20organic%20extraction%20or%20protein%20precipitation%20were%20successfully%20applied%20to%20quantify%20DDA%20in%20solid%20and%20liquid%20tissues.%20The%20protein%20precipitation%20method%20was%20the%20fastest.%20The%20fact%20that%20this%20method%20is%20automatable%20opens%20up%20possibilities%20to%20study%20DDA%20metabolism%20in%20large%20cohorts%20of%20patients.%22%2C%22date%22%3A%22Aug%2012%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jsbmb.2019.105447%22%2C%22ISSN%22%3A%221879-1220%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%2C%22S3JJUU84%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A31Z%22%7D%7D%2C%7B%22key%22%3A%22AETDJ6BM%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Paludetto%20et%20al.%22%2C%22parsedDate%22%3A%222019-05-20%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPaludetto%2C%20Marie-No%26%23xEB%3Blle%2C%20Florent%20Puisset%2C%20Etienne%20Chatelut%2C%20and%20C%26%23xE9%3Bcile%20Arellano.%20%26%23x201C%3BIdentifying%20the%20Reactive%20Metabolites%20of%20Tyrosine%20Kinase%20Inhibitors%20in%20a%20Comprehensive%20Approach%3A%20Implications%20for%20Drug-Drug%20Interactions%20and%20Hepatotoxicity.%26%23x201D%3B%20%3Ci%3EMedicinal%20Research%20Reviews%3C%5C%2Fi%3E%2C%20May%2020%2C%202019.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fmed.21577%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fmed.21577%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Identifying%20the%20reactive%20metabolites%20of%20tyrosine%20kinase%20inhibitors%20in%20a%20comprehensive%20approach%3A%20Implications%20for%20drug-drug%20interactions%20and%20hepatotoxicity%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-No%5Cu00eblle%22%2C%22lastName%22%3A%22Paludetto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Puisset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Arellano%22%7D%5D%2C%22abstractNote%22%3A%22Tyrosine%20kinase%20inhibitors%20%28TKI%29%20are%20small%20heterocyclic%20molecules%20targeting%20transmembrane%20and%20cytoplasmic%20tyrosine%20kinases%20that%20have%20met%20with%20considerable%20success%20in%20clinical%20oncology.%20TKI%20are%20associated%20with%20toxicities%20including%20liver%20injury%20that%20may%20be%20serious%20and%20even%20life-threatening.%20Many%20of%20them%20require%20warnings%20in%20drug%20labeling%20against%20liver%20injury%2C%20and%20five%20of%20them%20have%20Black%20Box%20Warning%20%28BBW%29%20labels.%20Although%20drug-induced%20liver%20injury%20is%20a%20matter%20of%20clinical%20and%20industrial%20concern%2C%20little%20is%20known%20about%20the%20underlying%20mechanisms%20that%20likely%20involve%20reactive%20metabolites%20%28RM%29.%20RM%20are%20electrophiles%20or%20radicals%20originating%20from%20the%20metabolic%20activation%20of%20particular%20functional%20groups%2C%20known%20as%20structural%20alerts%20or%20toxicophores.%20RM%20are%20able%20to%20covalently%20bind%20to%20proteins%20and%20macromolecules%2C%20causing%20cellular%20damage%20and%20even%20cell%20death.%20If%20the%20adducted%20protein%20is%20the%20enzyme%20involved%20in%20RM%20formation%2C%20time-dependent%20inhibition%20of%20the%20enzyme-also%20called%20mechanism-based%20inhibition%20%28MBI%29%20or%20inactivation-can%20occur%20and%20lead%20to%20pharmacokinetic%20drug-drug%20interactions.%20To%20mitigate%20RM%20liabilities%2C%20common%20practice%20in%20drug%20development%20includes%20avoiding%20structural%20alerts%20and%20assessing%20RM%20formation%20via%20RM%20trapping%20screens%20with%20soft%20and%20hard%20nucleophiles%20%28glutathione%2C%20potassium%20cyanide%2C%20and%20methoxylamine%29%20in%20liver%20microsomes.%20RM-positive%20derivatives%20are%20further%20optimized%20to%20afford%20drug%20candidates%20with%20blocked%20or%20minimized%20bioactivation%20potential.%20However%2C%20different%20structural%20alerts%20are%20still%20commonly%20used%20scaffolds%20in%20drug%20design%2C%20including%20in%20TKI%20structures.%20This%20review%20focuses%20on%20the%20current%20state%20of%20knowledge%20of%20the%20relations%20among%20TKI%20structures%2C%20bioactivation%20pathways%2C%20RM%20characterization%2C%20and%20hepatotoxicity%20and%20cytochrome%20P450%20MBI%20in%20vitro.%22%2C%22date%22%3A%22May%2020%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fmed.21577%22%2C%22ISSN%22%3A%221098-1128%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A19Z%22%7D%7D%2C%7B%22key%22%3A%223NK954Q3%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Puszkiel%20et%20al.%22%2C%22parsedDate%22%3A%222019-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPuszkiel%2C%20Alicja%2C%20Ga%26%23xEB%3Blle%20No%26%23xE9%3B%2C%20Audrey%20Bellesoeur%2C%20Nora%20Kramkimel%2C%20Marie-No%26%23xEB%3Blle%20Paludetto%2C%20Audrey%20Thomas-Schoemann%2C%20Michel%20Vidal%2C%20Fran%26%23xE7%3Bois%20Goldwasser%2C%20Etienne%20Chatelut%2C%20and%20Benoit%20Blanchet.%20%26%23x201C%3BClinical%20Pharmacokinetics%20and%20Pharmacodynamics%20of%20Dabrafenib.%26%23x201D%3B%20%3Ci%3EClinical%20Pharmacokinetics%3C%5C%2Fi%3E%2058%2C%20no.%204%20%28April%202019%29%3A%20451%26%23x2013%3B67.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs40262-018-0703-0%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs40262-018-0703-0%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20Pharmacokinetics%20and%20Pharmacodynamics%20of%20Dabrafenib%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alicja%22%2C%22lastName%22%3A%22Puszkiel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22No%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Bellesoeur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nora%22%2C%22lastName%22%3A%22Kramkimel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-No%5Cu00eblle%22%2C%22lastName%22%3A%22Paludetto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Thomas-Schoemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Vidal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Goldwasser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Blanchet%22%7D%5D%2C%22abstractNote%22%3A%22Dabrafenib%20is%20a%20potent%20and%20selective%20inhibitor%20of%20BRAF-mutant%20kinase%20that%20is%20approved%2C%20as%20monotherapy%20or%20in%20combination%20with%20trametinib%20%28mitogen-activated%20protein%20kinase%20%28MAPK%29%20kinase%20%28MEK%29%20inhibitor%29%2C%20for%20unresectable%20or%20metastatic%20BRAF-mutated%20melanoma%2C%20advanced%20non-small%20cell%20lung%20cancer%20and%20anaplastic%20thyroid%20cancer%20harbouring%20the%20BRAFV600E%20mutation.%20The%20recommended%20dose%20of%20dabrafenib%20is%20150%5Cu00a0mg%20twice%20daily%20%28bid%29%20under%20fasted%20conditions.%20After%20single%20oral%20administration%20of%20the%20recommended%20dose%2C%20the%20absolute%20oral%5Cu00a0bioavailability%20%28F%29%20of%20dabrafenib%20is%2095%25.%20Dabrafenib%20shows%20a%20time-dependent%20increase%20in%20apparent%20clearance%20%28CL%5C%2FF%29%20following%20multiple%20doses%2C%20which%20is%20likely%20due%20to%20induction%20of%20its%20own%20metabolism%20through%20cytochrome%20P450%20%28CYP%29%5Cu00a03A4.%20Therefore%2C%20steady%20state%20is%20reached%20only%20after%2014%5Cu00a0days%20of%20daily%20dose%20administration.%20Moreover%2C%20the%20extent%20of%20this%20auto-induction%20process%20is%20dependent%20on%20the%20dose%2C%20which%20explains%20why%20dabrafenib%20systemic%20exposure%20at%20steady%20state%20increases%20less%20than%20dose%20proportionally%20over%20the%20dose%20range%20of%2075-300%5Cu00a0mg%20bid.%20The%20main%20elimination%20route%20of%20dabrafenib%20is%20the%20oxidative%20metabolism%20via%20CYP3A4%5C%2F2C8%20and%20biliary%20excretion.%20Among%20the%20three%20major%20metabolites%20identified%2C%20hydroxy-dabrafenib%20appears%20to%20contribute%20to%20the%20pharmacological%20activity.%20Age%2C%20sex%20and%20body%20weight%20did%20not%20have%20any%20clinically%20significant%20influence%20on%20plasma%20exposure%20to%20dabrafenib.%20No%20dose%20adjustment%20is%20needed%20for%20patients%20with%20mild%20renal%20or%20hepatic%20impairment%2C%20whereas%20the%20impacts%20of%20severe%20impairment%20on%20dabrafenib%20pharmacokinetics%20remain%20unknown.%20Considering%20that%20dabrafenib%20is%20a%20substrate%20of%20CYP3A4%5C%2F2C8%20and%20is%20a%20CYP3A4%5C%2F2B6%5C%2F2C%20inducer%2C%20drug-drug%20interactions%20are%20expected%20with%20dabrafenib.%20The%20relationship%20between%20clinical%20outcomes%20and%20plasma%20exposure%20to%20dabrafenib%20and%20hydroxy-dabrafenib%20should%20be%20investigated%20more%20deeply.%22%2C%22date%22%3A%22Apr%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs40262-018-0703-0%22%2C%22ISSN%22%3A%221179-1926%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-10-11T11%3A40%3A14Z%22%7D%7D%2C%7B%22key%22%3A%22RGQCWAHA%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Spinau%20et%20al.%22%2C%22parsedDate%22%3A%222019-03%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESpinau%2C%20Coline%2C%20Florent%20Puisset%2C%20and%20Etienne%20Chatelut.%20%26%23x201C%3BCarboplatine%20versus%20cisplatine%20-%20Pharmacocin%26%23xE9%3Btique%2C%20cytotoxicit%26%23xE9%3B%2C%20indications%20th%26%23xE9%3Brapeutiques.%26%23x201D%3B%20%3Ci%3EONKO%2B%3C%5C%2Fi%3E%2011%2C%20no.%2085%20%28March%202019%29%3A%2043%26%23x2013%3B52.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Carboplatine%20versus%20cisplatine%20-%20Pharmacocin%5Cu00e9tique%2C%20cytotoxicit%5Cu00e9%2C%20indications%20th%5Cu00e9rapeutiques%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Coline%22%2C%22lastName%22%3A%22Spinau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Puisset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22f%5Cu00e9v%5C%2Fmar%202019%22%2C%22language%22%3A%22Fran%5Cu00e7ais%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A07Z%22%7D%7D%2C%7B%22key%22%3A%222HEDQ8VI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Le%20Louedec%20et%20al.%22%2C%22parsedDate%22%3A%222019-02-27%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELe%20Louedec%2C%20F%26%23xE9%3Blicien%2C%20Catherine%20Alix-Panabi%26%23xE8%3Bres%2C%20Thierry%20Lafont%2C%20Ben%20C.%20Allal%2C%20Renaud%20Garrel%2C%20Laurence%20Digue%2C%20Jo%26%23xEB%3Bl%20Guigay%2C%20et%20al.%20%26%23x201C%3BCetuximab%20Pharmacokinetic%5C%2FPharmacodynamics%20Relationships%20in%20Advanced%20Head%20and%20Neck%20Carcinoma%20Patients.%26%23x201D%3B%20%3Ci%3EBritish%20Journal%20of%20Clinical%20Pharmacology%3C%5C%2Fi%3E%2C%20February%2027%2C%202019.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbcp.13907%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbcp.13907%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cetuximab%20Pharmacokinetic%5C%2FPharmacodynamics%20relationships%20in%20advanced%20head%20and%20neck%20carcinoma%20patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%5Cu00e9licien%22%2C%22lastName%22%3A%22Le%20Louedec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Alix-Panabi%5Cu00e8res%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Lafont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ben%20C.%22%2C%22lastName%22%3A%22Allal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renaud%22%2C%22lastName%22%3A%22Garrel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Digue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jo%5Cu00ebl%22%2C%22lastName%22%3A%22Guigay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Cupissol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Lallemant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Alfonsi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karine%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martine%22%2C%22lastName%22%3A%22Mazel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Becher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Perriard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Thomas%22%7D%5D%2C%22abstractNote%22%3A%22AIMS%3A%20Cetuximab%20associated%20with%20cisplatin%20and%205-fluorouracil%20is%20used%20to%20treat%20patients%20with%20inoperable%20or%20metastatic%20head%20and%20neck%20squamous%20cell%20carcinomas%20up%20until%20disease%20progression%20or%20unacceptable%20toxicities.%20To%20date%2C%20no%20biomarkers%20of%20efficacy%20are%20available%20to%20select%20patients%20who%20will%20benefit%20from%20treatment.%5CnMETHODS%3A%20An%20ancillary%20pharmacokinetics%20%28PK%29%20exploration%20was%20performed%20in%20the%20context%20of%20a%20prospective%20study%20investigating%20circulating-tumor%20cells%20vs.%20progression-free%20survival%20%28PFS%29.%20Cetuximab%20plasma%20concentrations%20were%20analyzed%20according%20to%20a%20population%20PK%20model.%20Individual%20exposure%20parameters%20were%20confronted%20with%20soluble%20epidermal%20growth%20factor%20receptor%20%28sEGFR%29%20concentrations%2C%20tumor%20response%20and%20PFS.%5CnRESULTS%3A%20PK%20data%20%2828%20patients%2C%20203%20observations%29%20were%20best%20described%20by%20a%20two-compartment%20model%20with%20linear%20elimination.%20Performance%20status%20%28PS%29%20significantly%20correlated%20to%20both%20cetuximab%20clearance%20and%20central%20volume%20of%20distribution%20with%20both%20parameters%20increasing%20by%2033.3%25%20%2895%25%20CI%201%25%20-%2065.6%25%29%20for%20each%201-point%20increase%20of%20PS%20compared%20to%20PS%3D0.%20Univariate%20analysis%20showed%20that%20patients%20with%20higher%20trough%20cetuximab%20concentrations%20at%20day%207%20%28CminD7%20%29%20had%20better%20tumor%20response%20%28p%20%3D%200.03%29%20and%20longer%20PFS%20%28p%20%3D%200.035%29.%20However%2C%20multivariate%20analysis%20revealed%20that%20only%20PS%20and%20tumor%20size%20at%20baseline%20remained%20significantly%20associated%20with%20PFS.%20Levels%20of%20sEGFR%20increased%20during%20cetuximab%20treatment%20but%20were%20not%20associated%20with%20PFS%20in%20the%20multivariate%20analysis.%5CnCONCLUSIONS%3A%20Our%20study%20prospectively%20indicates%20that%20PS%20is%20likely%20a%20confounding%20factor%20in%20the%20relationship%20between%20cetuximab%20PK%20and%20PFS%2C%20patients%20with%20a%20poor%20PS%20having%20lower%20cetuximab%20plasma%20exposure%20and%20lower%20PFS.%22%2C%22date%22%3A%22Feb%2027%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fbcp.13907%22%2C%22ISSN%22%3A%221365-2125%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22JEFE6RWS%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Puszkiel%20et%20al.%22%2C%22parsedDate%22%3A%222019-02-20%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPuszkiel%2C%20Alicja%2C%20C%26%23xE9%3Bcile%20Arellano%2C%20Christelle%20Vachoux%2C%20Alexandre%20Evrard%2C%20Val%26%23xE9%3Brie%20Le%20Morvan%2C%20Jean-Christophe%20Boyer%2C%20Jacques%20Robert%2C%20et%20al.%20%26%23x201C%3BFactors%20Affecting%20Tamoxifen%20Metabolism%20in%20Breast%20Cancer%20Patients%3B%20Preliminary%20Results%20of%20the%20French%20PHACS%20Study%20%28NCT01127295%29.%26%23x201D%3B%20%3Ci%3EClinical%20Pharmacology%20and%20Therapeutics%3C%5C%2Fi%3E%2C%20February%2020%2C%202019.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcpt.1404%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcpt.1404%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Factors%20affecting%20tamoxifen%20metabolism%20in%20breast%20cancer%20patients%3B%20preliminary%20results%20of%20the%20French%20PHACS%20study%20%28NCT01127295%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alicja%22%2C%22lastName%22%3A%22Puszkiel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Arellano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christelle%22%2C%22lastName%22%3A%22Vachoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Evrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Le%20Morvan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Christophe%22%2C%22lastName%22%3A%22Boyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Delmas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Dalenc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Debled%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Venat-Bouvet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%22%2C%22lastName%22%3A%22Jacot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Suc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Sillet%20Bach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Henri%22%2C%22lastName%22%3A%22Roch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melanie%22%2C%22lastName%22%3A%22White-Koning%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Thomas%22%7D%5D%2C%22abstractNote%22%3A%22In%20addition%20to%20the%20effect%20of%20CYP2D6%20genetic%20polymorphisms%2C%20the%20metabolism%20of%20tamoxifen%20may%20be%20impacted%20by%20other%20factors%20with%20possible%20consequences%20on%20therapeutic%20outcome%20%28efficacy%2C%20toxicity%29.%20This%20analysis%20focused%20on%20the%20pharmacokinetic-pharmacogenetic%20evaluation%20of%20tamoxifen%20in%20730%20adjuvant%20breast%20cancer%20patients%20included%20in%20a%20prospective%20multicenter%20study.%20Plasma%20concentrations%20of%20tamoxifen%20and%20six%20major%20metabolites%2C%20the%20genotype%20for%2063%20single%20nucleotide%20polymorphisms%20and%20co-medications%20were%20obtained%206%20months%20after%20treatment%20initiation.%20Plasma%20concentrations%20of%20endoxifen%20were%20significantly%20associated%20with%20CYP2D6%20diplotype%20%28p%20%3C%200.0001%29%2C%20CYP3A4%2A22%20genotype%20%28p%20%3D%200.0003%29%20and%20concomitant%20intake%20of%20potent%20CYP2D6%20inhibitors%20%28p%20%3C%200.001%29.%20Comparison%20of%20endoxifen%20levels%20showed%20that%20the%20CYP2D6%20phenotype%20classification%20could%20be%20improved%20by%20grouping%20IM%5C%2FIM%20and%20IM%5C%2FPM%20diplotype%20into%20intermediate%20metaboliser%20%28IM%29%20phenotype%20for%20future%20use%20in%20tamoxifen%20therapy%20optimisation.%20Finally%2C%20the%20multivariable%20regression%20analysis%20showed%20that%20formation%20of%20tamoxifen%20metabolites%20was%20independently%20impacted%20by%20CYP2D6%20diplotype%20and%20CYP3A4%2A22%2C%20CYP2C19%2A2%20and%20CYP2B6%2A6%20genetic%20polymorphisms.%20This%20article%20is%20protected%20by%20copyright.%20All%20rights%20reserved.%22%2C%22date%22%3A%22Feb%2020%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fcpt.1404%22%2C%22ISSN%22%3A%221532-6535%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22GJCYRVVF%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Puszkiel%20et%20al.%22%2C%22parsedDate%22%3A%222019-02%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPuszkiel%2C%20Alicja%2C%20Mathilde%20Bauriaud-Mallet%2C%20Roxane%20Bourgeois%2C%20Lawrence%20Dierickx%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Courbon%2C%20and%20Etienne%20Chatelut.%20%26%23x201C%3BEvaluation%20of%20the%20Interaction%20of%20Amino%20Acid%20Infusion%20on%20177Lu-Dotatate%20Pharmacokinetics%20in%20Patients%20with%20Gastroenteropancreatic%20Neuroendocrine%20Tumors.%26%23x201D%3B%20%3Ci%3EClinical%20Pharmacokinetics%3C%5C%2Fi%3E%2058%2C%20no.%202%20%28February%202019%29%3A%20213%26%23x2013%3B22.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs40262-018-0674-1%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs40262-018-0674-1%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evaluation%20of%20the%20Interaction%20of%20Amino%20Acid%20Infusion%20on%20177Lu-Dotatate%20Pharmacokinetics%20in%20Patients%20with%20Gastroenteropancreatic%20Neuroendocrine%20Tumors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alicja%22%2C%22lastName%22%3A%22Puszkiel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Bauriaud-Mallet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roxane%22%2C%22lastName%22%3A%22Bourgeois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lawrence%22%2C%22lastName%22%3A%22Dierickx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Courbon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVE%3A%20177Lu-Dotatate%20is%20a%20radio-labeled%20analog%20of%20somatostatin%20used%20in%20the%20treatment%20of%20somatostatin%20receptor-positive%20gastroenteropancreatic%20neuroendocrine%20tumors.%20In%20order%20to%20prevent%20nephrotoxic%20effects%20of%20177Lu-Dotatate%20a%20co-infusion%20of%20amino%20acids%20%28AA%29%20is%20administered%2C%20resulting%20in%20a%20decrease%20in%20tubular%20renal%20reabsorption%20of%20177Lu-Dotatate.%20This%20study%20aimed%20to%20quantify%20the%20impact%20of%20AA%20co-infusion%20on%20the%20pharmacokinetics%20of%20177Lu-Dotatate%20in%20cancer%20patients%20and%20to%20evaluate%20its%20relationship%20with%20toxicity%20during%20the%20first%20treatment%20cycle%20%28C1%29.%5CnMETHODS%3A%207.4%5Cu00a0GBq%20of%20177Lu-Dotatate%20was%20administered%20to%2042%20patients%20over%20a%2030-min%20intravenous%20infusion.%20Infusion%20of%20AA%20started%202%5Cu00a0h%20before%20and%20continued%20for%206%5Cu00a0h%20after%20the%20infusion%20of%20177Lu-Dotatate.%20Radioactivity-time%20data%20%28n%5Cu2009%3D%5Cu2009346%29%20were%20analyzed%20using%20NONMEM%5Cu00ae%20%28version%207.2.0%29.%5CnRESULTS%3A%20177Lu-Dotatate%20pharmacokinetics%20was%20best%20described%20by%20a%20three-compartment%20model%20with%20first-order%20elimination.%20AA%20co-infusion%20had%20a%20significant%20effect%20%28%27fixed%20effect%27%29%20on%20177Lu-Dotatate%20pharmacokinetics%2C%20with%20a%20mean%20value%20of%201.5-fold%20%2895%25%20confidence%20interval%201.03-1.97%29%20increase%20in%20the%20elimination%20rate%20constant%20%28k10%29%20from%200.204%20to%200.306%5Cu00a0h-1%2C%20but%20this%20AA%20co-infusion%20effect%20was%20associated%20with%20a%20large%20inter-individual%20variability%20%28IIV%29%20of%20104%25.%20The%20individual%20k10%20values%20increased%20during%20concomitant%20AA%20infusion%20by%20a%20factor%20ranging%20from%201.01%20to%2021.3%20for%2027%20patients%2C%20whereas%20the%20opposite%20effect%20was%20observed%20in%2015%20patients%20%28range%200.36-0.99%29%20of%20whom%20seven%20had%20a%20k10%20value%20lower%20than%200.85.%20This%20variability%20in%20AA%20effect%20contributed%20to%20the%20variability%20in%20177Lu-Dotatate%20plasma%20exposure%20%28area%20under%20the%20concentration-time%20curve%20from%20time%20zero%20to%20Day%5Cu00a015%20for%20C1%20%5BAUCDay15%5D%29%20that%20correlated%20with%20lymphopenia%20observed%20at%20Day%2015%20%28p%5Cu2009%3D%5Cu20090.004%29.%5CnCONCLUSIONS%3A%20A%20substantial%20effect%20of%20AA%20co-infusion%20on%20177Lu-Dotatate%20pharmacokinetics%20was%20shown%20but%20was%20associated%20with%20high%20IIV%2C%20contributing%20to%20IIV%20in%20hematological%20toxicity.%22%2C%22date%22%3A%22Feb%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs40262-018-0674-1%22%2C%22ISSN%22%3A%221179-1926%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-10-11T11%3A41%3A33Z%22%7D%7D%2C%7B%22key%22%3A%22IEKE9PRZ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Veal%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EVeal%2C%20Gareth%20J.%2C%20Edward%20B.%20Amankwatia%2C%20Marie-No%26%23xEB%3Blle%20Paludetto%2C%20Till%20M%26%23xF6%3Bcklinghoff%2C%20Fiona%20Thomson%2C%20Nicolas%20Andr%26%23xE9%3B%2C%20Joseph%20Ciccolini%2C%20and%20Etienne%20Chatelut.%20%26%23x201C%3BPharmacodynamic%20Therapeutic%20Drug%20Monitoring%20for%20Cancer%3A%20Challenges%2C%20Advances%2C%20and%20Future%20Opportunities.%26%23x201D%3B%20%3Ci%3ETherapeutic%20Drug%20Monitoring%3C%5C%2Fi%3E%2041%2C%20no.%202%20%282019%29%3A%20142%26%23x2013%3B59.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FFTD.0000000000000606%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FFTD.0000000000000606%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pharmacodynamic%20Therapeutic%20Drug%20Monitoring%20for%20Cancer%3A%20Challenges%2C%20Advances%2C%20and%20Future%20Opportunities%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gareth%20J.%22%2C%22lastName%22%3A%22Veal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edward%20B.%22%2C%22lastName%22%3A%22Amankwatia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-No%5Cu00eblle%22%2C%22lastName%22%3A%22Paludetto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Till%22%2C%22lastName%22%3A%22M%5Cu00f6cklinghoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fiona%22%2C%22lastName%22%3A%22Thomson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Andr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Ciccolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%5D%2C%22abstractNote%22%3A%22In%20the%20modern%20era%20of%20cancer%20treatment%2C%20with%20targeted%20agents%20superseding%20more%20traditional%20cytotoxic%20chemotherapeutics%2C%20it%20is%20becoming%20increasingly%20important%20to%20use%20stratified%20medicine%20approaches%20to%20ensure%20that%20patients%20receive%20the%20most%20appropriate%20drugs%20and%20treatment%20schedules.%20In%20this%20context%2C%20there%20is%20significant%20potential%20for%20the%20use%20of%20pharmacodynamic%20biomarkers%20to%20provide%20pharmacological%20information%2C%20which%20could%20be%20used%20in%20a%20therapeutic%20drug%20monitoring%20setting.%20This%20review%20focuses%20on%20discussing%20some%20of%20the%20challenges%20faced%20to%20date%20in%20translating%20preclinical%20pharmacodynamic%20biomarker%20approaches%20to%20a%20clinical%20setting.%20Recent%20advances%20in%20important%20areas%20including%20circulating%20biomarkers%20and%20pharmacokinetic%5C%2Fpharmacodynamic%20modeling%20approaches%20are%20discussed%2C%20and%20selected%20examples%20of%20anticancer%20drugs%20where%20there%20is%20existing%20evidence%20to%20potentially%20advance%20pharmacodynamic%20therapeutic%20drug%20monitoring%20approaches%20to%20deliver%20more%20effective%20treatment%20are%20discussed.%20Although%20we%20may%20not%20yet%20be%20in%20a%20position%20to%20systematically%20implement%20therapeutic%20drug%20monitoring%20approaches%20based%20on%20pharmacodynamic%20information%20in%20a%20cancer%20patient%20setting%2C%20such%20approaches%20are%20likely%20to%20become%20more%20commonplace%20in%20the%20coming%20years.%20Based%20on%20ever-increasing%20levels%20of%20pharmacodynamic%20information%20being%20generated%20on%20newer%20anticancer%20drugs%2C%20facilitated%20by%20increasingly%20advanced%20and%20accessible%20experimental%20approaches%20available%20to%20researchers%20to%20collect%20these%20data%2C%20we%20can%20now%20look%20forward%20optimistically%20to%20significant%20advances%20being%20made%20in%20this%20area.%22%2C%22date%22%3A%2204%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FFTD.0000000000000606%22%2C%22ISSN%22%3A%221536-3694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A10Z%22%7D%7D%2C%7B%22key%22%3A%22LHUTCY4Y%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Moeung%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMoeung%2C%20Sotheara%2C%20Christine%20Chevreau%2C%20Vianney%20Poinsignon%2C%20J%26%23xE9%3Br%26%23xF4%3Bme%20Guitton%2C%20B%26%23xE9%3Bn%26%23xE9%3Bdicte%20Leli%26%23xE8%3Bvre%2C%20Joseph%20Ciccolini%2C%20Laurence%20Gladieff%2C%20et%20al.%20%26%23x201C%3BEstimation%20of%20Unbound%20Carboplatin%20Clearance%20From%20Total%20Plasma%20Concentrations%20as%20a%20Means%20of%20Facilitating%20Therapeutic%20Drug%20Monitoring.%26%23x201D%3B%20%3Ci%3ETherapeutic%20Drug%20Monitoring%3C%5C%2Fi%3E%2041%2C%20no.%201%20%282019%29%3A%2066%26%23x2013%3B74.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FFTD.0000000000000569%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FFTD.0000000000000569%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Estimation%20of%20Unbound%20Carboplatin%20Clearance%20From%20Total%20Plasma%20Concentrations%20as%20a%20Means%20of%20Facilitating%20Therapeutic%20Drug%20Monitoring%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sotheara%22%2C%22lastName%22%3A%22Moeung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Chevreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vianney%22%2C%22lastName%22%3A%22Poinsignon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Guitton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9n%5Cu00e9dicte%22%2C%22lastName%22%3A%22Leli%5Cu00e8vre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Ciccolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Gladieff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Massart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aude%22%2C%22lastName%22%3A%22Fl%5Cu00e9chon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%5Cu00e9my%22%2C%22lastName%22%3A%22Delva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwena%5Cu00eblle%22%2C%22lastName%22%3A%22Gravis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Lotz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques-Olivier%22%2C%22lastName%22%3A%22Bay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Gross-Goupil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Delahousse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Lochon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Chatelut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Thomas%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Therapeutic%20drug%20monitoring%20of%20carboplatin%20is%20based%20on%20its%20unbound%20clearance%20%28CLU%29%20determined%20by%20Bayesian%20analysis%20on%20unbound%20%28U%29%20concentrations.%20However%2C%20the%20ultrafiltration%20of%20plasma%20samples%20presents%20technical%20and%20time%20constraints.%20Therefore%2C%20this%20study%20aims%20to%20estimate%20CLU%20using%20total%20plasma%20%28P%29%20concentrations.%5CnMETHODS%3A%20U%20and%20P%20concentration%20data%20of%20407%20patients%20were%20obtained%20from%202%20clinical%20studies%20in%20which%20actual%20CLU%20had%20been%20determined%20for%20each%20patient.%20The%20patients%20were%20then%20split%20into%20development%20%28277%20patients%29%20and%20prospective%20data%20sets%20%28130%20patients%29.%20Two%20approaches%20were%20evaluated.%20PK-model-only%20approach%3A%20a%203-compartment%20pharmacokinetic%20%28PK%29%20model%20based%20on%20U%20and%20P%20concentrations%20and%20taking%20into%20account%20the%20protein%20binding%20process%20was%20developed.%20The%20model%20with%20patient%20covariates%20was%20also%20evaluated.%20Linear%20regression%20approach%3A%20an%20equation%20%28CLU%20%3D%20aCLP%20%2B%20b%29%20was%20obtained%20by%20linear%20regression%20analysis%20between%20actual%20CLU%20and%20CLP%2C%20which%20is%20the%20total%20plasma%20clearance%20obtained%20by%20analyzing%20P%20concentrations%20according%20to%20a%202-compartment%20PK%20model.%20Predictive%20performance%20was%20then%20assessed%20within%20the%20prospective%20data%20set%20by%20estimating%20CLU%20from%20P%20concentrations%20using%20each%20approach%20and%20computing%20the%20relative%20percentage%20error%20%28PE%29%20between%20estimated%20CLU%20and%20actual%20CLU.%5CnRESULTS%3A%20The%20linear%20regression%20equation%20was%20CLU%20%28L%5C%2Fh%29%20%3D%201.15%20CLP%20%28L%5C%2Fh%29%20%2B%200.13.%20The%20mean%20PE%20%28MPE%29%20between%20CLU%20%28estimated%20using%20the%20equation%29%20and%20the%20actual%20CLU%20was%20%2B1.2%25%20%28ranging%20from%20-31%25%20to%20%2B33%25%29%20and%20the%20mean%20absolute%20PE%20%28MAPE%29%20was%209.7%25.%20With%20the%203-compartment%20PK%20model%2C%20the%20MPE%20was%20%2B2.3%25%20%28ranging%20from%20-41%25%20to%20%2B31%25%29%20and%20the%20MAPE%20was%2011.1%25.%20Inclusion%20of%20covariates%20in%20the%203-compartment%20model%20did%20not%20improve%20the%20estimation%20of%20CLU%20%5BMPE%20%3D%20%2B6.3%25%20%28from%20-33%25%20to%20%2B37%25%29%3B%20MAPE%20%3D%2011.4%25%5D.%5CnCONCLUSIONS%3A%20The%20linear%20equation%20gives%20a%20relatively%20good%20estimation%20of%20CLU%20based%20on%20P%20concentrations%2C%20making%20PK-based%20carboplatin%20dose%20adaptation%20possible%20for%20centers%20without%20ultrafiltration%20facilities.%22%2C%22date%22%3A%2202%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FFTD.0000000000000569%22%2C%22ISSN%22%3A%221536-3694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NMTDPBH9%22%5D%2C%22dateModified%22%3A%222021-10-11T11%3A41%3A28Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Paludetto, Marie-Noëlle, Jean-Luc Stigliani, Anne Robert, Vania Bernardes-Génisson, Etienne Chatelut, Florent Puisset, and Cécile Arellano. “Involvement of Pazopanib and Sunitinib Aldehyde Reactive Metabolites in Toxicity and Drug-Drug Interactions in Vitro and in Patient Samples.” Chemical Research in Toxicology<\/i>, September 26, 2019. https:\/\/doi.org\/10.1021\/acs.chemrestox.9b00205<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Soulès, Régis, Fabien Audouard-Combe, Emilie Huc-Claustre, Philippe de Medina, Arnaud Rives, Etienne Chatelut, Florence Dalenc, et al. “A Fast UPLC-HILIC Method for an Accurate Quantification of Dendrogenin A in Human Tissues.” The Journal of Steroid Biochemistry and Molecular Biology<\/i> 194 (August 12, 2019): 105447. https:\/\/doi.org\/10.1016\/j.jsbmb.2019.105447<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Paludetto, Marie-Noëlle, Florent Puisset, Etienne Chatelut, and Cécile Arellano. “Identifying the Reactive Metabolites of Tyrosine Kinase Inhibitors in a Comprehensive Approach: Implications for Drug-Drug Interactions and Hepatotoxicity.” Medicinal Research Reviews<\/i>, May 20, 2019. https:\/\/doi.org\/10.1002\/med.21577<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Puszkiel, Alicja, Gaëlle Noé, Audrey Bellesoeur, Nora Kramkimel, Marie-Noëlle Paludetto, Audrey Thomas-Schoemann, Michel Vidal, François Goldwasser, Etienne Chatelut, and Benoit Blanchet. “Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib.” Clinical Pharmacokinetics<\/i> 58, no. 4 (April 2019): 451–67. https:\/\/doi.org\/10.1007\/s40262-018-0703-0<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Spinau, Coline, Florent Puisset, and Etienne Chatelut. “Carboplatine versus cisplatine - Pharmacocinétique, cytotoxicité, indications thérapeutiques.” ONKO+<\/i> 11, no. 85 (March 2019): 43–52.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Le Louedec, Félicien, Catherine Alix-Panabières, Thierry Lafont, Ben C. Allal, Renaud Garrel, Laurence Digue, Joël Guigay, et al. “Cetuximab Pharmacokinetic\/Pharmacodynamics Relationships in Advanced Head and Neck Carcinoma Patients.” British Journal of Clinical Pharmacology<\/i>, February 27, 2019. https:\/\/doi.org\/10.1111\/bcp.13907<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Puszkiel, Alicja, Cécile Arellano, Christelle Vachoux, Alexandre Evrard, Valérie Le Morvan, Jean-Christophe Boyer, Jacques Robert, et al. “Factors Affecting Tamoxifen Metabolism in Breast Cancer Patients; Preliminary Results of the French PHACS Study (NCT01127295).” Clinical Pharmacology and Therapeutics<\/i>, February 20, 2019. https:\/\/doi.org\/10.1002\/cpt.1404<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Puszkiel, Alicja, Mathilde Bauriaud-Mallet, Roxane Bourgeois, Lawrence Dierickx, Frédéric Courbon, and Etienne Chatelut. “Evaluation of the Interaction of Amino Acid Infusion on 177Lu-Dotatate Pharmacokinetics in Patients with Gastroenteropancreatic Neuroendocrine Tumors.” Clinical Pharmacokinetics<\/i> 58, no. 2 (February 2019): 213–22. https:\/\/doi.org\/10.1007\/s40262-018-0674-1<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Veal, Gareth J., Edward B. Amankwatia, Marie-Noëlle Paludetto, Till Möcklinghoff, Fiona Thomson, Nicolas André, Joseph Ciccolini, and Etienne Chatelut. “Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future Opportunities.” Therapeutic Drug Monitoring<\/i> 41, no. 2 (2019): 142–59. https:\/\/doi.org\/10.1097\/FTD.0000000000000606<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Moeung, Sotheara, Christine Chevreau, Vianney Poinsignon, Jérôme Guitton, Bénédicte Lelièvre, Joseph Ciccolini, Laurence Gladieff, et al. “Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring.” Therapeutic Drug Monitoring<\/i> 41, no. 1 (2019): 66–74. https:\/\/doi.org\/10.1097\/FTD.0000000000000569<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

LES MEMBRES DE L\u2019\u00c9QUIPE<\/strong><\/h2>\n

[\/et_pb_text][et_pb_divider color=”#F19532″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” max_width=”none” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

\n
<\/div>\n\n\n
\n
\n
\n
\n
\n
\"\"<\/a><\/div>\n
Jeanne Petit<\/a><\/div>\n
Doctorant \/ PhD student<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Matthieu Gracia<\/a><\/div>\n
Hospitalo-Universitaire \/ University teacher hospital practitioner<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Lawrence Dierickx<\/a><\/div>\n
Clinicien Chercheur \/ Researcher hospital practitioner<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Christelle Vachoux<\/a><\/div>\n
Technicien de laboratoire \/ Laboratory Technician<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Fabienne Thomas<\/a><\/div>\n
Enseignant chercheur \/ University researcher<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
C\u00e9cile Arellano<\/a><\/div>\n
Enseignant chercheur \/ University researcher<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
\u00c9tienne Chatelut<\/a><\/div>\n
Hospitalo-Universitaire \/ University teacher hospital practitioner<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Marie Lambert<\/a><\/div>\n
Clinicien Chercheur \/ Researcher hospital practitioner<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Ben Allal<\/a><\/div>\n
Clinicien Chercheur \/ Researcher hospital practitioner<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Aur\u00e9lie Brice<\/a><\/div>\n
Technicien de laboratoire \/ Laboratory Technician<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Sabrina Marsili<\/a><\/div>\n
Technicien de laboratoire \/ Laboratory Technician<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
F\u00e9licien Le-Louedec<\/a><\/div>\n
Doctorant \/ PhD student<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Thierry Lafont<\/a><\/div>\n
Technicien de laboratoire \/ Laboratory Technician<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Malika Yakoubi<\/a><\/div>\n
Technicien de laboratoire \/ Laboratory Technician<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Melanie White-Koning<\/a><\/div>\n
Enseignant chercheur \/ University researcher<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Ayman AL SAATI<\/a><\/div>\n
Hospitalo-Universitaire \/ University teacher hospital practitioner<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n <\/div>\n<\/div><\/div>\n\n
<\/div><\/div>\n\n